0001213900-21-059044.txt : 20211115 0001213900-21-059044.hdr.sgml : 20211115 20211115094734 ACCESSION NUMBER: 0001213900-21-059044 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCEAN BIO CHEM INC CENTRAL INDEX KEY: 0000350737 STANDARD INDUSTRIAL CLASSIFICATION: SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842] IRS NUMBER: 591564329 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-11102 FILM NUMBER: 211407034 BUSINESS ADDRESS: STREET 1: 4041 SW 47TH AVE CITY: FORT LAUDERDALE STATE: FL ZIP: 33314 BUSINESS PHONE: 9545876280 MAIL ADDRESS: STREET 1: 4041 SW 47TH AVE CITY: FT LAUDERDALE STATE: FL ZIP: 33028 FORMER COMPANY: FORMER CONFORMED NAME: STAR BRITE CORP DATE OF NAME CHANGE: 19841204 10-Q 1 f10q0921_oceanbio.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

 

or

 

   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission File Number: 0-11102

 

OCEAN BIO-CHEM, INC.

(Exact name of registrant as specified in its charter)

 

Florida   59-1564329

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

4041 SW 47 Avenue, Fort Lauderdale, Florida   33314
(Address of principal executive offices)   (Zip Code)

 

954-587-6280

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act.

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.01 par value   OBCI   The NASDAQ Stock Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer 
Non-accelerated filer   Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No 

 

At November 11, 2021, 9,485,799 shares of the registrant’s common stock were outstanding.

 

 

 

 

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

 

    Page
PART I Financial Information:  
     
Item 1. Financial Statements 1
     
  Condensed consolidated balance sheets at September 30, 2021 (unaudited) and December 31, 2020 1
     
  Condensed consolidated statements of operations (unaudited) for the three and nine months ended September 30, 2021 and 2020 2
     
  Condensed consolidated statements of comprehensive income (unaudited) for the three and nine months ended September 30, 2021 and 2020 3
     
  Condensed consolidated statements of shareholders’ equity (unaudited) for the three and nine months ended September 30, 2021 and 2020 4-5
     
  Condensed consolidated statements of cash flows (unaudited) for the nine months ended September 30, 2021 and 2020 6
     
  Notes to condensed consolidated financial statements 7-17
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18-23
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 23
     
Item 4. Controls and Procedures 23
     
PART II Other Information:  
     
Item 1A. Risk Factors 24
     
Item 6. Exhibits 24
     
  Signatures 25

 

i

 

 

PART 1 - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30,
2021
   December 31,
2020
 
   (Unaudited)     
ASSETS        
Current Assets:        
Cash  $10,679,703   $11,123,726 
Trade accounts receivable less allowances of approximately $492,000 and $326,000, respectively   17,226,890    8,326,939 
Receivables due from affiliated companies   624,748    1,496,104 
Restricted cash   
-
    477,426 
Inventories, net   16,788,800    13,175,756 
Prepaid expenses and other current assets   1,970,210    1,259,786 
Total Current Assets   47,290,351    35,859,737 
           
Property, plant and equipment, net   14,180,888    10,101,962 
Operating lease – right to use   204,434    268,920 
Intangible assets, net   1,451,814    1,665,299 
Total Assets  $63,127,487   $47,895,918 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current Liabilities:          
Current portion of long-term debt, net  $737,995   $500,694 
Current portion of operating lease liability   88,783    86,377 
Accounts payable – trade   5,082,599    1,966,010 
Accrued expenses payable   1,820,964    1,142,825 
Total Current Liabilities   7,730,341    3,695,906 
           
Deferred tax liability   412,795    380,218 
Operating lease liability, less current portion   115,651    182,543 
Long-term debt, less current portion and debt issuance costs   7,983,559    3,730,180 
Total Liabilities   16,242,346    7,988,847 
           
COMMITMENTS AND CONTINGENCIES   
 
    
 
 
           
Shareholders’ Equity:          
Common stock - $.01 par value, 12,000,000 shares authorized; 9,485,799 and 9,481,799 shares issued and outstanding   94,858    94,818 
Additional paid in capital   10,871,840    10,816,100 
Accumulated other comprehensive loss   (294,997)   (294,324)
Retained earnings   36,213,440    29,290,477 
Total Shareholders’ Equity   46,885,141    39,907,071 
           
Total Liabilities and Shareholders’ Equity  $63,127,487   $47,895,918 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
                 
Net sales  $21,483,054   $19,161,372   $50,303,263   $42,682,497 
                     
Cost of goods sold   14,028,573    10,414,131    30,195,629    23,085,473 
                     
Gross profit   7,454,481    8,747,241    20,107,634    19,597,024 
                     
Operating Expenses:                    
Advertising and promotion   955,812    723,446    3,163,209    2,265,382 
Selling and administrative   2,292,301    2,030,787    6,906,770    6,242,862 
Total operating expenses   3,248,113    2,754,233    10,069,979    8,508,244 
                     
Operating income   4,206,368    5,993,008    10,037,655    11,088,780 
                     
Other (expense) income                    
Interest (expense), net   (35,776)   (39,615)   (113,786)   (93,695)
Gain on insurance settlement   
-
    
-
    
-
    126,210 
                     
Income before income taxes   4,170,592    5,953,393    9,923,869    11,121,295 
                     
Provision for income taxes   (899,731)   (1,296,563)   (2,147,424)   (2,385,263)
                     
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
                     
Earnings per common share – basic and diluted  $0.34   $0.49   $0.82   $0.92 
                     
Dividends declared per common share  $0.03   $0.02   $0.09   $0.06 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
                 
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
Foreign currency translation adjustment   (1,154)   (281)   (673)   (1,663)
                     
Comprehensive income  $3,269,707   $4,656,549   $7,775,772   $8,734,369 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

THREE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

(UNAUDITED)

 

       Additional   Accumulated Other         
   Common Stock   Paid In   Comprehensive   Retained     
   Shares   Amount   Capital   Loss   Earnings   Total 
                         
June 30, 2021   9,485,799   $94,858   $10,871,840   $(293,843)  $33,227,153   $43,900,008 
                               
Net income   -    
-
    
-
    
-
    3,270,861    3,270,861 
                               
Dividends, common stock   -    
-
    
-
    
-
    (284,574)   (284,574)
                               
Foreign currency translation adjustment   -    
-
    
-
    (1,154)   
-
    (1,154)
                               
September 30, 2021   9,485,799   $94,858   $10,871,840   $(294,997)  $36,213,440   $46,885,141 

 

       Additional   Accumulated
Other
         
   Common Stock   Paid In   Comprehensive   Retained     
   Shares   Amount   Capital   Loss   Earnings   Total 
                         
June 30, 2020   9,462,105   $94,621   $10,545,898   $(295,873)  $24,131,874   $34,476,520 
                               
Net income   -    
-
    
-
    
-
    4,656,830    4,656,830 
                               
Dividends, common stock   -    
-
    
-
    
-
    (189,242)   (189,242)
                               
Foreign currency translation adjustment   -    
-
    
-
    (281)   
-
    (281)
                               
September 30, 2020   9,462,105   $94,621   $10,545,898   $(296,154)  $28,599,462   $38,943,827 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

(UNAUDITED)

 

       Additional   Accumulated Other         
   Common Stock   Paid In   Comprehensive   Retained     
   Shares   Amount   Capital   Loss   Earnings   Total 
                         
December 31, 2020   9,481,799   $94,818   $10,816,100   $(294,324)  $29,290,477   $39,907,071 
                               
Net income   -    
-
    
-
    
-
    7,776,445    7,776,445 
                               
Dividends, common stock   -    
-
    
-
    
-
    (853,482)   (853,482)
                               
Stock based compensation   4,000    40    55,740    
-
    
-
    55,780 
                               
Foreign currency translation adjustment   -    
-
    
-
    (673)   
-
    (673)
                               
September 30, 2021   9,485,799   $94,858   $10,871,840   $(294,997)  $36,213,440   $46,885,141 

 

       Additional   Accumulated
Other
         
   Common Stock   Paid In   Comprehensive   Retained     
   Shares   Amount   Capital   Loss   Earnings   Total 
                         
December 31, 2019   9,442,809   $94,428   $10,503,171   $(294,491)  $20,431,156   $30,734,264 
                               
Net income   -    
-
    
-
    
-
    8,736,032    8,736,032 
                               
Dividends, common stock   -    
-
    
-
    
-
    (567,726)   (567,726)
                               
Options exercised   15,296    153    20,547    
-
    
-
    20,700 
                               
Stock based compensation   4,000    40    22,180    
-
    
-
    22,220 
                               
Foreign currency translation adjustment   -    
-
    
-
    (1,663)   
-
    (1,663)
                               
September 30, 2020   9,462,105   $94,621   $10,545,898   $(296,154)  $28,599,462   $38,943,827 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   Nine Months Ended 
   September 30, 
   2021   2020 
Cash flows from operating activities:        
Net income  $7,776,445   $8,736,032 
Adjustments to reconcile net income to net cash provided by operating activities:          
           
Depreciation and amortization   1,105,542    1,020,179 
Deferred income taxes   32,577    88,377 
Stock based compensation   55,780    22,220 
Provision for bad debts   170,978    213,398 
Provision for slow moving and obsolete inventory   24,450    47,146 
Impairment of equipment   
-
    65,725 
Other operating non-cash items   (690)   (1,061)
Cash used related to 2019 chemical incident   
-
    (200,665)
Gain on insurance settlement   
-
    (126,210)
           
Changes in assets and liabilities:          
           
Trade accounts receivable   (9,070,929)   (9,343,556)
Receivables due from affiliated companies   871,356    (145,840)
Inventories   (3,637,494)   (2,812,905)
Prepaid expenses and other current assets   (710,424)   (43,784)
Accounts payable – trade   3,116,589    2,709,747 
Income taxes payable   
-
    267,402 
Accrued expenses payable   678,139    881,019 
Net cash provided by operating activities   412,319    1,377,224 
           
Cash flows from investing activities:          
Insurance proceeds received for damaged machinery and equipment   
-
    411,657 
Purchases of property, plant and equipment   (4,956,102)   (1,549,077)
Net cash used in investing activities   (4,956,102)   (1,137,420)
           
Cash flows from financing activities:          
Payments on long-term debt   (513,990)   (381,616)
Proceeds from term loan   4,989,789    
-
 
Proceeds from CARES Act note   
-
    1,556,800 
Repayment of CARES Act note   
-
    (1,556,800)
Dividends paid to common shareholders   (853,482)   (567,726)
Proceeds from exercise of stock options   
-
    20,700 
Net cash provided by (used in) financing activities   3,622,317    (928,642)
           
Effect of exchange rate on cash   17    (602)
           
Net decrease in cash and restricted cash   (921,449)   (689,440)
           
Cash and restricted cash at beginning of period   11,601,152    8,010,420 
Cash and restricted cash at end of period  $10,679,703   $7,320,980 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest during period excluding capitalized interest  $95,858   $107,147 
Cash paid for income taxes during period  $2,175,938   $2,029,484 
Cash paid under operating lease  $71,100   $71,100 
           
Cash  $10,679,703   $6,581,944 
Restricted cash   
-
    739,036 
Total cash and restricted cash  $10,679,703   $7,320,980 
           
Noncash lease activities:          
Finance lease right to use assets exchanged for finance lease liabilities  $
-
   $96,039 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

 

 

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1.SUMMARY OF ACCOUNTING POLICIES

 

Interim reporting

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior period data have been reclassified to conform to the current period presentation.  Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.

 

The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

 

The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021.

 

The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

 

7

 

 

2.INVENTORIES

 

The Company’s inventories at September 30, 2021 and December 31, 2020 consisted of the following:

 

    September 30,
2021
    December 31,
2020
 
Raw materials   $ 7,659,240     $ 5,393,961  
Finished goods     9,444,391       8,072,176  
Inventories, gross     17,103,631       13,466,137  
                 
Inventory reserves     (314,831 )     (290,381 )
                 
Inventories, net   $ 16,788,800     $ 13,175,756  

 

The inventory reserves shown in the table above reflect slow moving and obsolete inventory.

 

The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company’s products. The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the customer’s warehouses, which are included in inventories, net, amounted to approximately $1,047,000 and $629,000 at September 30, 2021 and December 31, 2020, respectively.

 

3.PROPERTY, PLANT & EQUIPMENT

 

The Company’s property, plant and equipment at September 30, 2021 and December 31, 2020 consisted of the following:

 

  

Estimated

Useful
Life

  September 30,
2021
  

December 31,

2020

 
            
Land     $278,325   $278,325 
Building and improvements  30 years   9,696,070    9,563,406 
Manufacturing and warehouse equipment  6-20 years   12,889,187    11,959,563 
Office equipment and furniture  3-5 years   1,907,868    1,880,387 
Leasehold improvements  10-15 years   587,183    587,183 
Finance leases – right to use  5 years   113,741    113,741 
Vehicles  3 years   10,020    10,020 
Construction in process      4,313,064    464,203 
 Property, plant and equipment, gross      29,795,458    24,856,828 
              
Less accumulated depreciation      (15,614,570)   (14,754,866)
              
Property, plant and equipment, net     $14,180,888   $10,101,962 

 

The Company’s wholly owned subsidiary, Kinpak Inc. (“Kinpak”), has started a 69,000 square foot expansion of its manufacturing, warehouse and distribution facilities in Montgomery, AL. The expansion is expected to be completed in early 2022. For more information see our Current Report on Form 8-K filed on February 3, 2021.

 

8

 

 

Depreciation expense totaled $302,866 (of which $277,931 is included in cost of goods sold and $24,935 is included in selling and administrative expenses) and $273,490 (of which $248,528 is included in cost of goods sold and $24,962 is included in selling and administrative expenses) for the three months ended September 30, 2021 and 2020, respectively, and $877,176 (of which $803,302 is included in cost of goods sold and $73,874 is included in selling and administrative expenses) and $791,981 (of which $717,907 is included in cost of goods sold and $74,074 is included in selling and administrative expenses) for the nine months ended September 30, 2021 and 2020, respectively.

 

4.LEASES

 

The Company has one operating lease and two finance leases.

 

Under the operating lease, the Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by Peter G. Dornau, the Company’s Chairman, President and Chief Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a maximum annual 2% increase in subsequent years, although the entity has not raised the minimum base rent since the Company entered into a previous lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party. Operating lease expense was $24,339 and $24,521 for the three months ended September 30, 2021 and 2020, respectively, and $73,017 and $73,564 for the nine months ended September 30, 2021 and 2020, respectively.  At September 30, 2021 and December 31, 2020, the Company had a right to use asset and a corresponding liability of $204,434 and $268,920, respectively, related to the operating lease. Set forth below is a schedule of future minimum rent payments under the operating lease.

 

Twelve-month period ending September 30,
2022  $94,800 
2023   94,800 
2024   23,700 
Total future minimum lease payments   213,300 
Less imputed interest   (8,866)
Total operating lease liability  $204,434 

 

The Company’s two finance leases relate to office equipment. See Note 3 for information regarding the carrying value of the Company’s finance lease right to use assets and Note 7 for information regarding the finance lease payment schedule.

 

Expenses incurred with respect to the Company’s leases during the three and nine months ended September 30, 2021 and 2020 are set forth below.

 

   Three
Months
Ended
September 30,
2021
  

Three

Months

Ended
September 30,
2020

 
Operating lease expense  $24,339   $24,521 
Finance lease amortization   5,302    5,406 
Finance lease interest   385    361 
Total lease expense  $30,026   $30,288 

 

9

 

 

   Nine
Months
Ended
September 30,
2021
  

Nine

Months

Ended
September 30,
2020

 
Operating lease expense  $73,017   $73,564 
Finance lease amortization   15,833    16,938 
Finance lease interest   1,230    679 
Total lease expense  $90,080   $91,181 

 

The remaining lease term with respect to the operating lease, weighted average remaining lease term with respect to the finance leases and discount rate with respect to the operating lease and finance leases at September 30, 2021 and December 31, 2020 are set forth below:

 

   September 30,
2021
 
Remaining lease term – operating lease   2.25 years 
Weighted average remaining lease term – finance leases   3.9 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

   December 31,
2020
 
Remaining lease term – operating lease   3.0 years 
Weighted average remaining lease term – finance leases   4.6 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

10

 

 

5.INTANGIBLE ASSETS

 

The Company’s intangible assets at September 30, 2021 and December 31, 2020 consisted of the following:

 

September 30, 2021

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $583,896   $38,837 
Trade names and trademarks   1,715,325    655,684    1,059,641 
Customer list   584,468    357,882    226,586 
Product formulas   292,234    178,941    113,293 
Royalty rights   160,000    146,543    13,457 
Total intangible assets  $3,374,760   $1,922,946   $1,451,814 

 

December 31, 2020

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $544,644   $78,089 
Trade names and trademarks   1,715,325    626,413    1,088,912 
Customer list   584,468    270,212    314,256 
Product formulas   292,234    135,107    157,127 
Royalty rights   160,000    133,085    26,915 
Total intangible assets  $3,374,760   $1,709,461   $1,665,299 

 

Amortization expense related to intangible assets was $71,162 for each of the three months ended September 30, 2021 and 2020, and $213,485 and $213,486 for the nine months ended September 30, 2021 and 2020, respectively.

 

11

 

 

6.REVOLVING LINE OF CREDIT

 

On August 6, 2021, the Company and Regions Bank (“the “Lender”) entered into a Business Loan Agreement (the “Business Loan Agreement”), effective as of July 30, 2021, under which the Company was provided a revolving line of credit in the amount of Six Million Dollars ($6,000,000). The Business Loan Agreement supersedes the Company’s previous $6,000,000 revolving line of credit from the Lender, entered into on August 31, 2018, that was scheduled to expire on August 31, 2021. The revolving line of credit under the Business Loan Agreement is evidenced by a promissory note and is secured principally by the Company’s inventory and accounts receivable.

 

The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. All outstanding principal plus all accrued unpaid interest is due upon Lender’s demand or when the Business Loan Agreement expires on August 30, 2024.

 

There has been no negative impact in the availability of funds to the Company as a result of the COVID-19 pandemic.

 

At September 30, 2021 and December 31, 2020, the Company had no borrowings under the revolving line of credit provided by the current and former Business Loan Agreements.

 

7.LONG TERM DEBT

 

Term Loan

 

On July 30, 2021, Kinpak  and Regions Bank (the “Lender”) entered into a Credit Agreement (the “Credit Agreement”), effective as of July 20, 2021, under which the Company was extended a term loan (the “Term Loan”) in the original principal amount of Five Million Dollars ($5,000,000). The Company is using the proceeds of the Term Loan for a 69,000 square foot expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama. The Term Loan is evidenced by a promissory note (the “Note”) and is secured by a second priority mortgage of the assets pledged in Kinpak’s industrial development bond financing obtained on September 26, 2017 (see below for further information).

 

The Company has unconditionally guaranteed the payment to the Lender promptly when due, by acceleration or otherwise, of all obligations of Kinpak to the Lender.

 

The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.

 

The Credit Agreement provides that prepayments on the Term Loan are subject to a prepayment penalty of 5% during the first year the Term Loan is outstanding, with such penalty declining 1% each year thereafter until there is no prepayment penalty after five years. However, the Lender has agreed to waive the prepayment provisions.

 

The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income. The Credit Agreement also requires that the majority shareholder’s ownership does not drop below 50% of the outstanding shares of Kinpak.

 

12

 

 

The Credit Agreement contains cross-default and cross-collateral provisions relating to any other indebtedness with the Lender, including without limitation the Company’s obligations under its $6,000,000 revolving line of credit from the Lender.

 

The Credit Agreement also contains negative covenants restricting the Company’s ability to, among other things, create or assume indebtedness for borrowed money exceeding $250,000 other than trade payables incurred in the normal course of business, create liens other than permitted liens (as defined in the Credit Agreement), acquire an interest in another entity or incur any obligation as surety or guarantor other than in the ordinary course of business.

 

Industrial Development Bond Financing

 

On September 26, 2017, Kinpak indirectly obtained a $4,500,000 loan from Regions Capital Advantage, Inc. (the “Lender”). The proceeds of the loan have been used in full as of June 30, 2021, principally to pay or reimburse costs relating to the expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, as well as the purchase and installation of associated machinery and equipment (the “Expansion Project”).

 

The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Kinpak inherited the lease structure when it first acquired its facilities from its predecessor-in-interest in 1996. The Lease provides that prior to the maturity date of the Bond, Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.

 

The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027 in the amount of $1,799,201. The Bond provides that the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.

 

Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.

 

Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In connection with the guarantee agreement under which the Company provided its guarantee, the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. At September 30, 2021, the Company was in compliance with these financial covenants.

 

The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are being amortized over the life of the Bond.

 

13

 

 

Other Long-Term Obligations

 

In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. If the note is prepaid in full, the entire outstanding balance of the note (including all unpaid amounts allocated to interest over the remaining term of the note) must be paid.

 

In connection with the Company’s agreement to purchase assets of Check Corporation, the Company agreed to pay Check Corporation (dba Damp Check®) $100,000 in equal installments of approximately $4,348 over a 23-month period that commenced on January 15, 2020, with a final payment due and payable on November 15, 2021. The Company recorded $97,012 as principal, and the remaining $2,988, representing an imputed interest rate of 3.15% per annum, will be recorded as interest expense over the 23 months. 

 

On June 22, 2020, the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%.

 

At September 30, 2021 and December 31, 2020, the Company was obligated under lease agreements covering office equipment utilized in the Company’s operations (inclusive of the lease referenced in the preceding paragraph). The office equipment leases, aggregating approximately $84,000 and $100,000 at September 30, 2021 and December 31, 2020, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum. The office equipment leases are classified as finance leases. During the three months ended September 30, 2021 and 2020, the Company paid $5,687 ($5,302 principal and $385 interest) and $5,767 ($5,406 principal and $361 interest), respectively, and during the nine months ended September 30, 2021 and 2020, the Company paid $17,063 ($15,833 principal and $1,230 interest) and $17,617 ($16,938 principal and $679 interest), respectively, under the lease agreements.

 

The following table provides information regarding the Company’s long-term debt at September 30, 2021 and December 31, 2020:

 

   Current Portion   Long Term Portion 
   September 30,
2021
   December 31,
2020
   September 30,
2021
   December 31,
2020
 
Term loan  $263,746   $
-
   $4,689,609   $
-
 
Obligations related to industrial development bond financing   272,492   $263,881   $3,173,834   $3,454,904 
Note payable related to Snappy Marine asset acquisition   192,277    188,187    164,495    309,218 
Obligation related to Check Corporation asset acquisition   8,662    47,082    
-
    
-
 
Office equipment finance leases   21,455    21,160    62,719    78,847 
Total principal of long- term debt   758,632    520,310    8,090,657    3,842,969 
Debt issuance costs   (20,637)   (19,616)   (107,098)   (112,789)
Total long- term debt  $737,995   $500,694   $7,983,559   $3,730,180 

 

Required principal payments under the Company’s long- term obligations are set forth below:

 

Twelve-month period ending September 30,    
2022  $758,632 
2023   740,016 
2024   591,431 
2025   609,084 
2026   610,985 
Thereafter   5,539,141 
Total  $8,849,289 

 

14

 

 

8.RELATED PARTY TRANSACTIONS

 

The Company sells products to companies affiliated with Peter G. Dornau, who is the Company’s Chairman, President and Chief Executive Officer. The affiliated companies resell, outside of the United States and Canada, products they purchase from the Company. The Company also provides administrative services to these companies and pays certain business-related expenditures for the affiliated companies, for which the Company is reimbursed. Sales to the affiliated companies aggregated approximately $588,000 and $334,000 for the three months ended September 30, 2021 and 2020, respectively, and approximately $1,644,000 and $1,366,000 for the nine months ended September 30, 2021 and 2020, respectively. Fees for administrative services aggregated approximately $161,000 and $166,000 for the three months ended September 30, 2021 and 2020, respectively, and approximately $618,000 and $646,000 for the nine months ended September 30, 2021 and 2020, respectively. Amounts billed to the affiliated companies to reimburse the Company for business related expenditures made on behalf of the affiliated companies aggregated approximately $30,000 and $28,000 during the three months ended September 30, 2021 and 2020, respectively, and approximately $93,000 and $79,000 during the nine months ended September 30, 2021 and 2020, respectively.  The Company had accounts receivable from the affiliated companies in connection with the product sales, administrative services and business- related expenditures aggregating approximately $625,000 and $1,496,000 at September 30, 2021 and December 31, 2020, respectively.

 

An entity that is owned by the Company’s Chairman, President and Chief Executive Officer provides several services to the Company.  Under this arrangement, the Company paid the entity an aggregate of approximately $15,000 ($12,000 for research and development services and $3,000 for charter boat services that the Company used to provide sales incentives to customers) and $12,000 for research and development services for the three months ended September 30, 2021 and 2020, respectively, and $59,000 ($36,000 for research and development services, $17,000 for charter boat services that the Company used to provide sales incentives for customers and $6,000 for the production of television commercials ) and $47,000 ($36,000 for research and development services, $9,000 for charter boat services that the Company used to provide sales incentives for customers and $2,000 for the production of television commercials) for the nine months ended September 30, 2021 and 2020, respectively. Expenditures for the research and development services are included in the condensed consolidated statements of operations within selling and administrative expenses. Expenditures for the charter boat services are included in the condensed consolidated statements of operations within advertising and promotion expenses.

 

The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer. See Note 4 for a description of the lease terms.

 

A director of the Company is Regional Executive Vice President of an insurance broker through which the Company sources most of its insurance needs.  During the three months ended September 30, 2021 and 2020, the Company paid an aggregate of approximately $816,000 and $471,000, respectively, and during the nine months ended September 30, 2021 and 2020, the Company paid an aggregate of approximately $1,645,000 and $984,000, respectively in insurance premiums on policies obtained through the insurance broker.

 

15

 

 

9.EARNINGS PER SHARE

 

Basic earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period. Diluted earnings per share reflect additional dilution from potential common stock issuances upon the exercise of outstanding stock options. The following table sets forth the computation of basic and diluted earnings per common share, as well as a reconciliation of the weighted average number of common shares outstanding to the weighted average number of shares outstanding on a diluted basis.

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2021   2020   2021   2020 
Earnings per common share – Basic                
                 
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
                     
Weighted average number of common shares outstanding   9,485,799    9,462,105    9,483,499    9,454,639 
                     
Earnings per common share – Basic  $0.34   $0.49   $0.82   $0.92 
                     
Earnings per common share – Diluted                    
                     
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
                     
Weighted average number of common shares outstanding   9,485,799    9,462,105    9,483,499    9,454,639 
                     
Dilutive effect of outstanding stock options   
-
    
-
    
-
    4,708 
                     
Weighted average number of common shares outstanding - Diluted   9,485,799    9,462,105    9,483,499    9,459,347 
                     
Earnings per common share – Diluted  $0.34   $0.49   $0.82   $0.92 

 

The Company had no stock options outstanding during any of the three and nine month periods ended September 30, 2021 and 2020 that were antidilutive and therefore not included in the diluted earnings per common share calculation. 

 

16

 

 

10.SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

 

No stock compensation expense was incurred during each of the three months ended September 30, 2021 and 2020. Stock compensation expense during the nine months ended September 30, 2021 and 2020 was $55,780 and $22,220, respectively, all of which relates to the shares of Company common stock issued to the Company’s non-employee directors as part of their compensation for service on the Board of Directors. At September 30, 2021, there were no outstanding stock options or unrecognized compensation expense related to stock options. 

 

11.CASH DIVIDENDS

 

The Company’s board of directors declared the following cash dividends during the nine months ended September 30, 2021 and 2020:

 

Nine months ended September 30, 2021

 

Declaration Date   Type   Record Date   Payment Date   Dividends
Per Share
    Amount  
February 25, 2021   Quarterly   March 11, 2021   March 25, 2021   $ 0.03     $ 284,454  
May 21, 2021   Quarterly   June 4, 2021   June 18, 2021     0.03       284,454  
August 26, 2021   Quarterly   September 9, 2021   September 23, 2021     0.03       284,574  
Total
 
 
 
 
 
 
  $ 0.09     $ 853,482  

 

Nine months ended September 30, 2020

 

Declaration Date   Type   Record Date   Payment Date   Dividends
Per Share
    Amount  
May 26, 2020   Special   June 9, 2020   June 23, 2020   $ 0.02     $ 189,242  
May 26, 2020   Quarterly   June 9, 2020   June 23, 2020     0.02       189,242  
August 26, 2020   Quarterly   September 9, 2020   September 23, 2020     0.02       189,242  
Total
 
 
 
 
 
 
  $ 0.06     $ 567,726  

 

12.CUSTOMER CONCENTRATION

 

During the three months ended September 30, 2021 and 2020, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. Net sales to these three customers respectively represented approximately 44.3% (22.0%, 12.3% and 10.0%) and 45.0% (17.8%, 13.8% and 13.4.%) of the Company’s net sales, respectively, for the three months ended September 30, 2021 and 2020.

 

During the nine months ended September 30, 2021, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. Net sales to these three customers represented approximately 45.1% (17.8%, 14.6% and 12.7%) of the Company’s net sales for the nine months ended September 30, 2021. During the nine months ended September 30, 2020, the Company had net sales to each of two customers that constituted in excess of 10% of its net sales. Net sales to these two customers represented approximately 32.8% (17.4% and 15.4%) of the Company’s net sales for the nine months ended September 30, 2020.

 

At September 30, 2021, four customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 63.9% (18.7%, 16.9%, 15.2% and 13.1%) of the Company’s gross trade accounts receivable at September 30, 2021. At December 31, 2020, three customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 63.6% (28.8%, 21.1%, and 13.7%) of the Company’s gross trade accounts receivable at December 31, 2020.

 

17

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-looking Statements:

 

Certain statements contained in this Quarterly Report on Form 10-Q, including without limitation, our ability to provide required capital to support inventory levels, the effect of price increases in raw materials that are petroleum or chemical based or commodity chemicals on our margins, and the sufficiency of funds provided through operations and existing sources of financing to satisfy our cash requirements constitute forward-looking statements. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe,” “may,” “will,” “expect,” “anticipate,” “intend,” or “could,” including the negative or other variations thereof or comparable terminology, are intended to identify forward-looking statements. These statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed or implied by such forward-looking statements. Factors that may affect these results include, but are not limited to, the impact of the COVID-19 pandemic on our business and the economy in general, the highly competitive nature of our industry; reliance on certain key customers; changes in consumer demand for marine, recreational vehicle and automotive products; expenditures on, and the effectiveness of our advertising and promotional efforts; adverse weather conditions; unanticipated litigation developments; exposure to market risks relating to changes in interest rates, foreign currency exchange rates and prices for raw materials that are petroleum or chemical based, availability in general of raw materials and other factors addressed in the sections entitled “Risk Factors” in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2020.

 

Overview:

 

We are engaged in the manufacture, marketing and distribution of a broad line of appearance, performance, and maintenance products for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, under the Star brite® and other trademarks within the United States and Canada. In addition, we produce private label formulations of many of our products for various customers and provide custom blending and packaging services for these and other products. We also manufacture, market and distribute chlorine dioxide-based deodorizing, disinfectant and sanitizing products. We sell our products through national retailers and to national and regional distributors. In addition, we sell products to two companies affiliated with Peter G. Dornau, our Chairman, President and Chief Executive Officer; these companies distribute the products outside of the United States and Canada.

 

Critical accounting estimates:

 

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Estimates” in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020 for information regarding our critical accounting estimates.

 

18

 

 

Results of Operations:

 

Three Months Ended September 30, 2021 Compared to the Three Months Ended September 30, 2020

 

The following table provides a summary of our financial results for the three months ended September 30, 2021 and 2020:

 

   For The Three Months Ended September 30, 
           Percent   Percentage of Net Sales 
   2021   2020   Change   2021   2020 
Net sales  $21,483,054   $19,161,372    12.1%   100.0%   100.0%
Cost of goods sold   14,028,573    10,414,131    34.7%   65.3%   54.3%
Gross profit   7,454,481    8,747,241    (14.8)%   34.7%   45.7%
Advertising and promotion   955,812    723,446    32.1%   4.4%   3.8%
Selling and administrative   2,292,301    2,030,787    12.9%   10.7%   10.6%
Operating income   4,206,368    5,993,008    (29.8)%   19.6%   31.3%
Interest (expense), net   (35,776)   (39,615)   (9.7)%   0.2%   0.2%
Provision for income taxes   (899,731)   (1,296,563)   (30.6)%   4.2%   6.8%
Net income  $3,270,861   $4,656,830    (29.8)%   15.2%   24.3%

 

Net sales for the three months ended September 30, 2021 increased by approximately $2,322,000, or 12.1%, as compared to the three months ended September 30, 2020. The increase was primarily attributable to increased sales of winterizing products partially offset by decreased sales of chlorine dioxide-based products (Performacide® and private label).

 

Cost of goods sold increased by approximately $3,614,000, or 34.7%, during the three months ended September 30, 2021, as compared to the three months ended September 30, 2020. The increase was principally a result of higher sales volume, the mix of sales, increased cost of raw materials, freight, and other manufacturing cost increases.

 

Gross profit decreased by approximately $1,293,000, or 14.8%, for the three months ended September 30, 2021, as compared to the three months ended September 30, 2020. Gross profit decreased due to the mix of sales and the cost of goods sold described above. As a percentage of net sales, gross profit was approximately 34.7% and 45.7% for the three months ended September 30, 2021 and 2020, respectively.

 

Advertising and promotion expenses increased by approximately $232,000, or 32.1%, during the three months ended September 30, 2021, as compared to the three months ended September 30, 2020. The increase in advertising and promotion expenses was principally a result of increased internet advertising and television advertising, trade show expenses and other marketing expenses partially offset by decreased cooperative advertising. As a percentage of net sales, advertising and promotion expenses increased to 4.4% for the three months ended September 30, 2021, from 3.8% for the three months ended September 30, 2020.  

 

Selling and administrative expenses increased by approximately $262,000, or 12.9%, during the three months ended September 30, 2021, as compared to the three months ended September 30, 2020. The increase in selling and administrative expenses was primarily a result of the higher variable expenses principally higher sales commissions to independent sales representatives and Company salesmen. In addition, the Company had higher employee compensation and benefits and product testing by independent testing laboratories. As a percentage of net sales, selling and administrative expenses increased to 10.7% for the three months ended September 30, 2021, from 10.6% for the three months ended September 30, 2020. 

 

Interest (expense), net for the three months ended September 30, 2021 decreased by approximately $4,000 or 9.7%, as compared to the three months ended September 30, 2020.

 

19

 

 

Provision for income taxes for the three months ended September 30, 2021 was approximately $900,000, or 21.6% of our income before taxes. For the three months ended September 30, 2020 the provision was approximately $1,297,000, or 21.8% of our income before taxes.  

 

Nine Months Ended September 30, 2021 Compared to the Nine Months Ended September 30, 2020

 

The following table provides a summary of our financial results for the nine months ended September 30, 2021 and 2020:

 

   For The Nine Months Ended September 30, 
           Percent   Percentage of Net Sales 
   2021   2020   Change   2021   2020 
Net sales  $50,303,263   $42,682,497    17.9%   100.0%   100.0%
Cost of goods sold   30,195,629    23,085,473    30.8%   60.0%   54.1%
Gross profit   20,107,634    19,597,024    2.6%   40.0%   45.9%
Advertising and promotion   3,163,209    2,265,382    39.6%   6.3%   5.3%
Selling and administrative   6,906,770    6,242,862    10.6%   13.7%   14.6%
Operating income   10,037,655    11,088,780    (9.5)%   20.0%   26.0%
Interest (expense), net   (113,786)   (93,695)   21.4%   0.2%   0.2%
Gain on insurance settlement   -    126,210    (100.0)%   0.0%   0.3%
Provision for income taxes   (2,147,424)   (2,385,263)   (10.0)%   4.3%   5.6%
Net income  $7,776,445   $8,736,032    (11.0)%   15.5%   20.5%

 

Net sales for the nine months ended September 30, 2021 increased by approximately $7,621,000, or 17.9%, as compared to the nine months ended September 30, 2020. The increase in net sales was principally a result of increased sales of Star brite® branded marine products, private label marine products, and winterizing products, partially offset by a decrease in sales of chlorine dioxide-based products (Performacide® and private label).

 

Cost of goods sold increased by approximately $7,110,000, or 30.8%, during the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020. The increase in cost of goods sold was a result of higher sales volume, the mix of products sold described above, higher raw materials, freight and other manufacturing costs.

 

Gross profit increased by approximately $511,000, or 2.6%, for the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020. Gross profit increased due to our higher sales volume. As a percentage of net sales, gross profit was approximately 40.0% and 45.9% for the nine months ended September 30, 2021 and 2020, respectively.

 

Advertising and promotion expenses increased by approximately $898,000, or 39.6%, during the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020.    The increase in advertising and promotion expenses was principally a result of increased internet and television advertising, partially offset by decreased cooperative advertising with our customers. As a percentage of net sales, advertising and promotion expenses increased to 6.3% for the nine months ended September 30, 2021, from 5.3% for the nine months ended September 30, 2020.  

 

Selling and administrative expenses increased by approximately $664,000, or 10.6%, during the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020. The increase in selling and administrative expenses was primarily a result of our higher net sales which resulted in increased sales commissions and higher employee compensation expenses, increased insurance expenses, and product testing. As a percentage of net sales, selling and administrative expenses decreased to 13.7% for the nine months ended September 30, 2021, from 14.6% for the nine months ended September 30, 2020. 

 

20

 

 

Interest (expense), net for the nine months ended September 30, 2021 increased by approximately $20,000 or 21.4%, as compared to the nine months ended September 30, 2020. During the nine months ended September 30, 2020, the Company had interest income from a money market mutual fund account which the Company did not have in the nine months ended September 30, 2021. 

 

Gain on insurance settlement was approximately $126,000 during the nine months ended September 30, 2020. The Company received a check for approximately $412,000 from our insurance company to cover losses from a chemical incident at our Kinpak facility that took place in December 2019.

 

Provision for income taxes for the nine months ended September 30, 2021 was approximately $2,147,000, or 21.6% of our income before taxes. For the nine months ended September 30, 2020 the provision was approximately $2,385,000, or 21.4% of our income before taxes.  

 

Liquidity and capital resources:

 

Our cash balance was approximately $10,680,000 at September 30, 2021 and approximately $11,124,000 at December 31, 2020. In addition, we had restricted cash of approximately $477,000 at December 31, 2020. The restricted cash constituted amounts held in a custodial account to be used from time to time to fund additional capital expenditures in connection with the 2017 Expansion Project. At September 30, 2021, these amounts have been fully expended. See Note 7 to the condensed consolidated financial statements included in this report for additional information.

 

The following table summarizes our cash flows for the nine months ended September 30, 2021 and 2020:

 

  

Nine Months Ended

September 30,

 
   2021   2020 
Net cash provided by operating activities  $412,319   $1,377,224 
Net cash used in investing activities   (4,956,102)   (1,137,420)
Net cash provided by (used in) financing activities   3,622,317    (928,642)
Effect of exchange rate fluctuations on cash   17    (602)
Net decrease in cash and restricted cash  $(921,449)  $(689,440)

 

Net cash provided by operating activities for the nine months ended September 30, 2021 decreased by approximately $965,000, or 70.1%, as compared to the nine months ended September 30, 2020. During the nine months ended September 30, 2021, net income decreased by approximately $960,000, noncash adjustments to net income increased by approximately $260,000, and changes in working capital used approximately $265,000 more in cash, as compared to the nine months ended September 30, 2020.

 

Net trade accounts receivable at September 30, 2021 aggregated approximately $17,227,000, an increase of approximately $8,900,000, or 106.9%, as compared to approximately $8,327,000 in net trade accounts receivable outstanding at December 31, 2020.  The increase was principally a result of our net sales during the third quarter of 2021. Receivables due from affiliated companies aggregated approximately $625,000 at September 30, 2021, a decrease of approximately $871,000, or 58.2%, from receivables due from affiliated companies of approximately $1,496,000 at December 31, 2020. The decrease was a result of payments received during the nine months ended September 30, 2021.

 

Inventories, net were approximately $16,789,000 and $13,176,000 at September 30, 2021 and December 31, 2020, respectively, representing an increase of approximately $3,613,000, or 27.4%, during the nine months ended September 30, 2021. The increase in inventories is principally due to the combination of anticipated higher costs and availability of raw materials and the continuation of strong sales.

 

21

 

 

Net cash used in investing activities for the nine months ended September 30, 2021 increased by approximately $3,819,000, or 335.7%, as compared to the nine months ended September 30, 2020. The increase in cash used was principally to expand our manufacturing, warehouse and distribution facilities at Kinpak. Additionally, the Company received insurance proceeds (see Results of Operations) of approximately $412,000 during the nine months ended September 30, 2020.

 

Net cash provided by financing activities for the nine months ended September 30, 2021 was approximately $3,622,000 as compared to net cash used in financing of approximately $929,000 for the nine months ended September 30, 2020. During the nine months ended September 30, 2021, the Company received proceeds of approximately $4,990,000 from a term loan related to the expansion at Kinpak (see Note 7). In the nine months ended September 30, 2021, the Company paid dividends to common shareholders aggregating approximately $853,000 and made payments on long term debt of approximately $514,000, as compared to dividends paid to common shareholders aggregating approximately $568,000 and payments on long term debt of approximately $382,000 in the nine months ended September 30, 2020. Additionally, the Company received proceeds from the exercise of stock options of approximately $21,000 during the nine months ended September 30, 2020.

 

See Notes 6 and 7 to the condensed consolidated financial statements included in this report for information concerning our principal credit facilities, consisting of Kinpak’s obligations relating to a term loan, the payment of which we have guaranteed, an industrial development bond financing, the payment of which we have guaranteed, and a revolving line of credit. At September 30, 2021 and December 31, 2020, we had outstanding balances of approximately $4,953,000 and $0, respectively under Kinpak’s obligation relating to the term loan, $3,446,000 and $3,719,000, respectively, under Kinpak’s obligations relating to the industrial development bond financing, and no borrowings under our revolving credit facility.

 

The loan agreement pertaining to our revolving credit facility, as amended, has a stated term that expires on August 31, 2021, although, as was the case with earlier revolving lines of credit provided to us in recent years, amounts outstanding are payable on demand. Nevertheless, the loan agreement pertaining to our revolving line of credit, as amended, contains various covenants, including financial covenants that are described in Note 6 to the condensed consolidated financial statements included in this report.  At September 30, 2021, we were in compliance with these financial covenants. The revolving credit facility is subject to several events of default, including a decline of the majority shareholder’s ownership below 50% of our outstanding shares.

 

Our guarantee of Kinpak’s obligations related to the industrial development bond financing are subject to various covenants, including financial covenants that are described in Note 7 to the condensed consolidated financial statements included in this report. At September 30, 2021, we were in compliance with these financial covenants.

 

In connection with our acquisition of assets of Snappy Marine, we issued a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). At September 30, 2021, we had an outstanding balance of $366,667 under the promissory note (including $356,772 recorded as principal and $9,895 to be recorded as interest expense over the remaining term of the note).

 

In connection with our agreement to purchase assets of Check Corporation (dba Damp CheckTM), we agreed to pay Check Corporation $100,000 in equal installments of approximately $4,348 over a 23-month period that commenced on January 15, 2020 with a final payment due and payable on November 15, 2021. We recorded $97,012 as principal, and the remaining $2,988, representing an imputed interest rate of 3.15% per annum, will be recorded as interest expense over the 23 months).  At September 30, 2021, we had an outstanding balance of $8,696 (including $8,662 recorded as principal and $34 to be recorded as interest expense over the remaining term of the agreement).

 

We also obtained financing through leases for office equipment, totaling approximately $84,000 and $100,000 at September 30, 2021 and December 31, 2020, respectively.

 

22

 

 

Some of our assets and liabilities are denominated in Canadian dollars and are subject to currency exchange rate fluctuations. We do not engage in currency hedging and address currency risk as a pricing issue. For the nine months ended September 30, 2021, we recorded $673 in foreign currency translation adjustments (decreasing shareholders’ equity by $673).

 

During the past few years, we have introduced a number of new products.  At times, new product introductions have required us to increase our overall inventory and have resulted in lower inventory turnover rates.  The effects of reduced inventory turnover have not been material to our overall operations.  We believe that all required capital to maintain such increases will continue to be provided by operations and our current revolving line of credit or a renewal or replacement of the facility.

 

Many of the raw materials that we use in the manufacturing process are petroleum or chemical based and commodity chemicals that are subject to fluctuating prices. The nature of our business does not enable us to pass through the price increases to our national retailer customers and to our distributors as promptly as we experience increases in raw material costs. This may, at times, adversely affect our margins.

 

We believe that funds provided through operations and our revolving line of credit will be sufficient to satisfy our cash requirements over at least the next twelve months.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not applicable

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures:

 

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures as of the end of the period covered by this report are effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act are (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure.

 

Change in Internal Controls over Financial Reporting:

 

No change in internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

23

 

 

PART II - OTHER INFORMATION

 

Item 1A. Risk Factors

 

The business, results of operations, financial condition, cash flow, and stock price of the Company can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”) and Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”) under the heading “Risk Factors,” any one or more of which could, directly or indirectly, cause the Company’s actual financial condition, operating results and cash flow to vary materially from past, or from anticipated future, financial condition operating results and cash flow. 

 

We may experience adverse effects from problems associated with supply chain and material costs.

 

The ongoing supply chain problems in the United States has led to increased costs of raw materials and disruptions in availability of raw materials. We may not be able to obtain the materials we need to manufacture our products on a timely basis or at all, and the higher costs cannot be passed on to customers in a timely manner, affecting profits. Any of these factors, in whole or in part, could materially and adversely affect the Company’s business, financial condition, operating results, cash flow, and stock price.

 

Item 6. Exhibits

 

Exhibit No.    Description
     
10.1   Credit Agreement dated July 20, 2021, between Kinpak and Regions (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021).
     
10.2  

Guaranty Agreement dated July 20, 2021, provided by the Company to Regions (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021).

     
10.3   Business Loan Agreement effective July 30, 2021 between the Company and Regions (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021).
     
10.4   Commercial Security Agreement dated July 30, 2021 between the Company and Regions (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021).
     
31.1     Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act.
32.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350.
32.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350.
101.INS   XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

24

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  OCEAN BIO-CHEM, INC.
   
Dated: November 12, 2021 /s/ Peter G. Dornau
  Peter G. Dornau
  Chairman of the Board, President and
  Chief Executive Officer
   
Dated: November 12, 2021 /s/ Jeffrey S. Barocas
  Jeffrey S. Barocas
  Vice President and
  Chief Financial Officer

 

 

25

 

 

OCEAN BIO CHEM INC false 954 --12-31 Q3 0000350737 587-6280 0000350737 2021-01-01 2021-09-30 0000350737 2021-11-11 0000350737 2021-09-30 0000350737 2020-12-31 0000350737 2021-07-01 2021-09-30 0000350737 2020-07-01 2020-09-30 0000350737 2020-01-01 2020-09-30 0000350737 us-gaap:CommonStockMember 2021-06-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000350737 us-gaap:RetainedEarningsMember 2021-06-30 0000350737 2021-06-30 0000350737 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000350737 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000350737 us-gaap:CommonStockMember 2021-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000350737 us-gaap:RetainedEarningsMember 2021-09-30 0000350737 us-gaap:CommonStockMember 2020-06-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000350737 us-gaap:RetainedEarningsMember 2020-06-30 0000350737 2020-06-30 0000350737 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000350737 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000350737 us-gaap:CommonStockMember 2020-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000350737 us-gaap:RetainedEarningsMember 2020-09-30 0000350737 2020-09-30 0000350737 us-gaap:CommonStockMember 2020-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000350737 us-gaap:RetainedEarningsMember 2020-12-31 0000350737 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000350737 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000350737 us-gaap:CommonStockMember 2019-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000350737 us-gaap:RetainedEarningsMember 2019-12-31 0000350737 2019-12-31 0000350737 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000350737 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000350737 us-gaap:LandMember 2021-09-30 0000350737 us-gaap:LandMember 2020-12-31 0000350737 us-gaap:BuildingImprovementsMember 2021-01-01 2021-09-30 0000350737 us-gaap:BuildingImprovementsMember 2021-09-30 0000350737 us-gaap:BuildingImprovementsMember 2020-12-31 0000350737 srt:MinimumMember obci:ManufacturingAndWarehouseEquipmentMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember obci:ManufacturingAndWarehouseEquipmentMember 2021-01-01 2021-09-30 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2021-09-30 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2020-12-31 0000350737 srt:MinimumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-09-30 0000350737 us-gaap:OfficeEquipmentMember 2021-09-30 0000350737 us-gaap:OfficeEquipmentMember 2020-12-31 0000350737 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0000350737 us-gaap:LeaseholdImprovementsMember 2021-09-30 0000350737 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000350737 obci:FinanceLeasesMember 2021-01-01 2021-09-30 0000350737 obci:FinanceLeasesMember 2021-09-30 0000350737 obci:FinanceLeasesMember 2020-12-31 0000350737 us-gaap:VehiclesMember 2021-01-01 2021-09-30 0000350737 us-gaap:VehiclesMember 2021-09-30 0000350737 us-gaap:VehiclesMember 2020-12-31 0000350737 obci:ConstructionInProcessMember 2021-09-30 0000350737 obci:ConstructionInProcessMember 2020-12-31 0000350737 us-gaap:PatentsMember 2021-09-30 0000350737 us-gaap:TrademarksAndTradeNamesMember 2021-09-30 0000350737 us-gaap:CustomerListsMember 2021-09-30 0000350737 obci:ProductFormulasMember 2021-09-30 0000350737 us-gaap:RoyaltyAgreementsMember 2021-09-30 0000350737 us-gaap:PatentsMember 2020-12-31 0000350737 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0000350737 us-gaap:CustomerListsMember 2020-12-31 0000350737 obci:ProductFormulasMember 2020-12-31 0000350737 us-gaap:RoyaltyAgreementsMember 2020-12-31 0000350737 2021-07-30 0000350737 2018-08-31 0000350737 obci:TermLoanMember 2021-07-30 0000350737 obci:TermLoanMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember obci:TermLoanMember 2021-01-01 2021-09-30 0000350737 srt:MinimumMember obci:TermLoanMember 2021-01-01 2021-09-30 0000350737 obci:TermLoanMember 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2017-09-01 2017-09-26 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2021-01-01 2021-09-30 0000350737 obci:OtherLongTermObligationsMember 2021-01-01 2021-09-30 0000350737 obci:OtherLongTermObligationsMember obci:CheckCorporationMember 2021-01-01 2021-09-30 0000350737 obci:OtherLongTermObligationsMember obci:CanonSolutionsAmericaIncMember 2020-06-01 2020-06-22 0000350737 obci:OtherLongTermObligationsMember 2021-09-30 0000350737 obci:OtherLongTermObligationsMember 2020-12-31 0000350737 srt:MinimumMember obci:OtherLongTermObligationsMember 2021-09-30 0000350737 srt:MaximumMember obci:OtherLongTermObligationsMember 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2021-07-01 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2020-07-01 2020-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2020-01-01 2020-09-30 0000350737 obci:TermLoanMember 2021-09-30 0000350737 obci:TermLoanMember 2020-12-31 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2021-09-30 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2020-12-31 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2021-09-30 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2020-12-31 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2021-09-30 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2020-12-31 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2021-09-30 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2020-12-31 0000350737 srt:ChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0000350737 srt:ChiefExecutiveOfficerMember 2020-07-01 2020-09-30 0000350737 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-09-30 0000350737 srt:ChiefExecutiveOfficerMember 2020-01-01 2020-09-30 0000350737 obci:InsuranceBrokerMember 2021-07-01 2021-09-30 0000350737 obci:InsuranceBrokerMember 2020-07-01 2020-09-30 0000350737 obci:InsuranceBrokerMember 2021-01-01 2021-09-30 0000350737 obci:InsuranceBrokerMember 2020-01-01 2020-09-30 0000350737 us-gaap:DividendDeclaredMember 2021-01-01 2021-09-30 0000350737 obci:DividendDeclaredOneMember 2021-01-01 2021-09-30 0000350737 obci:DividendDeclaredTwoMember 2021-01-01 2021-09-30 0000350737 obci:DividendDeclaredThreeMember 2020-01-01 2020-09-30 0000350737 obci:DividendDeclaredFourMember 2020-01-01 2020-09-30 0000350737 obci:DividendDeclaredFiveMember 2020-01-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerThreeMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerThreeMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember 2021-01-01 2021-09-30 0000350737 obci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerThreeMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2020-01-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2020-01-01 2020-09-30 0000350737 us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerOneMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerTwoMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerThreeMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerFourMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0000350737 us-gaap:AccountsReceivableMember obci:CustomerOneMember 2020-01-01 2020-12-31 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2020-01-01 2020-12-31 0000350737 us-gaap:AccountsReceivableMember obci:CustomerThreeMember 2020-01-01 2020-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqm
EX-31.1 2 f10q0921ex31-1_oceanbio.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATION

 

I, Peter G. Dornau certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ocean Bio-Chem, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: November 12, 2021 By: /s/ Peter G. Dornau
    Peter G. Dornau
    Chairman of the Board, President and
    Chief Executive Officer

EX-31.2 3 f10q0921ex31-2_oceanbio.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION

 

I, Jeffrey S. Barocas certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Ocean Bio-Chem, Inc;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: November 12, 2021 By: /s/ Jeffrey S. Barocas
    Jeffrey S. Barocas
    Vice President
    Chief Financial Officer

EX-32.1 4 f10q0921ex32-1_oceanbio.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(b)

UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350

 

I, Peter G. Dornau, Chief Executive Officer of Ocean Bio-Chem, Inc. (the "Company"), hereby certify that, based on my knowledge:

 

  1.

The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

  

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated:  November 12, 2021 By: /s/ Peter G. Dornau
    Peter G. Dornau
   

Chairman of the Board,

President and

   

Chief Executive Officer

EX-32.2 5 f10q0921ex32-2_oceanbio.htm CERTIFICATION

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(b)

UNDER THE SECURITIES EXCHANGE ACT AND 18 U.S.C. 1350

 

I, Jeffrey S. Barocas, Chief Financial Officer of Ocean Bio-Chem, Inc. (the "Company"), hereby certify that, based on my knowledge:

 

  1.

The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated:  November 12, 2021 By: /s/ Jeffrey S. Barocas
    Jeffrey S. Barocas
    Vice President
   

Chief Financial Officer

EX-101.SCH 6 obci-20210930.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property, Plant & Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Revolving Line of Credit link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Long Term Debt link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Securities Authorized for Issuance Under Equity Compensation Plans link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Cash Dividends link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Customer Concentration link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Property, Plant & Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Long Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Cash Dividends (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Summary of Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Inventories (Details) - Schedule of inventories link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Property, Plant & Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Property, Plant & Equipment (Details) - Schedule of property, plant and equipment link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Leases (Details) - Schedule of future minimum rent payments link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Leases (Details) - Schedule of expenses incurred with respect to the company's leases link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Leases (Details) - Schedule of components lease costs, lease term and discount rate link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Revolving Line of Credit (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Long Term Debt (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Long Term Debt (Details) - Schedule of company's long term debt link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Long Term Debt (Details) - Schedule of principal payments under long term obligations link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Earnings Per Share (Details) - Schedule of computation of basic and diluted earnings per common share link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Securities Authorized for Issuance Under Equity Compensation Plans (Details) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Cash Dividends (Details) - Schedule of declared cash dividends link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Customer Concentration (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 obci-20210930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 obci-20210930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 obci-20210930_lab.xml XBRL LABEL FILE EX-101.PRE 10 obci-20210930_pre.xml XBRL PRESENTATION FILE XML 11 f10q0921_oceanbio_htm.xml IDEA: XBRL DOCUMENT 0000350737 2021-01-01 2021-09-30 0000350737 2021-11-11 0000350737 2021-09-30 0000350737 2020-12-31 0000350737 2021-07-01 2021-09-30 0000350737 2020-07-01 2020-09-30 0000350737 2020-01-01 2020-09-30 0000350737 us-gaap:CommonStockMember 2021-06-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000350737 us-gaap:RetainedEarningsMember 2021-06-30 0000350737 2021-06-30 0000350737 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000350737 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000350737 us-gaap:CommonStockMember 2021-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000350737 us-gaap:RetainedEarningsMember 2021-09-30 0000350737 us-gaap:CommonStockMember 2020-06-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000350737 us-gaap:RetainedEarningsMember 2020-06-30 0000350737 2020-06-30 0000350737 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000350737 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000350737 us-gaap:CommonStockMember 2020-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000350737 us-gaap:RetainedEarningsMember 2020-09-30 0000350737 2020-09-30 0000350737 us-gaap:CommonStockMember 2020-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000350737 us-gaap:RetainedEarningsMember 2020-12-31 0000350737 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000350737 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000350737 us-gaap:CommonStockMember 2019-12-31 0000350737 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000350737 us-gaap:RetainedEarningsMember 2019-12-31 0000350737 2019-12-31 0000350737 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000350737 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000350737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000350737 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000350737 us-gaap:LandMember 2021-09-30 0000350737 us-gaap:LandMember 2020-12-31 0000350737 us-gaap:BuildingImprovementsMember 2021-01-01 2021-09-30 0000350737 us-gaap:BuildingImprovementsMember 2021-09-30 0000350737 us-gaap:BuildingImprovementsMember 2020-12-31 0000350737 srt:MinimumMember obci:ManufacturingAndWarehouseEquipmentMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember obci:ManufacturingAndWarehouseEquipmentMember 2021-01-01 2021-09-30 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2021-09-30 0000350737 obci:ManufacturingAndWarehouseEquipmentMember 2020-12-31 0000350737 srt:MinimumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-09-30 0000350737 us-gaap:OfficeEquipmentMember 2021-09-30 0000350737 us-gaap:OfficeEquipmentMember 2020-12-31 0000350737 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0000350737 us-gaap:LeaseholdImprovementsMember 2021-09-30 0000350737 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000350737 obci:FinanceLeasesMember 2021-01-01 2021-09-30 0000350737 obci:FinanceLeasesMember 2021-09-30 0000350737 obci:FinanceLeasesMember 2020-12-31 0000350737 us-gaap:VehiclesMember 2021-01-01 2021-09-30 0000350737 us-gaap:VehiclesMember 2021-09-30 0000350737 us-gaap:VehiclesMember 2020-12-31 0000350737 obci:ConstructionInProcessMember 2021-09-30 0000350737 obci:ConstructionInProcessMember 2020-12-31 0000350737 us-gaap:PatentsMember 2021-09-30 0000350737 us-gaap:TrademarksAndTradeNamesMember 2021-09-30 0000350737 us-gaap:CustomerListsMember 2021-09-30 0000350737 obci:ProductFormulasMember 2021-09-30 0000350737 us-gaap:RoyaltyAgreementsMember 2021-09-30 0000350737 us-gaap:PatentsMember 2020-12-31 0000350737 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0000350737 us-gaap:CustomerListsMember 2020-12-31 0000350737 obci:ProductFormulasMember 2020-12-31 0000350737 us-gaap:RoyaltyAgreementsMember 2020-12-31 0000350737 2021-07-30 0000350737 2018-08-31 0000350737 obci:TermLoanMember 2021-07-30 0000350737 obci:TermLoanMember 2021-01-01 2021-09-30 0000350737 srt:MaximumMember obci:TermLoanMember 2021-01-01 2021-09-30 0000350737 srt:MinimumMember obci:TermLoanMember 2021-01-01 2021-09-30 0000350737 obci:TermLoanMember 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2017-09-01 2017-09-26 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2021-01-01 2021-09-30 0000350737 obci:OtherLongTermObligationsMember 2021-01-01 2021-09-30 0000350737 obci:OtherLongTermObligationsMember obci:CheckCorporationMember 2021-01-01 2021-09-30 0000350737 obci:OtherLongTermObligationsMember obci:CanonSolutionsAmericaIncMember 2020-06-01 2020-06-22 0000350737 obci:OtherLongTermObligationsMember 2021-09-30 0000350737 obci:OtherLongTermObligationsMember 2020-12-31 0000350737 srt:MinimumMember obci:OtherLongTermObligationsMember 2021-09-30 0000350737 srt:MaximumMember obci:OtherLongTermObligationsMember 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2021-07-01 2021-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2020-07-01 2020-09-30 0000350737 obci:IndustrialDevelopmentBondFinancingMember 2020-01-01 2020-09-30 0000350737 obci:TermLoanMember 2021-09-30 0000350737 obci:TermLoanMember 2020-12-31 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2021-09-30 0000350737 obci:ObligationsRelatedToIndustrialDevelopmentBondFinancingMember 2020-12-31 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2021-09-30 0000350737 obci:NotePayableRelatedToAssetAcquisitionMember 2020-12-31 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2021-09-30 0000350737 obci:ObligationRelatedToCheckCorporationAssetAcquisitionMember 2020-12-31 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2021-09-30 0000350737 obci:OfficeEquipmentFinanceLeasesMember 2020-12-31 0000350737 srt:ChiefExecutiveOfficerMember 2021-07-01 2021-09-30 0000350737 srt:ChiefExecutiveOfficerMember 2020-07-01 2020-09-30 0000350737 srt:ChiefExecutiveOfficerMember 2021-01-01 2021-09-30 0000350737 srt:ChiefExecutiveOfficerMember 2020-01-01 2020-09-30 0000350737 obci:InsuranceBrokerMember 2021-07-01 2021-09-30 0000350737 obci:InsuranceBrokerMember 2020-07-01 2020-09-30 0000350737 obci:InsuranceBrokerMember 2021-01-01 2021-09-30 0000350737 obci:InsuranceBrokerMember 2020-01-01 2020-09-30 0000350737 us-gaap:DividendDeclaredMember 2021-01-01 2021-09-30 0000350737 obci:DividendDeclaredOneMember 2021-01-01 2021-09-30 0000350737 obci:DividendDeclaredTwoMember 2021-01-01 2021-09-30 0000350737 obci:DividendDeclaredThreeMember 2020-01-01 2020-09-30 0000350737 obci:DividendDeclaredFourMember 2020-01-01 2020-09-30 0000350737 obci:DividendDeclaredFiveMember 2020-01-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerThreeMember 2021-07-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerThreeMember 2020-07-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember 2021-01-01 2021-09-30 0000350737 obci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerThreeMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerOneMember 2020-01-01 2020-09-30 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2020-01-01 2020-09-30 0000350737 us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerOneMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerTwoMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerThreeMember 2021-01-01 2021-09-30 0000350737 us-gaap:AccountsReceivableMember obci:CustomerFourMember 2021-01-01 2021-09-30 0000350737 us-gaap:SalesRevenueNetMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0000350737 us-gaap:AccountsReceivableMember obci:CustomerOneMember 2020-01-01 2020-12-31 0000350737 us-gaap:SalesRevenueNetMember obci:CustomerTwoMember 2020-01-01 2020-12-31 0000350737 us-gaap:AccountsReceivableMember obci:CustomerThreeMember 2020-01-01 2020-12-31 shares iso4217:USD iso4217:USD shares pure utr:sqm 10-Q true 2021-09-30 2021 false 0-11102 FL 59-1564329 4041 SW 47 Avenue Fort Lauderdale, FL 33314 Common Stock, $0.01 par value OBCI NASDAQ Yes Yes Non-accelerated Filer true false false 9485799 10679703 11123726 492000 326000 17226890 8326939 624748 1496104 477426 16788800 13175756 1970210 1259786 47290351 35859737 14180888 10101962 204434 268920 1451814 1665299 63127487 47895918 737995 500694 88783 86377 5082599 1966010 1820964 1142825 7730341 3695906 412795 380218 115651 182543 7983559 3730180 16242346 7988847 0.01 0.01 12000000 12000000 9485799 9485799 9481799 9481799 94858 94818 10871840 10816100 -294997 -294324 36213440 29290477 46885141 39907071 63127487 47895918 21483054 19161372 50303263 42682497 14028573 10414131 30195629 23085473 7454481 8747241 20107634 19597024 955812 723446 3163209 2265382 2292301 2030787 6906770 6242862 3248113 2754233 10069979 8508244 4206368 5993008 10037655 11088780 35776 39615 113786 93695 126210 4170592 5953393 9923869 11121295 899731 1296563 2147424 2385263 3270861 4656830 7776445 8736032 0.34 0.49 0.82 0.92 0.03 0.02 0.09 0.06 3270861 4656830 7776445 8736032 -1154 -281 -673 -1663 3269707 4656549 7775772 8734369 9485799 94858 10871840 -293843 33227153 43900008 3270861 3270861 284574 284574 -1154 -1154 9485799 94858 10871840 -294997 36213440 46885141 9462105 94621 10545898 -295873 24131874 34476520 4656830 4656830 189242 189242 -281 -281 9462105 94621 10545898 -296154 28599462 38943827 9481799 94818 10816100 -294324 29290477 39907071 7776445 7776445 853482 853482 4000 40 55740 55780 -673 -673 9485799 94858 10871840 -294997 36213440 46885141 9442809 94428 10503171 -294491 20431156 30734264 8736032 8736032 567726 567726 15296 153 20547 20700 4000 40 22180 22220 -1663 -1663 9462105 94621 10545898 -296154 28599462 38943827 7776445 8736032 1105542 1020179 32577 88377 55780 22220 170978 213398 24450 47146 65725 690 1061 200665 126210 9070929 9343556 -871356 145840 3637494 2812905 710424 43784 3116589 2709747 267402 678139 881019 412319 1377224 411657 4956102 1549077 -4956102 -1137420 513990 381616 4989789 1556800 -1556800 853482 567726 20700 3622317 -928642 17 -602 -921449 -689440 11601152 8010420 10679703 7320980 95858 107147 2175938 2029484 71100 71100 10679703 6581944 739036 10679703 7320980 96039 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY OF ACCOUNTING POLICIES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interim reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior period data have been reclassified to conform to the current period presentation.  Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interim reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior period data have been reclassified to conform to the current period presentation.  Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INVENTORIES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s inventories at September 30, 2021 and December 31, 2020 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b>September 30,<br/> 2021</b></td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b>December 31,<br/> 2020</b></td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">7,659,240</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">5,393,961</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Finished goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">9,444,391</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">8,072,176</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, gross</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17,103,631</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,466,137</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventory reserves</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(314,831</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(290,381</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, net</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">16,788,800</td> <td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">13,175,756</td> <td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The inventory reserves shown in the table above reflect slow moving and obsolete inventory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company’s products. The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the customer’s warehouses, which are included in inventories, net, amounted to approximately $1,047,000 and $629,000 at September 30, 2021 and December 31, 2020, respectively.</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b>September 30,<br/> 2021</b></td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><b>December 31,<br/> 2020</b></td> <td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">7,659,240</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">5,393,961</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Finished goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">9,444,391</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">8,072,176</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, gross</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17,103,631</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">13,466,137</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventory reserves</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(314,831</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">(290,381</td> <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -29.7pt; padding-left: 29.7pt">Inventories, net</td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">16,788,800</td> <td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">13,175,756</td> <td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> 7659240 5393961 9444391 8072176 17103631 13466137 314831 290381 16788800 13175756 1047000 629000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPERTY, PLANT &amp; EQUIPMENT</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s property, plant and equipment at September 30, 2021 and December 31, 2020 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Estimated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Useful<br/> Life</b></p></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>December 31,<br/> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Land</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Building and improvements</td><td> </td> <td style="text-align: center">30 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,696,070</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,563,406</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing and warehouse equipment</td><td> </td> <td style="text-align: center">6-20 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,889,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,959,563</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Office equipment and furniture</td><td> </td> <td style="text-align: center">3-5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,907,868</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,880,387</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center">10-15 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">587,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">587,183</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance leases – right to use</td><td> </td> <td style="text-align: center">5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vehicles</td><td> </td> <td style="text-align: center">3 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Construction in process</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,313,064</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">464,203</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Property, plant and equipment, gross</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,795,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,856,828</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,614,570</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,754,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,180,888</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,101,962</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span>The Company’s w</span>holly owned subsidiary, Kinpak Inc. (“Kinpak”), <span>has started a 69,000 square foot expansion of its </span>manufacturing, warehouse and distribution facilities in Montgomery, AL. The expansion is expected to be completed in early 2022. For more information see our Current Report on Form 8-K filed on February 3, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span>Depreciation expense totaled $302,866 (of which $277,931 is included in cost of goods sold and $24,935 is included in selling and administrative expenses) and $273,490 (of which $248,528 is included in cost of goods sold and $24,962 is included in selling and administrative expenses) for the three months ended September 30, 2021 and 2020, respectively, and $877,176 (of which $803,302 is included in cost of goods sold and $73,874 is included in selling and administrative expenses) and $791,981 (of which $717,907 is included in cost of goods sold and $74,074 is included in selling and administrative expenses) for the nine months ended September 30, 2021 and 2020, respectively.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Estimated </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Useful<br/> Life</b></p></td><td style="text-align: center; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>December 31,<br/> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2020</b></p></td><td style="text-align: center; white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Land</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">278,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Building and improvements</td><td> </td> <td style="text-align: center">30 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,696,070</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,563,406</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing and warehouse equipment</td><td> </td> <td style="text-align: center">6-20 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,889,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,959,563</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Office equipment and furniture</td><td> </td> <td style="text-align: center">3-5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,907,868</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,880,387</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: center">10-15 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">587,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">587,183</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance leases – right to use</td><td> </td> <td style="text-align: center">5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,741</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vehicles</td><td> </td> <td style="text-align: center">3 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Construction in process</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,313,064</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">464,203</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> Property, plant and equipment, gross</td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,795,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,856,828</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,614,570</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,754,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Property, plant and equipment, net</td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,180,888</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,101,962</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> 278325 278325 P30Y 9696070 9563406 P6Y P20Y 12889187 11959563 P3Y P5Y 1907868 1880387 P10Y P15Y 587183 587183 P5Y 113741 113741 P3Y 10020 10020 4313064 464203 29795458 24856828 15614570 14754866 14180888 10101962 The Company’s wholly owned subsidiary, Kinpak Inc. (“Kinpak”), has started a 69,000 square foot expansion of its manufacturing, warehouse and distribution facilities in Montgomery, AL. 302866 277931 24935 273490 248528 24962 877176 803302 73874 791981 717907 74074 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEASES</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has one operating lease and two finance leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the operating lease, the Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by Peter G. Dornau, the Company’s Chairman, President and Chief Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a maximum annual 2% increase in subsequent years, although the entity has not raised the minimum base rent since the Company entered into a previous lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party. Operating lease expense was $24,339 and $24,521 for the three months ended September 30, 2021 and 2020, respectively, and $73,017 and $73,564 for the nine months ended September 30, 2021 and 2020, respectively.  At September 30, 2021 and December 31, 2020, the Company had a right to use asset and a corresponding liability of $204,434 and $268,920, respectively, related to the operating lease. Set forth below is a schedule of future minimum rent payments under the operating lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="5">Twelve-month period ending September 30,</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 88%; text-align: left">2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">213,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total operating lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">204,434</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s two finance leases relate to office equipment. See Note 3 for information regarding the carrying value of the Company’s finance lease right to use assets and Note 7 for information regarding the finance lease payment schedule.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenses incurred with respect to the Company’s leases during the three and nine months ended September 30, 2021 and 2020 are set forth below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three <br/> Months <br/> Ended <br/> September 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Three </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ended<br/> September 30,<br/> 2020</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,521</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance lease amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,406</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finance lease interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">361</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total lease expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,026</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,288</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine <br/> Months <br/> Ended <br/> September 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Nine </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ended<br/> September 30,<br/> 2020</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,017</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,564</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance lease amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finance lease interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,230</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">679</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total lease expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">90,080</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,181</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remaining lease term with respect to the operating lease, weighted average remaining lease term with respect to the finance leases and discount rate with respect to the operating lease and finance leases at September 30, 2021 and December 31, 2020 are set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2.25 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3.9 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3.0 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">4.6 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table> 2023-12-31 94800 0.02 24339 24521 73017 73564 204434 268920 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="5">Twelve-month period ending September 30,</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 88%; text-align: left">2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">213,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total operating lease liability</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">204,434</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 94800 94800 23700 213300 8866 204434 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three <br/> Months <br/> Ended <br/> September 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Three </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ended<br/> September 30,<br/> 2020</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,339</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,521</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance lease amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,406</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finance lease interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">385</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">361</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total lease expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,026</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,288</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine <br/> Months <br/> Ended <br/> September 30, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Nine </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Months</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ended<br/> September 30,<br/> 2020</b></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,017</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,564</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance lease amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finance lease interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,230</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">679</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total lease expense</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">90,080</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,181</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 24339 24521 5302 5406 385 361 30026 30288 73017 73564 15833 16938 1230 679 90080 91181 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2.25 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3.9 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3.0 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">4.6 years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Discount rate – operating lease</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr> </table> P2Y3M P3Y10M24D 0.037 0.018 P3Y P4Y7M6D 0.037 0.018 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTANGIBLE ASSETS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s intangible assets at September 30, 2021 and December 31, 2020 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 30, 2021</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">583,896</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">38,837</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">655,684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059,641</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">357,882</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,586</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178,941</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,293</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,457</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,922,946</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,451,814</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 31, 2020</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">544,644</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,089</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,088,912</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">270,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,256</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,127</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">133,085</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,915</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,709,461</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,665,299</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; "><span>Amortization expense related to intangible assets was $71,162 for each of the three months ended September 30, 2021 and 2020, and $213,485 and $213,486 for the nine months ended September 30, 2021 and 2020, respectively.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">583,896</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">38,837</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">655,684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,059,641</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">357,882</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">226,586</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">178,941</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113,293</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">146,543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,457</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,922,946</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,451,814</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Intangible Assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Patents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">622,733</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">544,644</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,089</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,715,325</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626,413</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,088,912</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer list</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">584,468</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">270,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,256</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Product formulas</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157,127</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Royalty rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">133,085</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,915</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total intangible assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,374,760</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,709,461</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,665,299</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 622733 583896 38837 1715325 655684 1059641 584468 357882 226586 292234 178941 113293 160000 146543 13457 3374760 1922946 1451814 622733 544644 78089 1715325 626413 1088912 584468 270212 314256 292234 135107 157127 160000 133085 26915 3374760 1709461 1665299 71162 71162 213485 213486 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REVOLVING LINE OF CREDIT</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">On August 6, 2021, the Company and Regions Bank (“the “Lender”) entered into a Business Loan Agreement (the “Business Loan Agreement”), effective as of July 30, 2021, under which the Company was provided a revolving line of credit in the amount of Six Million Dollars ($6,000,000). The Business Loan Agreement supersedes the Company’s previous $6,000,000 revolving line of credit from the Lender, entered into on August 31, 2018, that was scheduled to expire on August 31, 2021. The revolving line of credit under the Business Loan Agreement is evidenced by a promissory note and is secured principally by the Company’s inventory and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. All outstanding principal plus all accrued unpaid interest is due upon Lender’s demand or when the Business Loan Agreement expires on August 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been no negative impact in the availability of funds to the Company as a result of the COVID-19 pandemic.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2021 and December 31, 2020, the Company had no borrowings under the revolving line of credit provided by the current and former Business Loan Agreements.</p> 6000000 6000000 The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LONG TERM DEBT</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Term Loan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2021, Kinpak  and Regions Bank (the “Lender”) entered into a Credit Agreement (the “Credit Agreement”), effective as of July 20, 2021, under which the Company was extended a term loan (the “Term Loan”) in the original principal amount of Five Million Dollars ($5,000,000). The Company is using the proceeds of the Term Loan for a <span>69,000 square foot expansion of Kinpak’s </span>manufacturing, warehouse and distribution facilities in Montgomery, Alabama. The Term Loan is evidenced by a promissory note (the “Note”) and is secured by a second priority mortgage of the assets pledged in Kinpak’s industrial development bond financing obtained on September 26, 2017 (see below for further information).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has unconditionally guaranteed the payment to the Lender promptly when due, by acceleration or otherwise, of all obligations of Kinpak to the Lender.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement provides that prepayments on the Term Loan are subject to a prepayment penalty of 5% during the first year the Term Loan is outstanding, with such penalty declining 1% each year thereafter until there is no prepayment penalty after five years. However, the Lender has agreed to waive the prepayment provisions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income. The Credit Agreement also requires that the majority shareholder’s ownership does not drop below 50% of the outstanding shares of Kinpak.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement contains cross-default and cross-collateral provisions relating to any other indebtedness with the Lender, including without limitation the Company’s obligations under its $6,000,000 revolving line of credit from the Lender.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement also contains negative covenants restricting the Company’s ability to, among other things, create or assume indebtedness for borrowed money exceeding $250,000 other than trade payables incurred in the normal course of business, create liens other than permitted liens (as defined in the Credit Agreement), acquire an interest in another entity or incur any obligation as surety or guarantor other than in the ordinary course of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Industrial Development Bond Financing</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2017, Kinpak indirectly obtained a $4,500,000 loan from Regions Capital Advantage, Inc. (the “Lender”). The proceeds of the loan have been used in full as of June 30, 2021, principally to pay or reimburse costs relating to the expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, as well as the purchase and installation of associated machinery and equipment (the “Expansion Project”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Kinpak inherited the lease structure when it first acquired its facilities from its predecessor-in-interest in 1996. The Lease provides that prior to the maturity date of the Bond, Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027 in the amount of $1,799,201. The Bond provides that the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In connection with the guarantee agreement under which the Company provided its guarantee, the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. At September 30, 2021, the Company was in compliance with these financial covenants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are being amortized over the life of the Bond.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Long-Term Obligations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. If the note is prepaid in full, the entire outstanding balance of the note (including all unpaid amounts allocated to interest over the remaining term of the note) must be paid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In connection with the Company’s agreement to purchase assets of Check Corporation, the Company agreed to pay Check Corporation (dba Damp Check<sup>®</sup>) $100,000 in equal installments of approximately $4,348 over a 23-month period that commenced on January 15, 2020, with a final payment due and payable on November 15, 2021. The Company recorded $97,012 as principal, and the remaining $2,988, representing an imputed interest rate of 3.15% per annum, will be recorded as interest expense over the 23 months. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On June 22, 2020, the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2021 and December 31, 2020, the Company was obligated under lease agreements covering office equipment utilized in the Company’s operations (inclusive of the lease referenced in the preceding paragraph). The office equipment leases, aggregating approximately $84,000 and $100,000 at September 30, 2021 and December 31, 2020, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum. The office equipment leases are classified as finance leases. During the three months ended September 30, 2021 and 2020, the Company paid $5,687 ($5,302 principal and $385 interest) and $5,767 ($5,406 principal and $361 interest), respectively, and during the nine months ended September 30, 2021 and 2020, the Company paid $17,063 ($15,833 principal and $1,230 interest) and $17,617 ($16,938 principal and $679 interest), respectively, under the lease agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information regarding the Company’s long-term debt at September 30, 2021 and December 31, 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current Portion</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Long Term Portion</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left">Term loan</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">263,746</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,689,609</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Obligations related to industrial development bond financing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">272,492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">263,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,173,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,454,904</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Note payable related to Snappy Marine asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309,218</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Obligation related to Check Corporation asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment finance leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,455</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,719</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,847</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total principal of long- term debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">758,632</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">520,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,090,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,842,969</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,637</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,616</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,098</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,789</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total long- term debt</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">737,995</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">500,694</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,983,559</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,730,180</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Required principal payments under the Company’s long- term obligations are set forth below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Twelve-month period ending September 30,</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 88%; text-align: left">2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">758,632</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">740,016</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">591,431</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">609,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">610,985</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,539,141</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,849,289</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 5000000 69000 The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.  119 0.05 0.01 The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. 0.50 6000000 250000 4500000 4500000 1000 The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027 in the amount of $1,799,201. 118 In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account. the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. 196095 In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. 16667 the Company’s agreement to purchase assets of Check Corporation, the Company agreed to pay Check Corporation (dba Damp Check®) $100,000 in equal installments of approximately $4,348 over a 23-month period that commenced on January 15, 2020, with a final payment due and payable on November 15, 2021. The Company recorded $97,012 as principal, and the remaining $2,988, representing an imputed interest rate of 3.15% per annum, will be recorded as interest expense over the 23 months. the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%. The office equipment leases, aggregating approximately $84,000 and $100,000 at September 30, 2021 and December 31, 2020, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum. 84000 100000 0.0153 0.0386 5687 5302 385 5767 5406 361 17063 15833 1230 17617 16938 679 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current Portion</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Long Term Portion</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/> 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left">Term loan</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">263,746</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,689,609</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Obligations related to industrial development bond financing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">272,492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">263,881</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,173,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,454,904</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Note payable related to Snappy Marine asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188,187</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,495</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309,218</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Obligation related to Check Corporation asset acquisition</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment finance leases</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,455</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,719</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,847</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total principal of long- term debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">758,632</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">520,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,090,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,842,969</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Debt issuance costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,637</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,616</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(107,098</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,789</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total long- term debt</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">737,995</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">500,694</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,983,559</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,730,180</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 263746 4689609 272492 263881 3173834 3454904 192277 188187 164495 309218 8662 47082 21455 21160 62719 78847 758632 520310 8090657 3842969 20637 19616 107098 112789 737995 500694 7983559 3730180 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Twelve-month period ending September 30,</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 88%; text-align: left">2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">758,632</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">740,016</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">591,431</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">609,084</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">610,985</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,539,141</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,849,289</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 758632 740016 591431 609084 610985 5539141 8849289 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RELATED PARTY TRANSACTIONS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company sells products to companies affiliated with Peter G. Dornau, who is the Company’s Chairman, President and Chief Executive Officer. The affiliated companies resell, outside of the United States and Canada, products they purchase from the Company. The Company also provides administrative services to these companies and pays certain business-related expenditures for the affiliated companies, for which the Company is reimbursed. Sales to the affiliated companies aggregated approximately $588,000 and $334,000 for the three months ended September 30, 2021 and 2020, respectively, and approximately $1,644,000 and $1,366,000 for the nine months ended September 30, 2021 and 2020, respectively. Fees for administrative services aggregated approximately $161,000 and $166,000 for the three months ended September 30, 2021 and 2020, respectively, and approximately $618,000 and $646,000 for the nine months ended September 30, 2021 and 2020, respectively. Amounts billed to the affiliated companies to reimburse the Company for business related expenditures made on behalf of the affiliated companies aggregated approximately $30,000 and $28,000 during the three months ended September 30, 2021 and 2020, respectively, and approximately $93,000 and $79,000 during the nine months ended September 30, 2021 and 2020, respectively.  The Company had accounts receivable from the affiliated companies in connection with the product sales, administrative services and business- related expenditures aggregating approximately $625,000 and $1,496,000 at September 30, 2021 and December 31, 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An entity that is owned by the Company’s Chairman, President and Chief Executive Officer provides several services to the Company.  Under this arrangement, the Company paid the entity an aggregate of approximately $15,000 ($12,000 for research and development services and $3,000 for charter boat services that the Company used to provide sales incentives to customers) and $12,000 for research and development services for the three months ended September 30, 2021 and 2020, respectively, and $59,000 ($36,000 for research and development services, $17,000 for charter boat services that the Company used to provide sales incentives for customers and $6,000 for the production of television commercials ) and $47,000 ($36,000 for research and development services, $9,000 for charter boat services that the Company used to provide sales incentives for customers and $2,000 for the production of television commercials) for the nine months ended September 30, 2021 and 2020, respectively. Expenditures for the research and development services are included in the condensed consolidated statements of operations within selling and administrative expenses. Expenditures for the charter boat services are included in the condensed consolidated statements of operations within advertising and promotion expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer. See Note 4 for a description of the lease terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director of the Company is Regional Executive Vice President of an insurance broker through which the Company sources most of its insurance needs.  During the three months ended September 30, 2021 and 2020, the Company paid an aggregate of approximately $816,000 and $471,000, respectively, and during the nine months ended September 30, 2021 and 2020, the Company paid an aggregate of approximately $1,645,000 and $984,000, respectively in insurance premiums on policies obtained through the insurance broker.</p> 588000 334000 1644000 1366000 161000 166000 618000 646000 30000 28000 93000 79000 625000 1496000 15000 12000 3000 12000 59000 36000 17000 6000 47000 36000 9000 2000 816000 471000 1645000 984000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EARNINGS PER SHARE</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period. Diluted earnings per share reflect additional dilution from potential common stock issuances upon the exercise of outstanding stock options. The following table sets forth the computation of basic and diluted earnings per common share, as well as a reconciliation of the weighted average number of common shares outstanding to the weighted average number of shares outstanding on a diluted basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Earnings per common share – Basic</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Net income</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,270,861</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,656,830</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,776,445</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,736,032</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average number of common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,485,799</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,462,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,483,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,454,639</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Earnings per common share – Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Earnings per common share – Diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,270,861</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,656,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,776,445</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,736,032</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average number of common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,485,799</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,462,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,483,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,454,639</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of outstanding stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,708</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Weighted average number of common shares outstanding - Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,485,799</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,462,105</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,483,499</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,459,347</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Earnings per common share – Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.92</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company had no stock options outstanding during any of the three and nine month periods ended September 30, 2021 and 2020 that were antidilutive and therefore not included in the diluted earnings per common share calculation.</span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Earnings per common share – Basic</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Net income</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,270,861</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,656,830</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,776,445</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,736,032</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average number of common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,485,799</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,462,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,483,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,454,639</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Earnings per common share – Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.92</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Earnings per common share – Diluted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,270,861</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,656,830</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,776,445</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,736,032</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average number of common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,485,799</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,462,105</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,483,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,454,639</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of outstanding stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,708</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Weighted average number of common shares outstanding - Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,485,799</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,462,105</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,483,499</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">9,459,347</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Earnings per common share – Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.92</td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 3270861 4656830 7776445 8736032 9485799 9462105 9483499 9454639 0.34 0.49 0.82 0.92 3270861 4656830 7776445 8736032 9485799 9462105 9483499 9454639 4708 9485799 9462105 9483499 9459347 0.34 0.49 0.82 0.92 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>No stock compensation expense was incurred during each of the three months ended September 30, 2021 and 2020. </span>Stock compensation expense during the nine months ended September 30, 2021 and 2020 was $55,780 and $22,220, respectively, all of which relates to the shares of Company common stock issued to the Company’s non-employee directors as part of their compensation for service on the Board of Directors. At September 30, 2021, there were no outstanding stock options or unrecognized compensation expense related to stock<b> </b>options. </p> 0 0 55780 22220 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CASH DIVIDENDS</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s board of directors declared the following cash dividends during the nine months ended September 30, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nine months ended September 30, 2021</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="text-decoration: none"><b>Declaration Date</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="text-decoration: none"><b>Type</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Record Date</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="text-decoration: none"><b>Payment Date</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Dividends<br/> <span style="text-decoration: none">Per Share</span></b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="text-decoration: none"><b>Amount</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">February 25, 2021</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Quarterly</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">March 11, 2021</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">March 25, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">0.03</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">284,454</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">May 21, 2021</td> <td> </td> <td style="text-align: center">Quarterly</td> <td> </td> <td style="text-align: center">June 4, 2021</td> <td> </td> <td style="text-align: center">June 18, 2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.03</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">284,454</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">August 26, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">Quarterly</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 9, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 23, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">0.03</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">284,574</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-67">Total</div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-68"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-69"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-70"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">0.09</td> <td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">853,482</td> <td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nine months ended September 30, 2020</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="text-decoration: none"><b>Declaration Date</b></span></td> <td style="text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Type</b></span></td> <td style="text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Record Date</b></span></td> <td style="text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Payment Date</b></span></td> <td style="text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Dividends<br/> <span style="text-decoration: none">Per Share</span></b></td> <td style="text-align: center"><b> </b></td> <td style="text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Amount</b></span></td> <td style="text-align: center"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">May 26, 2020</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Special</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">June 9, 2020</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">June 23, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">0.02</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">189,242</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">May 26, 2020</td> <td> </td> <td style="text-align: center">Quarterly</td> <td> </td> <td style="text-align: center">June 9, 2020</td> <td> </td> <td style="text-align: center">June 23, 2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.02</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">189,242</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">August 26, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">Quarterly</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 9, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 23, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">0.02</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">189,242</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-71">Total</div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-72"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-73"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-74"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">0.06</td> <td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">567,726</td> <td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="text-decoration: none"><b>Declaration Date</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="text-decoration: none"><b>Type</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Record Date</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="text-decoration: none"><b>Payment Date</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Dividends<br/> <span style="text-decoration: none">Per Share</span></b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="text-decoration: none"><b>Amount</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">February 25, 2021</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Quarterly</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">March 11, 2021</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">March 25, 2021</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">0.03</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">284,454</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">May 21, 2021</td> <td> </td> <td style="text-align: center">Quarterly</td> <td> </td> <td style="text-align: center">June 4, 2021</td> <td> </td> <td style="text-align: center">June 18, 2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.03</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">284,454</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">August 26, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">Quarterly</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 9, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 23, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">0.03</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">284,574</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-67">Total</div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-68"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-69"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-70"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">0.09</td> <td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">853,482</td> <td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="text-decoration: none"><b>Declaration Date</b></span></td> <td style="text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Type</b></span></td> <td style="text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Record Date</b></span></td> <td style="text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Payment Date</b></span></td> <td style="text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Dividends<br/> <span style="text-decoration: none">Per Share</span></b></td> <td style="text-align: center"><b> </b></td> <td style="text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="text-decoration: none"><b>Amount</b></span></td> <td style="text-align: center"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">May 26, 2020</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Special</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">June 9, 2020</td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: center">June 23, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">0.02</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">189,242</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">May 26, 2020</td> <td> </td> <td style="text-align: center">Quarterly</td> <td> </td> <td style="text-align: center">June 9, 2020</td> <td> </td> <td style="text-align: center">June 23, 2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.02</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">189,242</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">August 26, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">Quarterly</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 9, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">September 23, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">0.02</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">189,242</td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-71">Total</div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-72"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-73"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-74"> </div></td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">0.06</td> <td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">567,726</td> <td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 2021-02-25 Quarterly 2021-03-11 2021-03-25 0.03 284454 2021-05-21 Quarterly 2021-06-04 2021-06-18 0.03 284454 2021-08-26 Quarterly 2021-09-09 2021-09-23 0.03 284574 0.09 853482 2020-05-26 Special 2020-06-09 2020-06-23 0.02 189242 2020-05-26 Quarterly 2020-06-09 2020-06-23 0.02 189242 2020-08-26 Quarterly 2020-09-09 2020-09-23 0.02 189242 0.06 567726 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CUSTOMER CONCENTRATION</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">During the three months ended September 30, 2021 and 2020, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. Net sales to these three customers respectively represented approximately 44.3% (22.0%, 12.3% and 10.0%) and 45.0% (17.8%, 13.8% and 13.4.%) of the Company’s net sales, respectively, for the three months ended September 30, 2021 and 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">During the nine months ended September 30, 2021, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. Net sales to these three customers represented approximately 45.1% (17.8%, 14.6% and 12.7%) of the Company’s net sales for the nine months ended September 30, 2021. During the nine months ended September 30, 2020, the Company had net sales to each of two customers that constituted in excess of 10% of its net sales. Net sales to these two customers represented approximately 32.8% (17.4% and 15.4%) of the Company’s net sales for the nine months ended September 30, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2021, four customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 63.9% (18.7%, 16.9%, 15.2% and 13.1%) of the Company’s gross trade accounts receivable at September 30, 2021. At December 31, 2020, three customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 63.6% (28.8%, 21.1%, and 13.7%) of the Company’s gross trade accounts receivable at December 31, 2020.</p> During the three months ended September 30, 2021 and 2020, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. During the three months ended September 30, 2021 and 2020, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. 0.443 0.22 0.123 0.10 0.45 0.178 0.138 0.134 During the nine months ended September 30, 2021, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. 0.451 0.178 0.146 0.127 0.328 0.174 0.154 At September 30, 2021, four customers constituted at least 10% of the Company’s gross trade accounts receivable. 0.639 0.187 0.169 0.152 0.131 0.636 0.288 0.211 0.137 OCEAN BIO CHEM INC false 954 --12-31 Q3 0000350737 587-6280 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2021
Nov. 11, 2021
Document Information Line Items    
Entity Registrant Name OCEAN BIO CHEM INC  
Trading Symbol OBCI  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   9,485,799
Amendment Flag false  
Entity Central Index Key 0000350737  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Sep. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 0-11102  
Entity Incorporation, State or Country Code FL  
Entity Tax Identification Number 59-1564329  
Entity Address, Address Line One 4041 SW  
Entity Address, Address Line Two 47 Avenue  
Entity Address, City or Town Fort Lauderdale,  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33314  
Title of 12(b) Security Common Stock, $0.01 par value  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
City Area Code 954  
Local Phone Number 587-6280  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current Assets:    
Cash $ 10,679,703 $ 11,123,726
Trade accounts receivable less allowances of approximately $492,000 and $326,000, respectively 17,226,890 8,326,939
Receivables due from affiliated companies 624,748 1,496,104
Restricted cash 477,426
Inventories, net 16,788,800 13,175,756
Prepaid expenses and other current assets 1,970,210 1,259,786
Total Current Assets 47,290,351 35,859,737
Property, plant and equipment, net 14,180,888 10,101,962
Operating lease – right to use 204,434 268,920
Intangible assets, net 1,451,814 1,665,299
Total Assets 63,127,487 47,895,918
Current Liabilities:    
Current portion of long-term debt, net 737,995 500,694
Current portion of operating lease liability 88,783 86,377
Accounts payable – trade 5,082,599 1,966,010
Accrued expenses payable 1,820,964 1,142,825
Total Current Liabilities 7,730,341 3,695,906
Deferred tax liability 412,795 380,218
Operating lease liability, less current portion 115,651 182,543
Long-term debt, less current portion and debt issuance costs 7,983,559 3,730,180
Total Liabilities 16,242,346 7,988,847
COMMITMENTS AND CONTINGENCIES
Common stock - $.01 par value, 12,000,000 shares authorized; 9,485,799 and 9,481,799 shares issued and outstanding 94,858 94,818
Additional paid in capital 10,871,840 10,816,100
Accumulated other comprehensive loss (294,997) (294,324)
Retained earnings 36,213,440 29,290,477
Total Shareholders’ Equity 46,885,141 39,907,071
Total Liabilities and Shareholders’ Equity $ 63,127,487 $ 47,895,918
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Trade accounts receivable allowance for doubtful accounts (in Dollars) $ 492,000 $ 326,000
Common stock, par value (in Dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 12,000,000 12,000,000
Common stock, shares issued 9,485,799 9,481,799
Common stock, shares outstanding 9,485,799 9,481,799
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Net sales $ 21,483,054 $ 19,161,372 $ 50,303,263 $ 42,682,497
Cost of goods sold 14,028,573 10,414,131 30,195,629 23,085,473
Gross profit 7,454,481 8,747,241 20,107,634 19,597,024
Operating Expenses:        
Advertising and promotion 955,812 723,446 3,163,209 2,265,382
Selling and administrative 2,292,301 2,030,787 6,906,770 6,242,862
Total operating expenses 3,248,113 2,754,233 10,069,979 8,508,244
Operating income 4,206,368 5,993,008 10,037,655 11,088,780
Other (expense) income        
Interest (expense), net (35,776) (39,615) (113,786) (93,695)
Gain on insurance settlement 126,210
Income before income taxes 4,170,592 5,953,393 9,923,869 11,121,295
Provision for income taxes (899,731) (1,296,563) (2,147,424) (2,385,263)
Net income $ 3,270,861 $ 4,656,830 $ 7,776,445 $ 8,736,032
Earnings per common share – basic and diluted (in Dollars per share) $ 0.34 $ 0.49 $ 0.82 $ 0.92
Dividends declared per common share (in Dollars per share) $ 0.03 $ 0.02 $ 0.09 $ 0.06
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net income $ 3,270,861 $ 4,656,830 $ 7,776,445 $ 8,736,032
Foreign currency translation adjustment (1,154) (281) (673) (1,663)
Comprehensive income $ 3,269,707 $ 4,656,549 $ 7,775,772 $ 8,734,369
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) - USD ($)
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive Loss
Retained Earnings
Total
Balance at Dec. 31, 2019 $ 94,428 $ 10,503,171 $ (294,491) $ 20,431,156 $ 30,734,264
Balance (in Shares) at Dec. 31, 2019 9,442,809        
Net income 8,736,032 8,736,032
Dividends, common stock (567,726) (567,726)
Options exercised $ 153 20,547 20,700
Options exercised (in Shares) 15,296        
Stock based compensation $ 40 22,180 22,220
Stock based compensation (in Shares) 4,000        
Foreign currency translation adjustment (1,663) (1,663)
Balance at Sep. 30, 2020 $ 94,621 10,545,898 (296,154) 28,599,462 38,943,827
Balance (in Shares) at Sep. 30, 2020 9,462,105        
Balance at Jun. 30, 2020 $ 94,621 10,545,898 (295,873) 24,131,874 34,476,520
Balance (in Shares) at Jun. 30, 2020 9,462,105        
Net income 4,656,830 4,656,830
Dividends, common stock (189,242) (189,242)
Foreign currency translation adjustment (281) (281)
Balance at Sep. 30, 2020 $ 94,621 10,545,898 (296,154) 28,599,462 38,943,827
Balance (in Shares) at Sep. 30, 2020 9,462,105        
Balance at Dec. 31, 2020 $ 94,818 10,816,100 (294,324) 29,290,477 39,907,071
Balance (in Shares) at Dec. 31, 2020 9,481,799        
Net income 7,776,445 7,776,445
Dividends, common stock (853,482) (853,482)
Stock based compensation $ 40 55,740 55,780
Stock based compensation (in Shares) 4,000        
Foreign currency translation adjustment (673) (673)
Balance at Sep. 30, 2021 $ 94,858 10,871,840 (294,997) 36,213,440 46,885,141
Balance (in Shares) at Sep. 30, 2021 9,485,799        
Balance at Jun. 30, 2021 $ 94,858 10,871,840 (293,843) 33,227,153 43,900,008
Balance (in Shares) at Jun. 30, 2021 9,485,799        
Net income 3,270,861 3,270,861
Dividends, common stock (284,574) (284,574)
Foreign currency translation adjustment (1,154) (1,154)
Balance at Sep. 30, 2021 $ 94,858 $ 10,871,840 $ (294,997) $ 36,213,440 $ 46,885,141
Balance (in Shares) at Sep. 30, 2021 9,485,799        
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net income $ 7,776,445 $ 8,736,032
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,105,542 1,020,179
Deferred income taxes 32,577 88,377
Stock based compensation 55,780 22,220
Provision for bad debts 170,978 213,398
Provision for slow moving and obsolete inventory 24,450 47,146
Impairment of equipment 65,725
Other operating non-cash items (690) (1,061)
Cash used related to 2019 chemical incident (200,665)
Gain on insurance settlement (126,210)
Changes in assets and liabilities:    
Trade accounts receivable (9,070,929) (9,343,556)
Receivables due from affiliated companies 871,356 (145,840)
Inventories (3,637,494) (2,812,905)
Prepaid expenses and other current assets (710,424) (43,784)
Accounts payable – trade 3,116,589 2,709,747
Income taxes payable 267,402
Accrued expenses payable 678,139 881,019
Net cash provided by operating activities 412,319 1,377,224
Cash flows from investing activities:    
Insurance proceeds received for damaged machinery and equipment 411,657
Purchases of property, plant and equipment (4,956,102) (1,549,077)
Net cash used in investing activities (4,956,102) (1,137,420)
Cash flows from financing activities:    
Payments on long-term debt (513,990) (381,616)
Proceeds from term loan 4,989,789
Proceeds from CARES Act note 1,556,800
Repayment of CARES Act note (1,556,800)
Dividends paid to common shareholders (853,482) (567,726)
Proceeds from exercise of stock options 20,700
Net cash provided by (used in) financing activities 3,622,317 (928,642)
Effect of exchange rate on cash 17 (602)
Net decrease in cash and restricted cash (921,449) (689,440)
Cash and restricted cash at beginning of period 11,601,152 8,010,420
Cash and restricted cash at end of period 10,679,703 7,320,980
Supplemental disclosure of cash flow information:    
Cash paid for interest during period excluding capitalized interest 95,858 107,147
Cash paid for income taxes during period 2,175,938 2,029,484
Cash paid under operating lease 71,100 71,100
Cash 10,679,703 6,581,944
Restricted cash 739,036
Total cash and restricted cash 10,679,703 7,320,980
Noncash lease activities:    
Finance lease right to use assets exchanged for finance lease liabilities $ 96,039
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF ACCOUNTING POLICIES
1.SUMMARY OF ACCOUNTING POLICIES

 

Interim reporting

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior period data have been reclassified to conform to the current period presentation.  Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.

 

The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

 

The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021.

 

The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

 

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories
9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
INVENTORIES
2.INVENTORIES

 

The Company’s inventories at September 30, 2021 and December 31, 2020 consisted of the following:

 

    September 30,
2021
    December 31,
2020
 
Raw materials   $ 7,659,240     $ 5,393,961  
Finished goods     9,444,391       8,072,176  
Inventories, gross     17,103,631       13,466,137  
                 
Inventory reserves     (314,831 )     (290,381 )
                 
Inventories, net   $ 16,788,800     $ 13,175,756  

 

The inventory reserves shown in the table above reflect slow moving and obsolete inventory.

 

The Company operates a vendor managed inventory program with one of its customers to improve the promotion of the Company’s products. The Company manages the inventory levels at this customer’s warehouses and recognizes revenue as the products are sold by the customer. The inventories managed at the customer’s warehouses, which are included in inventories, net, amounted to approximately $1,047,000 and $629,000 at September 30, 2021 and December 31, 2020, respectively.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant & Equipment
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT & EQUIPMENT
3.PROPERTY, PLANT & EQUIPMENT

 

The Company’s property, plant and equipment at September 30, 2021 and December 31, 2020 consisted of the following:

 

  

Estimated

Useful
Life

  September 30,
2021
  

December 31,

2020

 
            
Land     $278,325   $278,325 
Building and improvements  30 years   9,696,070    9,563,406 
Manufacturing and warehouse equipment  6-20 years   12,889,187    11,959,563 
Office equipment and furniture  3-5 years   1,907,868    1,880,387 
Leasehold improvements  10-15 years   587,183    587,183 
Finance leases – right to use  5 years   113,741    113,741 
Vehicles  3 years   10,020    10,020 
Construction in process      4,313,064    464,203 
 Property, plant and equipment, gross      29,795,458    24,856,828 
              
Less accumulated depreciation      (15,614,570)   (14,754,866)
              
Property, plant and equipment, net     $14,180,888   $10,101,962 

 

The Company’s wholly owned subsidiary, Kinpak Inc. (“Kinpak”), has started a 69,000 square foot expansion of its manufacturing, warehouse and distribution facilities in Montgomery, AL. The expansion is expected to be completed in early 2022. For more information see our Current Report on Form 8-K filed on February 3, 2021.

 

Depreciation expense totaled $302,866 (of which $277,931 is included in cost of goods sold and $24,935 is included in selling and administrative expenses) and $273,490 (of which $248,528 is included in cost of goods sold and $24,962 is included in selling and administrative expenses) for the three months ended September 30, 2021 and 2020, respectively, and $877,176 (of which $803,302 is included in cost of goods sold and $73,874 is included in selling and administrative expenses) and $791,981 (of which $717,907 is included in cost of goods sold and $74,074 is included in selling and administrative expenses) for the nine months ended September 30, 2021 and 2020, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Leases
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
LEASES
4.LEASES

 

The Company has one operating lease and two finance leases.

 

Under the operating lease, the Company leases its executive offices and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by Peter G. Dornau, the Company’s Chairman, President and Chief Executive Officer. The lease, as extended, expires on December 31, 2023. The lease requires an annual minimum base rent of $94,800 and provides for a maximum annual 2% increase in subsequent years, although the entity has not raised the minimum base rent since the Company entered into a previous lease agreement in 1998. Additionally, the leasing entity is entitled to reimbursement of all taxes, assessments, and any other expenses that arise from ownership. Each of the parties to the lease has agreed to review the terms of the lease every three years at the request of the other party. Operating lease expense was $24,339 and $24,521 for the three months ended September 30, 2021 and 2020, respectively, and $73,017 and $73,564 for the nine months ended September 30, 2021 and 2020, respectively.  At September 30, 2021 and December 31, 2020, the Company had a right to use asset and a corresponding liability of $204,434 and $268,920, respectively, related to the operating lease. Set forth below is a schedule of future minimum rent payments under the operating lease.

 

Twelve-month period ending September 30,
2022  $94,800 
2023   94,800 
2024   23,700 
Total future minimum lease payments   213,300 
Less imputed interest   (8,866)
Total operating lease liability  $204,434 

 

The Company’s two finance leases relate to office equipment. See Note 3 for information regarding the carrying value of the Company’s finance lease right to use assets and Note 7 for information regarding the finance lease payment schedule.

 

Expenses incurred with respect to the Company’s leases during the three and nine months ended September 30, 2021 and 2020 are set forth below.

 

   Three
Months
Ended
September 30,
2021
  

Three

Months

Ended
September 30,
2020

 
Operating lease expense  $24,339   $24,521 
Finance lease amortization   5,302    5,406 
Finance lease interest   385    361 
Total lease expense  $30,026   $30,288 

 

   Nine
Months
Ended
September 30,
2021
  

Nine

Months

Ended
September 30,
2020

 
Operating lease expense  $73,017   $73,564 
Finance lease amortization   15,833    16,938 
Finance lease interest   1,230    679 
Total lease expense  $90,080   $91,181 

 

The remaining lease term with respect to the operating lease, weighted average remaining lease term with respect to the finance leases and discount rate with respect to the operating lease and finance leases at September 30, 2021 and December 31, 2020 are set forth below:

 

   September 30,
2021
 
Remaining lease term – operating lease   2.25 years 
Weighted average remaining lease term – finance leases   3.9 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

   December 31,
2020
 
Remaining lease term – operating lease   3.0 years 
Weighted average remaining lease term – finance leases   4.6 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS
5.INTANGIBLE ASSETS

 

The Company’s intangible assets at September 30, 2021 and December 31, 2020 consisted of the following:

 

September 30, 2021

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $583,896   $38,837 
Trade names and trademarks   1,715,325    655,684    1,059,641 
Customer list   584,468    357,882    226,586 
Product formulas   292,234    178,941    113,293 
Royalty rights   160,000    146,543    13,457 
Total intangible assets  $3,374,760   $1,922,946   $1,451,814 

 

December 31, 2020

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $544,644   $78,089 
Trade names and trademarks   1,715,325    626,413    1,088,912 
Customer list   584,468    270,212    314,256 
Product formulas   292,234    135,107    157,127 
Royalty rights   160,000    133,085    26,915 
Total intangible assets  $3,374,760   $1,709,461   $1,665,299 

 

Amortization expense related to intangible assets was $71,162 for each of the three months ended September 30, 2021 and 2020, and $213,485 and $213,486 for the nine months ended September 30, 2021 and 2020, respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Revolving Line of Credit
9 Months Ended
Sep. 30, 2021
Revolving Line of Credit [Abstract]  
REVOLVING LINE OF CREDIT
6.REVOLVING LINE OF CREDIT

 

On August 6, 2021, the Company and Regions Bank (“the “Lender”) entered into a Business Loan Agreement (the “Business Loan Agreement”), effective as of July 30, 2021, under which the Company was provided a revolving line of credit in the amount of Six Million Dollars ($6,000,000). The Business Loan Agreement supersedes the Company’s previous $6,000,000 revolving line of credit from the Lender, entered into on August 31, 2018, that was scheduled to expire on August 31, 2021. The revolving line of credit under the Business Loan Agreement is evidenced by a promissory note and is secured principally by the Company’s inventory and accounts receivable.

 

The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis. All outstanding principal plus all accrued unpaid interest is due upon Lender’s demand or when the Business Loan Agreement expires on August 30, 2024.

 

There has been no negative impact in the availability of funds to the Company as a result of the COVID-19 pandemic.

 

At September 30, 2021 and December 31, 2020, the Company had no borrowings under the revolving line of credit provided by the current and former Business Loan Agreements.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Long Term Debt
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
LONG TERM DEBT
7.LONG TERM DEBT

 

Term Loan

 

On July 30, 2021, Kinpak  and Regions Bank (the “Lender”) entered into a Credit Agreement (the “Credit Agreement”), effective as of July 20, 2021, under which the Company was extended a term loan (the “Term Loan”) in the original principal amount of Five Million Dollars ($5,000,000). The Company is using the proceeds of the Term Loan for a 69,000 square foot expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama. The Term Loan is evidenced by a promissory note (the “Note”) and is secured by a second priority mortgage of the assets pledged in Kinpak’s industrial development bond financing obtained on September 26, 2017 (see below for further information).

 

The Company has unconditionally guaranteed the payment to the Lender promptly when due, by acceleration or otherwise, of all obligations of Kinpak to the Lender.

 

The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.

 

The Credit Agreement provides that prepayments on the Term Loan are subject to a prepayment penalty of 5% during the first year the Term Loan is outstanding, with such penalty declining 1% each year thereafter until there is no prepayment penalty after five years. However, the Lender has agreed to waive the prepayment provisions.

 

The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income. The Credit Agreement also requires that the majority shareholder’s ownership does not drop below 50% of the outstanding shares of Kinpak.

 

The Credit Agreement contains cross-default and cross-collateral provisions relating to any other indebtedness with the Lender, including without limitation the Company’s obligations under its $6,000,000 revolving line of credit from the Lender.

 

The Credit Agreement also contains negative covenants restricting the Company’s ability to, among other things, create or assume indebtedness for borrowed money exceeding $250,000 other than trade payables incurred in the normal course of business, create liens other than permitted liens (as defined in the Credit Agreement), acquire an interest in another entity or incur any obligation as surety or guarantor other than in the ordinary course of business.

 

Industrial Development Bond Financing

 

On September 26, 2017, Kinpak indirectly obtained a $4,500,000 loan from Regions Capital Advantage, Inc. (the “Lender”). The proceeds of the loan have been used in full as of June 30, 2021, principally to pay or reimburse costs relating to the expansion of Kinpak’s manufacturing, warehouse and distribution facilities in Montgomery, Alabama, as well as the purchase and installation of associated machinery and equipment (the “Expansion Project”).

 

The loan was funded by the Lender’s purchase of a $4,500,000 industrial development bond (the “Bond”) issued by The Industrial Development Board of the City of Montgomery, Alabama (the “IDB”). The Bond is a limited obligation of the IDB and is payable solely out of revenues and receipts derived from the leasing or sale of Kinpak’s facilities. In this regard, Kinpak is obligated to fund the IDB’s payment obligations by providing rental payments under a lease between the IDB and Kinpak (the “Lease”), under which Kinpak leases its facilities from the IDB. Kinpak inherited the lease structure when it first acquired its facilities from its predecessor-in-interest in 1996. The Lease provides that prior to the maturity date of the Bond, Kinpak may repurchase the facilities for $1,000 if the Bond has been redeemed or fully paid.

 

The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027 in the amount of $1,799,201. The Bond provides that the interest rate will be subject to adjustment if it is determined by the United States Treasury Department, the Internal Revenue Service, or a similar government entity that the interest on the Bond is includable in the gross income of the Lender for federal income tax purposes.

 

Under the Lease, Kinpak is required to make rental payments for the account of the IDB to the Lender in such amounts and at such times as are necessary to enable the payment of all principal and interest due on the Bond and other charges, if any, payable in respect of the Bond. The Lease also provides that Kinpak may redeem the Bond, in whole or in part, by prepaying its rental payment obligations in an amount sufficient to effect the redemption. In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.

 

Payment of amounts due and payable under the Bond and other related agreements are guaranteed by the Company and its other consolidated subsidiaries. In connection with the guarantee agreement under which the Company provided its guarantee, the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures. At September 30, 2021, the Company was in compliance with these financial covenants.

 

The Company incurred debt financing costs of $196,095 in connection with the financing. These costs are shown as a reduction of the debt balance and are being amortized over the life of the Bond.

 

Other Long-Term Obligations

 

In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note). The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023. If the note is prepaid in full, the entire outstanding balance of the note (including all unpaid amounts allocated to interest over the remaining term of the note) must be paid.

 

In connection with the Company’s agreement to purchase assets of Check Corporation, the Company agreed to pay Check Corporation (dba Damp Check®) $100,000 in equal installments of approximately $4,348 over a 23-month period that commenced on January 15, 2020, with a final payment due and payable on November 15, 2021. The Company recorded $97,012 as principal, and the remaining $2,988, representing an imputed interest rate of 3.15% per annum, will be recorded as interest expense over the 23 months. 

 

On June 22, 2020, the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%.

 

At September 30, 2021 and December 31, 2020, the Company was obligated under lease agreements covering office equipment utilized in the Company’s operations (inclusive of the lease referenced in the preceding paragraph). The office equipment leases, aggregating approximately $84,000 and $100,000 at September 30, 2021 and December 31, 2020, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum. The office equipment leases are classified as finance leases. During the three months ended September 30, 2021 and 2020, the Company paid $5,687 ($5,302 principal and $385 interest) and $5,767 ($5,406 principal and $361 interest), respectively, and during the nine months ended September 30, 2021 and 2020, the Company paid $17,063 ($15,833 principal and $1,230 interest) and $17,617 ($16,938 principal and $679 interest), respectively, under the lease agreements.

 

The following table provides information regarding the Company’s long-term debt at September 30, 2021 and December 31, 2020:

 

   Current Portion   Long Term Portion 
   September 30,
2021
   December 31,
2020
   September 30,
2021
   December 31,
2020
 
Term loan  $263,746   $
-
   $4,689,609   $
-
 
Obligations related to industrial development bond financing   272,492   $263,881   $3,173,834   $3,454,904 
Note payable related to Snappy Marine asset acquisition   192,277    188,187    164,495    309,218 
Obligation related to Check Corporation asset acquisition   8,662    47,082    
-
    
-
 
Office equipment finance leases   21,455    21,160    62,719    78,847 
Total principal of long- term debt   758,632    520,310    8,090,657    3,842,969 
Debt issuance costs   (20,637)   (19,616)   (107,098)   (112,789)
Total long- term debt  $737,995   $500,694   $7,983,559   $3,730,180 

 

Required principal payments under the Company’s long- term obligations are set forth below:

 

Twelve-month period ending September 30,    
2022  $758,632 
2023   740,016 
2024   591,431 
2025   609,084 
2026   610,985 
Thereafter   5,539,141 
Total  $8,849,289 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
8.RELATED PARTY TRANSACTIONS

 

The Company sells products to companies affiliated with Peter G. Dornau, who is the Company’s Chairman, President and Chief Executive Officer. The affiliated companies resell, outside of the United States and Canada, products they purchase from the Company. The Company also provides administrative services to these companies and pays certain business-related expenditures for the affiliated companies, for which the Company is reimbursed. Sales to the affiliated companies aggregated approximately $588,000 and $334,000 for the three months ended September 30, 2021 and 2020, respectively, and approximately $1,644,000 and $1,366,000 for the nine months ended September 30, 2021 and 2020, respectively. Fees for administrative services aggregated approximately $161,000 and $166,000 for the three months ended September 30, 2021 and 2020, respectively, and approximately $618,000 and $646,000 for the nine months ended September 30, 2021 and 2020, respectively. Amounts billed to the affiliated companies to reimburse the Company for business related expenditures made on behalf of the affiliated companies aggregated approximately $30,000 and $28,000 during the three months ended September 30, 2021 and 2020, respectively, and approximately $93,000 and $79,000 during the nine months ended September 30, 2021 and 2020, respectively.  The Company had accounts receivable from the affiliated companies in connection with the product sales, administrative services and business- related expenditures aggregating approximately $625,000 and $1,496,000 at September 30, 2021 and December 31, 2020, respectively.

 

An entity that is owned by the Company’s Chairman, President and Chief Executive Officer provides several services to the Company.  Under this arrangement, the Company paid the entity an aggregate of approximately $15,000 ($12,000 for research and development services and $3,000 for charter boat services that the Company used to provide sales incentives to customers) and $12,000 for research and development services for the three months ended September 30, 2021 and 2020, respectively, and $59,000 ($36,000 for research and development services, $17,000 for charter boat services that the Company used to provide sales incentives for customers and $6,000 for the production of television commercials ) and $47,000 ($36,000 for research and development services, $9,000 for charter boat services that the Company used to provide sales incentives for customers and $2,000 for the production of television commercials) for the nine months ended September 30, 2021 and 2020, respectively. Expenditures for the research and development services are included in the condensed consolidated statements of operations within selling and administrative expenses. Expenditures for the charter boat services are included in the condensed consolidated statements of operations within advertising and promotion expenses.

 

The Company leases office and warehouse facilities in Fort Lauderdale, Florida from an entity controlled by its Chairman, President and Chief Executive Officer. See Note 4 for a description of the lease terms.

 

A director of the Company is Regional Executive Vice President of an insurance broker through which the Company sources most of its insurance needs.  During the three months ended September 30, 2021 and 2020, the Company paid an aggregate of approximately $816,000 and $471,000, respectively, and during the nine months ended September 30, 2021 and 2020, the Company paid an aggregate of approximately $1,645,000 and $984,000, respectively in insurance premiums on policies obtained through the insurance broker.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
9.EARNINGS PER SHARE

 

Basic earnings per share are calculated by dividing net income by the weighted average number of shares outstanding during the reporting period. Diluted earnings per share reflect additional dilution from potential common stock issuances upon the exercise of outstanding stock options. The following table sets forth the computation of basic and diluted earnings per common share, as well as a reconciliation of the weighted average number of common shares outstanding to the weighted average number of shares outstanding on a diluted basis.

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2021   2020   2021   2020 
Earnings per common share – Basic                
                 
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
                     
Weighted average number of common shares outstanding   9,485,799    9,462,105    9,483,499    9,454,639 
                     
Earnings per common share – Basic  $0.34   $0.49   $0.82   $0.92 
                     
Earnings per common share – Diluted                    
                     
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
                     
Weighted average number of common shares outstanding   9,485,799    9,462,105    9,483,499    9,454,639 
                     
Dilutive effect of outstanding stock options   
-
    
-
    
-
    4,708 
                     
Weighted average number of common shares outstanding - Diluted   9,485,799    9,462,105    9,483,499    9,459,347 
                     
Earnings per common share – Diluted  $0.34   $0.49   $0.82   $0.92 

 

The Company had no stock options outstanding during any of the three and nine month periods ended September 30, 2021 and 2020 that were antidilutive and therefore not included in the diluted earnings per common share calculation. 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Securities Authorized for Issuance Under Equity Compensation Plans
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS
10.SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

 

No stock compensation expense was incurred during each of the three months ended September 30, 2021 and 2020. Stock compensation expense during the nine months ended September 30, 2021 and 2020 was $55,780 and $22,220, respectively, all of which relates to the shares of Company common stock issued to the Company’s non-employee directors as part of their compensation for service on the Board of Directors. At September 30, 2021, there were no outstanding stock options or unrecognized compensation expense related to stock options. 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Cash Dividends
9 Months Ended
Sep. 30, 2021
Cash Dividends [Abstract]  
CASH DIVIDENDS
11.CASH DIVIDENDS

 

The Company’s board of directors declared the following cash dividends during the nine months ended September 30, 2021 and 2020:

 

Nine months ended September 30, 2021

 

Declaration Date   Type   Record Date   Payment Date   Dividends
Per Share
    Amount  
February 25, 2021   Quarterly   March 11, 2021   March 25, 2021   $ 0.03     $ 284,454  
May 21, 2021   Quarterly   June 4, 2021   June 18, 2021     0.03       284,454  
August 26, 2021   Quarterly   September 9, 2021   September 23, 2021     0.03       284,574  
Total
 
 
 
 
 
 
  $ 0.09     $ 853,482  

 

Nine months ended September 30, 2020

 

Declaration Date   Type   Record Date   Payment Date   Dividends
Per Share
    Amount  
May 26, 2020   Special   June 9, 2020   June 23, 2020   $ 0.02     $ 189,242  
May 26, 2020   Quarterly   June 9, 2020   June 23, 2020     0.02       189,242  
August 26, 2020   Quarterly   September 9, 2020   September 23, 2020     0.02       189,242  
Total
 
 
 
 
 
 
  $ 0.06     $ 567,726  
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Customer Concentration
9 Months Ended
Sep. 30, 2021
Risks and Uncertainties [Abstract]  
CUSTOMER CONCENTRATION
12.CUSTOMER CONCENTRATION

 

During the three months ended September 30, 2021 and 2020, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. Net sales to these three customers respectively represented approximately 44.3% (22.0%, 12.3% and 10.0%) and 45.0% (17.8%, 13.8% and 13.4.%) of the Company’s net sales, respectively, for the three months ended September 30, 2021 and 2020.

 

During the nine months ended September 30, 2021, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. Net sales to these three customers represented approximately 45.1% (17.8%, 14.6% and 12.7%) of the Company’s net sales for the nine months ended September 30, 2021. During the nine months ended September 30, 2020, the Company had net sales to each of two customers that constituted in excess of 10% of its net sales. Net sales to these two customers represented approximately 32.8% (17.4% and 15.4%) of the Company’s net sales for the nine months ended September 30, 2020.

 

At September 30, 2021, four customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 63.9% (18.7%, 16.9%, 15.2% and 13.1%) of the Company’s gross trade accounts receivable at September 30, 2021. At December 31, 2020, three customers constituted at least 10% of the Company’s gross trade accounts receivable. The gross trade accounts receivable balances for these customers represented approximately 63.6% (28.8%, 21.1%, and 13.7%) of the Company’s gross trade accounts receivable at December 31, 2020.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Accounting Policies, by Policy (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Interim reporting

Interim reporting

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior period data have been reclassified to conform to the current period presentation.  Unless the context indicates otherwise, the term “Company” refers to Ocean Bio-Chem, Inc. and its subsidiaries.

 

The unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Securities and Exchange Commission Regulation S-X.  Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

 

The financial information furnished herein reflects all adjustments, consisting of normal recurring items that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the interim periods. The results of operations for the three months and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021.

 

The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

 

Use of estimates

Use of estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Tables)
9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Schedule of inventories
    September 30,
2021
    December 31,
2020
 
Raw materials   $ 7,659,240     $ 5,393,961  
Finished goods     9,444,391       8,072,176  
Inventories, gross     17,103,631       13,466,137  
                 
Inventory reserves     (314,831 )     (290,381 )
                 
Inventories, net   $ 16,788,800     $ 13,175,756  

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant & Equipment (Tables)
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Schedule of property, plant and equipment
  

Estimated

Useful
Life

  September 30,
2021
  

December 31,

2020

 
            
Land     $278,325   $278,325 
Building and improvements  30 years   9,696,070    9,563,406 
Manufacturing and warehouse equipment  6-20 years   12,889,187    11,959,563 
Office equipment and furniture  3-5 years   1,907,868    1,880,387 
Leasehold improvements  10-15 years   587,183    587,183 
Finance leases – right to use  5 years   113,741    113,741 
Vehicles  3 years   10,020    10,020 
Construction in process      4,313,064    464,203 
 Property, plant and equipment, gross      29,795,458    24,856,828 
              
Less accumulated depreciation      (15,614,570)   (14,754,866)
              
Property, plant and equipment, net     $14,180,888   $10,101,962 

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Tables)
9 Months Ended
Sep. 30, 2021
Leases Disclosure [Abstract]  
Schedule of future minimum rent payments
Twelve-month period ending September 30,
2022  $94,800 
2023   94,800 
2024   23,700 
Total future minimum lease payments   213,300 
Less imputed interest   (8,866)
Total operating lease liability  $204,434 

 

Schedule of expenses incurred with respect to the company's leases
   Three
Months
Ended
September 30,
2021
  

Three

Months

Ended
September 30,
2020

 
Operating lease expense  $24,339   $24,521 
Finance lease amortization   5,302    5,406 
Finance lease interest   385    361 
Total lease expense  $30,026   $30,288 

 

   Nine
Months
Ended
September 30,
2021
  

Nine

Months

Ended
September 30,
2020

 
Operating lease expense  $73,017   $73,564 
Finance lease amortization   15,833    16,938 
Finance lease interest   1,230    679 
Total lease expense  $90,080   $91,181 

 

Schedule of components lease costs, lease term and discount rate
   September 30,
2021
 
Remaining lease term – operating lease   2.25 years 
Weighted average remaining lease term – finance leases   3.9 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%

 

   December 31,
2020
 
Remaining lease term – operating lease   3.0 years 
Weighted average remaining lease term – finance leases   4.6 years 
Discount rate – operating lease   3.7%
Weighted average discount rate – finance leases   1.8%
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $583,896   $38,837 
Trade names and trademarks   1,715,325    655,684    1,059,641 
Customer list   584,468    357,882    226,586 
Product formulas   292,234    178,941    113,293 
Royalty rights   160,000    146,543    13,457 
Total intangible assets  $3,374,760   $1,922,946   $1,451,814 

 

Intangible Assets  Cost   Accumulated
Amortization
   Net 
Patents  $622,733   $544,644   $78,089 
Trade names and trademarks   1,715,325    626,413    1,088,912 
Customer list   584,468    270,212    314,256 
Product formulas   292,234    135,107    157,127 
Royalty rights   160,000    133,085    26,915 
Total intangible assets  $3,374,760   $1,709,461   $1,665,299 

 

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Long Term Debt (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of company's long term debt
   Current Portion   Long Term Portion 
   September 30,
2021
   December 31,
2020
   September 30,
2021
   December 31,
2020
 
Term loan  $263,746   $
-
   $4,689,609   $
-
 
Obligations related to industrial development bond financing   272,492   $263,881   $3,173,834   $3,454,904 
Note payable related to Snappy Marine asset acquisition   192,277    188,187    164,495    309,218 
Obligation related to Check Corporation asset acquisition   8,662    47,082    
-
    
-
 
Office equipment finance leases   21,455    21,160    62,719    78,847 
Total principal of long- term debt   758,632    520,310    8,090,657    3,842,969 
Debt issuance costs   (20,637)   (19,616)   (107,098)   (112,789)
Total long- term debt  $737,995   $500,694   $7,983,559   $3,730,180 

 

Schedule of principal payments under long term obligations
Twelve-month period ending September 30,    
2022  $758,632 
2023   740,016 
2024   591,431 
2025   609,084 
2026   610,985 
Thereafter   5,539,141 
Total  $8,849,289 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of computation of basic and diluted earnings per common share
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2021   2020   2021   2020 
Earnings per common share – Basic                
                 
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
                     
Weighted average number of common shares outstanding   9,485,799    9,462,105    9,483,499    9,454,639 
                     
Earnings per common share – Basic  $0.34   $0.49   $0.82   $0.92 
                     
Earnings per common share – Diluted                    
                     
Net income  $3,270,861   $4,656,830   $7,776,445   $8,736,032 
                     
Weighted average number of common shares outstanding   9,485,799    9,462,105    9,483,499    9,454,639 
                     
Dilutive effect of outstanding stock options   
-
    
-
    
-
    4,708 
                     
Weighted average number of common shares outstanding - Diluted   9,485,799    9,462,105    9,483,499    9,459,347 
                     
Earnings per common share – Diluted  $0.34   $0.49   $0.82   $0.92 

 

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Cash Dividends (Tables)
9 Months Ended
Sep. 30, 2021
Cash Dividends [Abstract]  
Schedule of declared cash dividends
Declaration Date   Type   Record Date   Payment Date   Dividends
Per Share
    Amount  
February 25, 2021   Quarterly   March 11, 2021   March 25, 2021   $ 0.03     $ 284,454  
May 21, 2021   Quarterly   June 4, 2021   June 18, 2021     0.03       284,454  
August 26, 2021   Quarterly   September 9, 2021   September 23, 2021     0.03       284,574  
Total
 
 
 
 
 
 
  $ 0.09     $ 853,482  

 

Declaration Date   Type   Record Date   Payment Date   Dividends
Per Share
    Amount  
May 26, 2020   Special   June 9, 2020   June 23, 2020   $ 0.02     $ 189,242  
May 26, 2020   Quarterly   June 9, 2020   June 23, 2020     0.02       189,242  
August 26, 2020   Quarterly   September 9, 2020   September 23, 2020     0.02       189,242  
Total
 
 
 
 
 
 
  $ 0.06     $ 567,726  
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Inventories managed at the customer's warehouses $ 1,047,000 $ 629,000
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Details) - Schedule of inventories - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Schedule of inventories [Abstract]    
Raw materials $ 7,659,240 $ 5,393,961
Finished goods 9,444,391 8,072,176
Inventories, gross 17,103,631 13,466,137
Inventory reserves (314,831) (290,381)
Inventories, net $ 16,788,800 $ 13,175,756
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant & Equipment (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Property, Plant and Equipment [Abstract]        
Project involving the expansion of manufacturing, warehouse and distribution facilities, description     The Company’s wholly owned subsidiary, Kinpak Inc. (“Kinpak”), has started a 69,000 square foot expansion of its manufacturing, warehouse and distribution facilities in Montgomery, AL.  
Depreciation expense $ 302,866 $ 273,490 $ 877,176 $ 791,981
Depreciation included in cost of goods sold 277,931 248,528 803,302 717,907
Selling and administrative expenses $ 24,935 $ 24,962 $ 73,874 $ 74,074
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant & Equipment (Details) - Schedule of property, plant and equipment - USD ($)
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 29,795,458 $ 24,856,828
Less accumulated depreciation (15,614,570) (14,754,866)
Property, plant and equipment, net 14,180,888 10,101,962
Land [Member]    
Property, Plant and Equipment [Line Items]    
Land $ 278,325 278,325
Building and improvements [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 30 years  
Building and improvements $ 9,696,070 9,563,406
Manufacturing and warehouse equipment [Member]    
Property, Plant and Equipment [Line Items]    
Manufacturing and warehouse equipment 12,889,187 11,959,563
Office equipment and furniture [Member]    
Property, Plant and Equipment [Line Items]    
Office equipment and furniture 1,907,868 1,880,387
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Leasehold improvements $ 587,183 587,183
Finance leases – right to use [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 5 years  
Finance leases – right to use $ 113,741 113,741
Vehicles [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 3 years  
Vehicles $ 10,020 10,020
Construction in process [Member]    
Property, Plant and Equipment [Line Items]    
Construction in process $ 4,313,064 $ 464,203
Minimum [Member] | Manufacturing and warehouse equipment [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 6 years  
Minimum [Member] | Office equipment and furniture [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 3 years  
Minimum [Member] | Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 10 years  
Maximum [Member] | Manufacturing and warehouse equipment [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 20 years  
Maximum [Member] | Office equipment and furniture [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 5 years  
Maximum [Member] | Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Estimated Useful Life 15 years  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Leases Of Lesse Disclosure [Abstract]          
Expires date     Dec. 31, 2023    
Annual minimum base rent     $ 94,800    
Percentage of maximum annual increase from base rent     2.00%    
Operating lease expense $ 24,339 $ 24,521 $ 73,017 $ 73,564  
Operating lease right to use asset and corresponding liability $ 204,434   $ 204,434   $ 268,920
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Details) - Schedule of future minimum rent payments
Sep. 30, 2021
USD ($)
Schedule of future minimum rent payments [Abstract]  
2022 $ 94,800
2023 94,800
2024 23,700
Total future minimum lease payments 213,300
Less imputed interest (8,866)
Total operating lease liability $ 204,434
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Details) - Schedule of expenses incurred with respect to the company's leases - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Schedule of expenses incurred with respect to the company's leases [Abstract]        
Operating lease expense $ 24,339 $ 24,521 $ 73,017 $ 73,564
Finance lease amortization 5,302 5,406 15,833 16,938
Finance lease interest 385 361 1,230 679
Total lease expense $ 30,026 $ 30,288 $ 90,080 $ 91,181
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Details) - Schedule of components lease costs, lease term and discount rate
Sep. 30, 2021
Dec. 31, 2020
Schedule of components lease costs, lease term and discount rate [Abstract]    
Remaining lease term – operating lease 2 years 3 months 3 years
Weighted average remaining lease term – finance leases 3 years 10 months 24 days 4 years 7 months 6 days
Discount rate – operating lease 3.70% 3.70%
Weighted average discount rate – finance leases 1.80% 1.80%
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization expense related to intangible assets $ 71,162 $ 71,162 $ 213,485 $ 213,486
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets (Details) - Schedule of intangible assets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost $ 3,374,760 $ 3,374,760
Intangible assets, Accumulated Amortization 1,922,946 1,709,461
Intangible assets, Net 1,451,814 1,665,299
Patents [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 622,733 622,733
Intangible assets, Accumulated Amortization 583,896 544,644
Intangible assets, Net 38,837 78,089
Trade names and trademarks [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 1,715,325 1,715,325
Intangible assets, Accumulated Amortization 655,684 626,413
Intangible assets, Net 1,059,641 1,088,912
Customer list [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 584,468 584,468
Intangible assets, Accumulated Amortization 357,882 270,212
Intangible assets, Net 226,586 314,256
Product Formulas [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 292,234 292,234
Intangible assets, Accumulated Amortization 178,941 135,107
Intangible assets, Net 113,293 157,127
Royalty rights [Member]    
Intangible Assets (Details) - Schedule of intangible assets [Line Items]    
Intangible assets, Cost 160,000 160,000
Intangible assets, Accumulated Amortization 146,543 133,085
Intangible assets, Net $ 13,457 $ 26,915
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Revolving Line of Credit (Details) - USD ($)
9 Months Ended
Sep. 30, 2021
Jul. 30, 2021
Aug. 31, 2018
Line Of Credit Facilities [Abstract]      
Maximum revolving credit line of credit provided in business loan agreement   $ 6,000,000 $ 6,000,000
Description of interest on the revolving line of credit The Business Loan Agreement bears interest at a variable annual rate of LIBOR plus 1.35%, computed on a 365/360 basis.    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Long Term Debt (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 22, 2020
Sep. 26, 2017
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jul. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Term Loan [Member]                
Long Term Debt (Details) [Line Items]                
Original principal amount             $ 5,000,000  
Area of square foot (in Square Meters) | m²             69,000  
Term loan, description         The Term Loan bears interest at an annual rate of 3.25% and is due in 119 monthly installments of $35,249 each, plus interest then accrued, beginning on August 20, 2021. The final installment shall be due and payable on July 20, 2031 in an amount equal to all principal and interest then remaining unpaid. Assuming that all amounts due prior to that date are paid in a timely manner, the final installment would be $1,977,047.       
Number of installments         119      
Financial covenants under credit agreement, description         The Credit Agreement includes financial covenants requiring that the Company maintain a minimum fixed charge coverage ratio (generally, the ratio of (A) EBITDA for the most recently completed four fiscal quarters minus the sum of the Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures during such period to (B) prior period current maturities of Company long term debt plus interest expense incurred over the most recently completed four fiscal quarters) of at least 1.20 to 1, tested quarterly, and a maximum “debt to cap” ratio (generally, funded debt divided by the sum of net worth and funded debt) of 0.75 to 1, as of the end of each fiscal quarter.      
Majority shareholder's ownership, percentage     50.00%   50.00%      
Maximum revolving credit line of credit provided in business loan agreement     $ 6,000,000   $ 6,000,000      
Indebtedness excluding trade payables     250,000   $ 250,000      
Industrial Development Bond Financing [Member]                
Long Term Debt (Details) [Line Items]                
Number of installments         118      
Proceeds of the bond sale   $ 4,500,000            
Lender's purchase of industrial development bond   $ 4,500,000            
Repurchase price of facilities if bond has been redeemed or fully paid     1,000   $ 1,000      
Bond redemptions, description         The Bond bears interest at the rate of 3.07% per annum, calculated on the basis of a 360-day year and the actual number of days elapsed (subject to increase to 6.07% per annum upon the occurrence of an event of default), and is payable in 118 monthly installments of $31,324 beginning on November 1, 2017 and ending on August 1, 2027, with a final principal and interest payment to be made on September 1, 2027 in the amount of $1,799,201.      
Term loan, description         In addition, the Lease contains provisions relating to the Expansion Project, including limitations on utilization of Bond proceeds, deposit of unused proceeds into a custodial account (as described below) and investment of monies held in the custodial account.      
Financial covenants under credit agreement, description         the Company is subject to certain covenants, including financial covenants requiring that the Company maintain (i) a minimum fixed charge ratio (generally, the ratio of (A) EBITDA minus the sum of Company’s distributions to its shareholders, taxes paid and unfunded capital expenditures to (B) current maturities of Company long-term debt plus interest expense) of 1.20 to 1, tested quarterly, and (ii) a ratio of funded debt (as defined in the guaranty agreement) divided by the sum of net worth and funded debt of 0.75 to 1, tested quarterly. For purposes of computing the fixed charge coverage ratio, “EBITDA” generally is defined as net income before taxes and depreciation expense plus amortization expense, plus interest expense, plus non-recurring and/or non-cash losses and expenses, minus non-recurring and/or non-cash gains and income; “unfunded capital expenditures” generally is defined as capital expenditures made from Company funds other than funds borrowed through term debt incurred to finance such capital expenditures.      
Payments for debt issuance costs         $ 196,095      
Payments of lease agreement     5,687 $ 5,767 17,063 $ 17,617    
Principal under lease agreement     5,302 5,406 15,833 16,938    
Interest under lease agreement     385 $ 361 $ 1,230 $ 679    
Other Long Term Obligations [Member]                
Long Term Debt (Details) [Line Items]                
Promissory note, description         In connection with the Company’s agreement to purchase assets of Snappy Marine, Inc. (“Snappy Marine”) on July 13, 2018, the Company provided to Snappy Marine a promissory note in the amount of $1,000,000, including interest (of the $1,000,000 amount of the promissory note, $930,528 was recorded as principal, and the remaining $69,472, representing an imputed interest rate of 2.87% per annum, is being recorded as interest expense over the term of the note).      
Debt payment, terms         The note is payable in equal installments of $16,667 over a 60- month period that commenced on August 1, 2018, with a final payment due and payable on July 1, 2023.      
Notes payable equal installment         $ 16,667      
Office equipment leases, description         The office equipment leases, aggregating approximately $84,000 and $100,000 at September 30, 2021 and December 31, 2020, respectively, have maturities through 2025 and carry interest rates ranging from approximately 1.53% to 3.86% per annum.      
Office equipment leases     $ 84,000   $ 84,000     $ 100,000
Check Corporation [Member] | Other Long Term Obligations [Member]                
Long Term Debt (Details) [Line Items]                
Promissory note, description         the Company’s agreement to purchase assets of Check Corporation, the Company agreed to pay Check Corporation (dba Damp Check®) $100,000 in equal installments of approximately $4,348 over a 23-month period that commenced on January 15, 2020, with a final payment due and payable on November 15, 2021. The Company recorded $97,012 as principal, and the remaining $2,988, representing an imputed interest rate of 3.15% per annum, will be recorded as interest expense over the 23 months.      
Canon Solutions America, Inc [Member] | Other Long Term Obligations [Member]                
Long Term Debt (Details) [Line Items]                
Lease agreement, description the Company entered into a lease agreement with Canon Solutions America, Inc. to lease office equipment. The lease obligates the Company to pay $100,009 in 63 equal monthly payments of $1,587. The lease is classified as a finance lease. The Company recorded a lease liability which is included in long term debt and a corresponding right to use asset that is included in property, plant and equipment of $96,039 based on a discount rate of 1.53%.              
Maximum [Member] | Term Loan [Member]                
Long Term Debt (Details) [Line Items]                
Prepayment penalty, percentage         5.00%      
Maximum [Member] | Other Long Term Obligations [Member]                
Long Term Debt (Details) [Line Items]                
Percentage of interest rates     3.86%   3.86%      
Minimum [Member] | Term Loan [Member]                
Long Term Debt (Details) [Line Items]                
Term loan, percentage         1.00%      
Minimum [Member] | Other Long Term Obligations [Member]                
Long Term Debt (Details) [Line Items]                
Percentage of interest rates     1.53%   1.53%      
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Long Term Debt (Details) - Schedule of company's long term debt - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Total principal of long- term debt, Current Portion $ 758,632 $ 520,310
Total principal of long- term debt, Long Term Portion 8,090,657 3,842,969
Debt issuance costs, Current Portion (20,637) (19,616)
Debt issuance costs, Long Term Portion (107,098) (112,789)
Total long- term debt, Current Portion 737,995 500,694
Total long- term debt, Long Term Portion 7,983,559 3,730,180
Term loan [Member]    
Debt Instrument [Line Items]    
Term loan, Current Portion 263,746
Term loan, Long Term portion 4,689,609
Obligations related to industrial development bond financing [Member]    
Debt Instrument [Line Items]    
Obligations related to industrial development bond financing, Current Portion 272,492 263,881
Obligations related to industrial development bond financing, Long Term portion 3,173,834 3,454,904
Note payable related to Snappy Marine asset acquisition [Member]    
Debt Instrument [Line Items]    
Note payable related to Snappy Marine asset acquisition, Current Portion 192,277 188,187
Note payable related to Snappy Marine asset acquisition, Long Term Portion 164,495 309,218
Obligation related to Check Corporation asset acquisition [Member]    
Debt Instrument [Line Items]    
Obligation related to Check Corporation asset acquisition, Current Portion 8,662 47,082
Obligation related to Check Corporation asset acquisition, Long Term Portion
Office equipment finance leases [Member]    
Debt Instrument [Line Items]    
Equipment leases, Current Portion 21,455 21,160
Equipment leases, Long Term Portion $ 62,719 $ 78,847
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Long Term Debt (Details) - Schedule of principal payments under long term obligations
Sep. 30, 2021
USD ($)
Schedule of principal payments under long term obligations [Abstract]  
2022 $ 758,632
2023 740,016
2024 591,431
2025 609,084
2026 610,985
Thereafter 5,539,141
Total $ 8,849,289
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Related Party Transactions (Details) [Line Items]          
Sales to the affiliated companies $ 588,000 $ 334,000 $ 1,644,000 $ 1,366,000  
Charges to the affiliated companies for services 161,000 166,000 618,000 646,000  
Reimburse business related expenditures 30,000 28,000 93,000 79,000  
Receivable due from affiliated companies 625,000   625,000   $ 1,496,000
Chief Executive Officer [Member]          
Related Party Transactions (Details) [Line Items]          
Amounts paid to entity owned by Company's CEO 15,000   59,000 47,000  
Research and development costs 12,000 12,000 36,000 36,000  
Charter boat services 3,000   17,000 9,000  
The production of television commercials     6,000 2,000  
Insurance Broker [Member]          
Related Party Transactions (Details) [Line Items]          
Insurance premiums paid $ 816,000 $ 471,000 $ 1,645,000 $ 984,000  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings Per Share (Details) - Schedule of computation of basic and diluted earnings per common share - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Earnings per common share – Basic        
Net income (in Dollars) $ 3,270,861 $ 4,656,830 $ 7,776,445 $ 8,736,032
Weighted average number of common shares outstanding 9,485,799 9,462,105 9,483,499 9,454,639
Earnings per common share – Basic (in Dollars per share) $ 0.34 $ 0.49 $ 0.82 $ 0.92
Earnings per common share – Diluted        
Net income (in Dollars) $ 3,270,861 $ 4,656,830 $ 7,776,445 $ 8,736,032
Weighted average number of common shares outstanding 9,485,799 9,462,105 9,483,499 9,454,639
Dilutive effect of outstanding stock options 4,708
Weighted average number of common shares outstanding - Diluted 9,485,799 9,462,105 9,483,499 9,459,347
Earnings per common share – Diluted (in Dollars per share) $ 0.34 $ 0.49 $ 0.82 $ 0.92
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Securities Authorized for Issuance Under Equity Compensation Plans (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]        
Stock based compensation $ 0 $ 0 $ 55,780 $ 22,220
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Cash Dividends (Details) - Schedule of declared cash dividends - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]        
Declaration Date    
Type    
Record Date    
Payment Date    
Dividends Per Share     $ 0.09 $ 0.06
Amount $ 284,574 $ 189,242 $ 853,482 $ 567,726
Dividend Declared [Member]        
Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]        
Declaration Date     Feb. 25, 2021  
Type     Quarterly  
Record Date     Mar. 11, 2021  
Payment Date     Mar. 25, 2021  
Dividends Per Share     $ 0.03  
Amount     $ 284,454  
Dividend Declared One [Member]        
Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]        
Declaration Date     May 21, 2021  
Type     Quarterly  
Record Date     Jun. 04, 2021  
Payment Date     Jun. 18, 2021  
Dividends Per Share     $ 0.03  
Amount     $ 284,454  
Dividend Declared Two [Member]        
Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]        
Declaration Date     Aug. 26, 2021  
Type     Quarterly  
Record Date     Sep. 09, 2021  
Payment Date     Sep. 23, 2021  
Dividends Per Share     $ 0.03  
Amount     $ 284,574  
Dividend Declared Three [Member]        
Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]        
Declaration Date       May 26, 2020
Type       Special
Record Date       Jun. 09, 2020
Payment Date       Jun. 23, 2020
Dividends Per Share       $ 0.02
Amount       $ 189,242
Dividend Declared Four [Member]        
Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]        
Declaration Date       May 26, 2020
Type       Quarterly
Record Date       Jun. 09, 2020
Payment Date       Jun. 23, 2020
Dividends Per Share       $ 0.02
Amount       $ 189,242
Dividend Declared Five [Member]        
Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]        
Declaration Date       Aug. 26, 2020
Type       Quarterly
Record Date       Sep. 09, 2020
Payment Date       Sep. 23, 2020
Dividends Per Share       $ 0.02
Amount       $ 189,242
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Customer Concentration (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Net Sales [Member]          
Customer Concentration (Details) [Line Items]          
Concentration risk, description During the three months ended September 30, 2021 and 2020, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. During the three months ended September 30, 2021 and 2020, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales. During the nine months ended September 30, 2021, the Company had net sales to each of three customers that constituted in excess of 10% of its net sales.    
Accounts Receivable [Member]          
Customer Concentration (Details) [Line Items]          
Concentration risk, description     At September 30, 2021, four customers constituted at least 10% of the Company’s gross trade accounts receivable.    
Accounts Receivable [Member] | Net Sales [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage 44.30% 45.00% 63.90% 32.80% 63.60%
Accounts Receivable [Member] | Customer Two [Member] | Net Sales [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage     45.10%    
Customer One [Member] | Net Sales [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage 22.00% 17.80% 17.80% 17.40%  
Customer One [Member] | Accounts Receivable [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage     18.70%   28.80%
Customer Two [Member] | Net Sales [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage 12.30% 13.80% 14.60% 15.40% 21.10%
Customer Two [Member] | Accounts Receivable [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage     16.90%    
Customer Three [Member] | Net Sales [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage 10.00% 13.40% 12.70%    
Customer Three [Member] | Accounts Receivable [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage     15.20%   13.70%
Customer Four [Member] | Accounts Receivable [Member]          
Customer Concentration (Details) [Line Items]          
Concentration Risk Percentage     13.10%    
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 158 326 1 false 45 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://oceanbiochem.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://oceanbiochem.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://oceanbiochem.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Shareholders??? Equity (Unaudited) Sheet http://oceanbiochem.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Shareholders??? Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://oceanbiochem.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Summary of Accounting Policies Sheet http://oceanbiochem.com/role/SummaryofAccountingPolicies Summary of Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Inventories Sheet http://oceanbiochem.com/role/Inventories Inventories Notes 9 false false R10.htm 009 - Disclosure - Property, Plant & Equipment Sheet http://oceanbiochem.com/role/PropertyPlantEquipment Property, Plant & Equipment Notes 10 false false R11.htm 010 - Disclosure - Leases Sheet http://oceanbiochem.com/role/Leases Leases Notes 11 false false R12.htm 011 - Disclosure - Intangible Assets Sheet http://oceanbiochem.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 012 - Disclosure - Revolving Line of Credit Sheet http://oceanbiochem.com/role/RevolvingLineofCredit Revolving Line of Credit Notes 13 false false R14.htm 013 - Disclosure - Long Term Debt Sheet http://oceanbiochem.com/role/LongTermDebt Long Term Debt Notes 14 false false R15.htm 014 - Disclosure - Related Party Transactions Sheet http://oceanbiochem.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 015 - Disclosure - Earnings Per Share Sheet http://oceanbiochem.com/role/EarningsPerShare Earnings Per Share Notes 16 false false R17.htm 016 - Disclosure - Securities Authorized for Issuance Under Equity Compensation Plans Sheet http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceUnderEquityCompensationPlans Securities Authorized for Issuance Under Equity Compensation Plans Notes 17 false false R18.htm 017 - Disclosure - Cash Dividends Sheet http://oceanbiochem.com/role/CashDividends Cash Dividends Notes 18 false false R19.htm 018 - Disclosure - Customer Concentration Sheet http://oceanbiochem.com/role/CustomerConcentration Customer Concentration Notes 19 false false R20.htm 019 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://oceanbiochem.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://oceanbiochem.com/role/SummaryofAccountingPolicies 20 false false R21.htm 020 - Disclosure - Inventories (Tables) Sheet http://oceanbiochem.com/role/InventoriesTables Inventories (Tables) Tables http://oceanbiochem.com/role/Inventories 21 false false R22.htm 021 - Disclosure - Property, Plant & Equipment (Tables) Sheet http://oceanbiochem.com/role/PropertyPlantEquipmentTables Property, Plant & Equipment (Tables) Tables http://oceanbiochem.com/role/PropertyPlantEquipment 22 false false R23.htm 022 - Disclosure - Leases (Tables) Sheet http://oceanbiochem.com/role/LeasesTables Leases (Tables) Tables http://oceanbiochem.com/role/Leases 23 false false R24.htm 023 - Disclosure - Intangible Assets (Tables) Sheet http://oceanbiochem.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://oceanbiochem.com/role/IntangibleAssets 24 false false R25.htm 024 - Disclosure - Long Term Debt (Tables) Sheet http://oceanbiochem.com/role/LongTermDebtTables Long Term Debt (Tables) Tables http://oceanbiochem.com/role/LongTermDebt 25 false false R26.htm 025 - Disclosure - Earnings Per Share (Tables) Sheet http://oceanbiochem.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://oceanbiochem.com/role/EarningsPerShare 26 false false R27.htm 026 - Disclosure - Cash Dividends (Tables) Sheet http://oceanbiochem.com/role/CashDividendsTables Cash Dividends (Tables) Tables http://oceanbiochem.com/role/CashDividends 27 false false R28.htm 028 - Disclosure - Inventories (Details) Sheet http://oceanbiochem.com/role/InventoriesDetails Inventories (Details) Details http://oceanbiochem.com/role/InventoriesTables 28 false false R29.htm 029 - Disclosure - Inventories (Details) - Schedule of inventories Sheet http://oceanbiochem.com/role/ScheduleofinventoriesTable Inventories (Details) - Schedule of inventories Details http://oceanbiochem.com/role/InventoriesTables 29 false false R30.htm 030 - Disclosure - Property, Plant & Equipment (Details) Sheet http://oceanbiochem.com/role/PropertyPlantEquipmentDetails Property, Plant & Equipment (Details) Details http://oceanbiochem.com/role/PropertyPlantEquipmentTables 30 false false R31.htm 031 - Disclosure - Property, Plant & Equipment (Details) - Schedule of property, plant and equipment Sheet http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable Property, Plant & Equipment (Details) - Schedule of property, plant and equipment Details http://oceanbiochem.com/role/PropertyPlantEquipmentTables 31 false false R32.htm 032 - Disclosure - Leases (Details) Sheet http://oceanbiochem.com/role/LeasesDetails Leases (Details) Details http://oceanbiochem.com/role/LeasesTables 32 false false R33.htm 033 - Disclosure - Leases (Details) - Schedule of future minimum rent payments Sheet http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable Leases (Details) - Schedule of future minimum rent payments Details http://oceanbiochem.com/role/LeasesTables 33 false false R34.htm 034 - Disclosure - Leases (Details) - Schedule of expenses incurred with respect to the company's leases Sheet http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable Leases (Details) - Schedule of expenses incurred with respect to the company's leases Details http://oceanbiochem.com/role/LeasesTables 34 false false R35.htm 035 - Disclosure - Leases (Details) - Schedule of components lease costs, lease term and discount rate Sheet http://oceanbiochem.com/role/ScheduleofcomponentsleasecostsleasetermanddiscountrateTable Leases (Details) - Schedule of components lease costs, lease term and discount rate Details http://oceanbiochem.com/role/LeasesTables 35 false false R36.htm 036 - Disclosure - Intangible Assets (Details) Sheet http://oceanbiochem.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://oceanbiochem.com/role/IntangibleAssetsTables 36 false false R37.htm 037 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets Sheet http://oceanbiochem.com/role/ScheduleofintangibleassetsTable Intangible Assets (Details) - Schedule of intangible assets Details http://oceanbiochem.com/role/IntangibleAssetsTables 37 false false R38.htm 038 - Disclosure - Revolving Line of Credit (Details) Sheet http://oceanbiochem.com/role/RevolvingLineofCreditDetails Revolving Line of Credit (Details) Details http://oceanbiochem.com/role/RevolvingLineofCredit 38 false false R39.htm 039 - Disclosure - Long Term Debt (Details) Sheet http://oceanbiochem.com/role/LongTermDebtDetails Long Term Debt (Details) Details http://oceanbiochem.com/role/LongTermDebtTables 39 false false R40.htm 040 - Disclosure - Long Term Debt (Details) - Schedule of company's long term debt Sheet http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable Long Term Debt (Details) - Schedule of company's long term debt Details http://oceanbiochem.com/role/LongTermDebtTables 40 false false R41.htm 041 - Disclosure - Long Term Debt (Details) - Schedule of principal payments under long term obligations Sheet http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable Long Term Debt (Details) - Schedule of principal payments under long term obligations Details http://oceanbiochem.com/role/LongTermDebtTables 41 false false R42.htm 042 - Disclosure - Related Party Transactions (Details) Sheet http://oceanbiochem.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://oceanbiochem.com/role/RelatedPartyTransactions 42 false false R43.htm 043 - Disclosure - Earnings Per Share (Details) - Schedule of computation of basic and diluted earnings per common share Sheet http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable Earnings Per Share (Details) - Schedule of computation of basic and diluted earnings per common share Details http://oceanbiochem.com/role/EarningsPerShareTables 43 false false R44.htm 044 - Disclosure - Securities Authorized for Issuance Under Equity Compensation Plans (Details) Sheet http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceUnderEquityCompensationPlansDetails Securities Authorized for Issuance Under Equity Compensation Plans (Details) Details http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceUnderEquityCompensationPlans 44 false false R45.htm 045 - Disclosure - Cash Dividends (Details) - Schedule of declared cash dividends Sheet http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable Cash Dividends (Details) - Schedule of declared cash dividends Details http://oceanbiochem.com/role/CashDividendsTables 45 false false R46.htm 046 - Disclosure - Customer Concentration (Details) Sheet http://oceanbiochem.com/role/CustomerConcentrationDetails Customer Concentration (Details) Details http://oceanbiochem.com/role/CustomerConcentration 46 false false All Reports Book All Reports f10q0921_oceanbio.htm f10q0921ex31-1_oceanbio.htm f10q0921ex31-2_oceanbio.htm f10q0921ex32-1_oceanbio.htm f10q0921ex32-2_oceanbio.htm obci-20210930.xsd obci-20210930_cal.xml obci-20210930_def.xml obci-20210930_lab.xml obci-20210930_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0921_oceanbio.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 158, "dts": { "calculationLink": { "local": [ "obci-20210930_cal.xml" ] }, "definitionLink": { "local": [ "obci-20210930_def.xml" ] }, "inline": { "local": [ "f10q0921_oceanbio.htm" ] }, "labelLink": { "local": [ "obci-20210930_lab.xml" ] }, "presentationLink": { "local": [ "obci-20210930_pre.xml" ] }, "schema": { "local": [ "obci-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 390, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 62, "http://oceanbiochem.com/20210930": 12, "http://xbrl.sec.gov/dei/2021": 7, "total": 81 }, "keyCustom": 65, "keyStandard": 261, "memberCustom": 23, "memberStandard": 19, "nsprefix": "obci", "nsuri": "http://oceanbiochem.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:TradingSymbol", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://oceanbiochem.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:TradingSymbol", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Property, Plant & Equipment", "role": "http://oceanbiochem.com/role/PropertyPlantEquipment", "shortName": "Property, Plant & Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LeasesOfLesseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Leases", "role": "http://oceanbiochem.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LeasesOfLesseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Intangible Assets", "role": "http://oceanbiochem.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Revolving Line of Credit", "role": "http://oceanbiochem.com/role/RevolvingLineofCredit", "shortName": "Revolving Line of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:LineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Long Term Debt", "role": "http://oceanbiochem.com/role/LongTermDebt", "shortName": "Long Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Related Party Transactions", "role": "http://oceanbiochem.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Earnings Per Share", "role": "http://oceanbiochem.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Securities Authorized for Issuance Under Equity Compensation Plans", "role": "http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceUnderEquityCompensationPlans", "shortName": "Securities Authorized for Issuance Under Equity Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:CashDividendsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Cash Dividends", "role": "http://oceanbiochem.com/role/CashDividends", "shortName": "Cash Dividends", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:CashDividendsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Customer Concentration", "role": "http://oceanbiochem.com/role/CustomerConcentration", "shortName": "Customer Concentration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets", "role": "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:InterimReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://oceanbiochem.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:InterimReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Inventories (Tables)", "role": "http://oceanbiochem.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Property, Plant & Equipment (Tables)", "role": "http://oceanbiochem.com/role/PropertyPlantEquipmentTables", "shortName": "Property, Plant & Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Leases (Tables)", "role": "http://oceanbiochem.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Intangible Assets (Tables)", "role": "http://oceanbiochem.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Long Term Debt (Tables)", "role": "http://oceanbiochem.com/role/LongTermDebtTables", "shortName": "Long Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Earnings Per Share (Tables)", "role": "http://oceanbiochem.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Cash Dividends (Tables)", "role": "http://oceanbiochem.com/role/CashDividendsTables", "shortName": "Cash Dividends (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c11", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInventoryInventoryAtOffSitePremises", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Inventories (Details)", "role": "http://oceanbiochem.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c11", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherInventoryInventoryAtOffSitePremises", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Inventories (Details) - Schedule of inventories", "role": "http://oceanbiochem.com/role/ScheduleofinventoriesTable", "shortName": "Inventories (Details) - Schedule of inventories", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "role": "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ProjectInvolvingExpansionOfManufacturingWarehouseAndDistributionFacilitiesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Property, Plant & Equipment (Details)", "role": "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails", "shortName": "Property, Plant & Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ProjectInvolvingExpansionOfManufacturingWarehouseAndDistributionFacilitiesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Property, Plant & Equipment (Details) - Schedule of property, plant and equipment", "role": "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable", "shortName": "Property, Plant & Equipment (Details) - Schedule of property, plant and equipment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Leases (Details)", "role": "http://oceanbiochem.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesFutureMinimumPaymentDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Leases (Details) - Schedule of future minimum rent payments", "role": "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable", "shortName": "Leases (Details) - Schedule of future minimum rent payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "obci:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesFutureMinimumPaymentDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Leases (Details) - Schedule of expenses incurred with respect to the company's leases", "role": "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable", "shortName": "Leases (Details) - Schedule of expenses incurred with respect to the company's leases", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "obci:OperatingLeasesExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "obci:ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Leases (Details) - Schedule of components lease costs, lease term and discount rate", "role": "http://oceanbiochem.com/role/ScheduleofcomponentsleasecostsleasetermanddiscountrateTable", "shortName": "Leases (Details) - Schedule of components lease costs, lease term and discount rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "obci:ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Intangible Assets (Details)", "role": "http://oceanbiochem.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets", "role": "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable", "shortName": "Intangible Assets (Details) - Schedule of intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c86", "decimals": "0", "first": true, "lang": null, "name": "obci:MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Revolving Line of Credit (Details)", "role": "http://oceanbiochem.com/role/RevolvingLineofCreditDetails", "shortName": "Revolving Line of Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c86", "decimals": "0", "first": true, "lang": null, "name": "obci:MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c88", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Long Term Debt (Details)", "role": "http://oceanbiochem.com/role/LongTermDebtDetails", "shortName": "Long Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c88", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://oceanbiochem.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:LongTermDebtPrincipalCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Long Term Debt (Details) - Schedule of company's long term debt", "role": "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable", "shortName": "Long Term Debt (Details) - Schedule of company's long term debt", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "obci:LongTermDebtPrincipalCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Long Term Debt (Details) - Schedule of principal payments under long term obligations", "role": "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable", "shortName": "Long Term Debt (Details) - Schedule of principal payments under long term obligations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Related Party Transactions (Details)", "role": "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Earnings Per Share (Details) - Schedule of computation of basic and diluted earnings per common share", "role": "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable", "shortName": "Earnings Per Share (Details) - Schedule of computation of basic and diluted earnings per common share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "2", "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Securities Authorized for Issuance Under Equity Compensation Plans (Details)", "role": "http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceUnderEquityCompensationPlansDetails", "shortName": "Securities Authorized for Issuance Under Equity Compensation Plans (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Cash Dividends (Details) - Schedule of declared cash dividends", "role": "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable", "shortName": "Cash Dividends (Details) - Schedule of declared cash dividends", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "obci:ConcentrationsRiskDescription", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c130", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ConcentrationsRiskDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Customer Concentration (Details)", "role": "http://oceanbiochem.com/role/CustomerConcentrationDetails", "shortName": "Customer Concentration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "obci:ConcentrationsRiskDescription", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c130", "decimals": null, "first": true, "lang": "en-US", "name": "obci:ConcentrationsRiskDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c4", "decimals": "0", "lang": null, "name": "obci:ForeignCurrencyTranslationAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c42", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Shareholders\u2019 Equity (Unaudited)", "role": "http://oceanbiochem.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statements of Shareholders\u2019 Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c42", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://oceanbiochem.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Summary of Accounting Policies", "role": "http://oceanbiochem.com/role/SummaryofAccountingPolicies", "shortName": "Summary of Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Inventories", "role": "http://oceanbiochem.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_oceanbio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 45, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oceanbiochem.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "obci_AmountsPaidToEntityOwnedByCompanysCEO": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts paid to entity owned by Company's CEO.", "label": "AmountsPaidToEntityOwnedByCompanysCEO", "terseLabel": "Amounts paid to entity owned by Company's CEO" } } }, "localname": "AmountsPaidToEntityOwnedByCompanysCEO", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_CanonSolutionsAmericaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CanonSolutionsAmericaIncMember", "terseLabel": "Canon Solutions America, Inc [Member]" } } }, "localname": "CanonSolutionsAmericaIncMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "obci_CashDividendsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Dividends [Abstract]" } } }, "localname": "CashDividendsAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_CashDividendsDetailsScheduleofdeclaredcashdividendsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Dividends (Details) - Schedule of declared cash dividends [Line Items]" } } }, "localname": "CashDividendsDetailsScheduleofdeclaredcashdividendsLineItems", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "stringItemType" }, "obci_CashDividendsDetailsScheduleofdeclaredcashdividendsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Dividends (Details) - Schedule of declared cash dividends [Table]" } } }, "localname": "CashDividendsDetailsScheduleofdeclaredcashdividendsTable", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "stringItemType" }, "obci_CashDividendsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash dividends including all tables.", "label": "CashDividendsTextBlock", "terseLabel": "CASH DIVIDENDS" } } }, "localname": "CashDividendsTextBlock", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CashDividends" ], "xbrltype": "textBlockItemType" }, "obci_CashPaidUnderOperatingLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid under operating lease.", "label": "CashPaidUnderOperatingLease", "terseLabel": "Cash paid under operating lease" } } }, "localname": "CashPaidUnderOperatingLease", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_CashUsedForExpensesAssociatedWithChemicalIncident": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash used for expenses associated with 2019 chemical incident.", "label": "CashUsedForExpensesAssociatedWithChemicalIncident", "negatedLabel": "Cash used related to 2019 chemical incident" } } }, "localname": "CashUsedForExpensesAssociatedWithChemicalIncident", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_ChargesToAffiliatedCompaniesForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charges to the affiliated companies for services.", "label": "ChargesToAffiliatedCompaniesForServices", "terseLabel": "Charges to the affiliated companies for services" } } }, "localname": "ChargesToAffiliatedCompaniesForServices", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_CheckCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CheckCorporationMember", "terseLabel": "Check Corporation [Member]" } } }, "localname": "CheckCorporationMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "obci_ComponentsOfLeaseCostsLeaseTermAndDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of lease costs, lease term and discount rate.", "label": "ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "terseLabel": "Schedule of components lease costs, lease term and discount rate" } } }, "localname": "ComponentsOfLeaseCostsLeaseTermAndDiscountRate", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "obci_ConcentrationRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "ConcentrationRiskPercentage", "terseLabel": "Concentration Risk Percentage" } } }, "localname": "ConcentrationRiskPercentage", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "percentItemType" }, "obci_ConcentrationRiskTradeReceivablesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of minimum percentage of gross trade receivables from a customer in order to require concentration risk disclosure.", "label": "ConcentrationRiskTradeReceivablesDescription", "terseLabel": "Concentration risk, description" } } }, "localname": "ConcentrationRiskTradeReceivablesDescription", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "obci_ConcentrationsRiskDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of minimum percentage of net sales from a customer in order to require concentration risk disclosure.", "label": "ConcentrationsRiskDescription", "terseLabel": "Concentration risk, description" } } }, "localname": "ConcentrationsRiskDescription", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "obci_ConstructionInProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConstructionInProcessMember", "terseLabel": "Construction in process [Member]" } } }, "localname": "ConstructionInProcessMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "obci_CustomerConcentrationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Concentration (Details) [Line Items]" } } }, "localname": "CustomerConcentrationDetailsLineItems", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "obci_CustomerConcentrationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Concentration (Details) [Table]" } } }, "localname": "CustomerConcentrationDetailsTable", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "obci_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerFourMember", "terseLabel": "Customer Four [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "obci_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerOneMember", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "obci_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerThreeMember", "terseLabel": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "obci_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerTwoMember", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "obci_DebtFinancingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of charge against earnings over the life of the debt.", "label": "DebtFinancingCosts", "terseLabel": "Payments for debt issuance costs" } } }, "localname": "DebtFinancingCosts", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_DepreciationExpenseIncludesInCostOfGoodsSold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period included in cost of goods sold that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production related depreciation.", "label": "DepreciationExpenseIncludesInCostOfGoodsSold", "terseLabel": "Depreciation included in cost of goods sold" } } }, "localname": "DepreciationExpenseIncludesInCostOfGoodsSold", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "obci_DepreciationExpenseIncludesInSellingAndAdministrativeExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period included in selling and administrative expenses that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes non-production related depreciation.", "label": "DepreciationExpenseIncludesInSellingAndAdministrativeExpenses", "terseLabel": "Selling and administrative expenses" } } }, "localname": "DepreciationExpenseIncludesInSellingAndAdministrativeExpenses", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "obci_DividendDeclaredFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DividendDeclaredFiveMember", "terseLabel": "Dividend Declared Five [Member]" } } }, "localname": "DividendDeclaredFiveMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "domainItemType" }, "obci_DividendDeclaredFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DividendDeclaredFourMember", "terseLabel": "Dividend Declared Four [Member]" } } }, "localname": "DividendDeclaredFourMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "domainItemType" }, "obci_DividendDeclaredOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DividendDeclaredOneMember", "terseLabel": "Dividend Declared One [Member]" } } }, "localname": "DividendDeclaredOneMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "domainItemType" }, "obci_DividendDeclaredThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DividendDeclaredThreeMember", "terseLabel": "Dividend Declared Three [Member]" } } }, "localname": "DividendDeclaredThreeMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "domainItemType" }, "obci_DividendDeclaredTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DividendDeclaredTwoMember", "terseLabel": "Dividend Declared Two [Member]" } } }, "localname": "DividendDeclaredTwoMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "domainItemType" }, "obci_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_DueFromAffiliatesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).", "label": "DueFromAffiliatesCurrent", "terseLabel": "Receivable due from affiliated companies" } } }, "localname": "DueFromAffiliatesCurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_FinanceLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for finance lease payments.", "label": "FinanceLeasePayments", "terseLabel": "Payments of lease agreement" } } }, "localname": "FinanceLeasePayments", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_FinanceLeaseRightsToUseAssetsExchangedForFinanceLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance lease right to use assets exchanged for finance lease liabilities.", "label": "FinanceLeaseRightsToUseAssetsExchangedForFinanceLeaseLiabilities", "terseLabel": "Finance lease right to use assets exchanged for finance lease liabilities" } } }, "localname": "FinanceLeaseRightsToUseAssetsExchangedForFinanceLeaseLiabilities", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_FinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinanceLeasesMember", "terseLabel": "Finance leases \u2013 right to use [Member]" } } }, "localname": "FinanceLeasesMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "obci_FinancialCovenantsUnderCreditAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial covenants under credit agreement, description.", "label": "FinancialCovenantsUnderCreditAgreementDescription", "terseLabel": "Financial covenants under credit agreement, description" } } }, "localname": "FinancialCovenantsUnderCreditAgreementDescription", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_ForeignCurrencyTranslationAdjustment": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "ForeignCurrencyTranslationAdjustment", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "ForeignCurrencyTranslationAdjustment", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "obci_GainOnInsuranceSettlement": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain on insurance settlement.", "label": "GainOnInsuranceSettlement", "terseLabel": "Gain on insurance settlement" } } }, "localname": "GainOnInsuranceSettlement", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "obci_GainOnInsuranceSettlements": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on insurance settlement.", "label": "GainOnInsuranceSettlements", "negatedLabel": "Gain on insurance settlement" } } }, "localname": "GainOnInsuranceSettlements", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_IndebtednessExcludingTradePayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial covenant that restricts our indebtedness excluding trade payables in the normal course of business.", "label": "IndebtednessExcludingTradePayables", "terseLabel": "Indebtedness excluding trade payables" } } }, "localname": "IndebtednessExcludingTradePayables", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_IndustrialDevelopmentBondFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IndustrialDevelopmentBondFinancingMember", "terseLabel": "Industrial Development Bond Financing [Member]" } } }, "localname": "IndustrialDevelopmentBondFinancingMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "obci_InsuranceBrokerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance broker member.", "label": "InsuranceBrokerMember", "terseLabel": "Insurance Broker [Member]" } } }, "localname": "InsuranceBrokerMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "obci_InsurancePremiumsPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Insurance premiums paid.", "label": "InsurancePremiumsPaid", "terseLabel": "Insurance premiums paid" } } }, "localname": "InsurancePremiumsPaid", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_InsuranceProceedsReceivedForDamagedMachineryAndEquipment": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the insurance proceeds received for damaged machinery and equipment.", "label": "InsuranceProceedsReceivedForDamagedMachineryAndEquipment", "terseLabel": "Insurance proceeds received for damaged machinery and equipment" } } }, "localname": "InsuranceProceedsReceivedForDamagedMachineryAndEquipment", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_IntangibleAssetsDetailsScheduleofintangibleassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of intangible assets [Line Items]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsLineItems", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "obci_IntangibleAssetsDetailsScheduleofintangibleassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of intangible assets [Table]" } } }, "localname": "IntangibleAssetsDetailsScheduleofintangibleassetsTable", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "obci_InterimReportingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interim Reporting, Policy.", "label": "InterimReportingPolicyPolicyTextBlock", "terseLabel": "Interim reporting" } } }, "localname": "InterimReportingPolicyPolicyTextBlock", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "obci_LeaseWithImputedInterestDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the unamortized amount of the discount on the note or receivable which is deducted from the face amount of the lease.", "label": "LeaseWithImputedInterestDiscount", "negatedLabel": "Less imputed interest" } } }, "localname": "LeaseWithImputedInterestDiscount", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_LeasesOfLesseDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases Of Lesse Disclosure [Abstract]" } } }, "localname": "LeasesOfLesseDisclosureAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_LeasesOfLesseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LeasesOfLesseDisclosureTextBlock", "terseLabel": "LEASES" } } }, "localname": "LeasesOfLesseDisclosureTextBlock", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "obci_LeasesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases Disclosure [Abstract]" } } }, "localname": "LeasesTablesLineItems", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "stringItemType" }, "obci_LeasesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases (Tables) [Table]" } } }, "localname": "LeasesTablesTable", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "stringItemType" }, "obci_LendersPurchaseOfIndustrialDevelopmentBond": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lender's purchase of industrial development bond.", "label": "LendersPurchaseOfIndustrialDevelopmentBond", "terseLabel": "Lender's purchase of industrial development bond" } } }, "localname": "LendersPurchaseOfIndustrialDevelopmentBond", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_LineOfCreditFacilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Line Of Credit Facilities [Abstract]" } } }, "localname": "LineOfCreditFacilitiesAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_LineOfCreditFacilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revolving line of credit.", "label": "LineOfCreditFacilitiesTextBlock", "terseLabel": "REVOLVING LINE OF CREDIT" } } }, "localname": "LineOfCreditFacilitiesTextBlock", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCredit" ], "xbrltype": "textBlockItemType" }, "obci_LongTermDebtDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt (Details) [Line Items]" } } }, "localname": "LongTermDebtDetailsLineItems", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_LongTermDebtDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt (Details) [Table]" } } }, "localname": "LongTermDebtDetailsTable", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_LongTermDebtPrincipalCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current having initial terms less than one year or the normal operating cycle, if longer.", "label": "LongTermDebtPrincipalCurrent", "terseLabel": "Total principal of long- term debt, Current Portion" } } }, "localname": "LongTermDebtPrincipalCurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_LongTermDebtPrincipalNonCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer.", "label": "LongTermDebtPrincipalNonCurrent", "terseLabel": "Total principal of long- term debt, Long Term Portion" } } }, "localname": "LongTermDebtPrincipalNonCurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ManufacturingAndWarehouseEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount at the balance sheet date of manufacturing and warehouse equipment.", "label": "ManufacturingAndWarehouseEquipment", "terseLabel": "Manufacturing and warehouse equipment" } } }, "localname": "ManufacturingAndWarehouseEquipment", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "obci_ManufacturingAndWarehouseEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing and warehouse equipment.", "label": "ManufacturingAndWarehouseEquipmentMember", "terseLabel": "Manufacturing and warehouse equipment [Member]" } } }, "localname": "ManufacturingAndWarehouseEquipmentMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "obci_MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity of the credit facility without consideration of any restrictions on the amount that could be borrowed or the amounts outstanding under the facility.", "label": "MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "terseLabel": "Maximum revolving credit line of credit provided in business loan agreement" } } }, "localname": "MaximumRevolvingCreditLineOfCreditProvidedInBusinessLoanAgreement", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/RevolvingLineofCreditDetails" ], "xbrltype": "monetaryItemType" }, "obci_NotePayableRelatedToAssetAcquisitionCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of note payable related to asset acquisition current portion.", "label": "NotePayableRelatedToAssetAcquisitionCurrentPortion", "terseLabel": "Note payable related to Snappy Marine asset acquisition, Current Portion" } } }, "localname": "NotePayableRelatedToAssetAcquisitionCurrentPortion", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_NotePayableRelatedToAssetAcquisitionLongTermPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of note payable related to asset acquisition, long term portion.", "label": "NotePayableRelatedToAssetAcquisitionLongTermPortion", "terseLabel": "Note payable related to Snappy Marine asset acquisition, Long Term Portion" } } }, "localname": "NotePayableRelatedToAssetAcquisitionLongTermPortion", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_NotePayableRelatedToAssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NotePayableRelatedToAssetAcquisitionMember", "terseLabel": "Note payable related to Snappy Marine asset acquisition [Member]" } } }, "localname": "NotePayableRelatedToAssetAcquisitionMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_NumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of installments.", "label": "NumberOfInstallments", "terseLabel": "Number of installments" } } }, "localname": "NumberOfInstallments", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "integerItemType" }, "obci_ObligationRelatedToCheckCorporationAssetAcquisitionCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, check corporation asset acquisition, classified as current having initial terms less than one year or the normal operating cycle, if longer.", "label": "ObligationRelatedToCheckCorporationAssetAcquisitionCurrent", "terseLabel": "Obligation related to Check Corporation asset acquisition, Current Portion" } } }, "localname": "ObligationRelatedToCheckCorporationAssetAcquisitionCurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ObligationRelatedToCheckCorporationAssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ObligationRelatedToCheckCorporationAssetAcquisitionMember", "terseLabel": "Obligation related to Check Corporation asset acquisition [Member]" } } }, "localname": "ObligationRelatedToCheckCorporationAssetAcquisitionMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_ObligationRelatedToCheckCorporationAssetAcquisitionNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, check corporation asset acquisition non current.", "label": "ObligationRelatedToCheckCorporationAssetAcquisitionNoncurrent", "terseLabel": "Obligation related to Check Corporation asset acquisition, Long Term Portion" } } }, "localname": "ObligationRelatedToCheckCorporationAssetAcquisitionNoncurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ObligationsRelatedToIndustrialDevelopmentBondFinancingCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, industrial development bond financing, classified as current having initial terms less than one year or the normal operating cycle, if longer.", "label": "ObligationsRelatedToIndustrialDevelopmentBondFinancingCurrent", "terseLabel": "Obligations related to industrial development bond financing, Current Portion" } } }, "localname": "ObligationsRelatedToIndustrialDevelopmentBondFinancingCurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_ObligationsRelatedToIndustrialDevelopmentBondFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ObligationsRelatedToIndustrialDevelopmentBondFinancingMember", "terseLabel": "Obligations related to industrial development bond financing [Member]" } } }, "localname": "ObligationsRelatedToIndustrialDevelopmentBondFinancingMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_ObligationsRelatedToIndustrialDevelopmentBondFinancingNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, industrial development bond financing non current.", "label": "ObligationsRelatedToIndustrialDevelopmentBondFinancingNonCurrent", "terseLabel": "Obligations related to industrial development bond financing, Long Term portion" } } }, "localname": "ObligationsRelatedToIndustrialDevelopmentBondFinancingNonCurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "obci_OfficeEquipmentFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OfficeEquipmentFinanceLeasesMember", "terseLabel": "Office equipment finance leases [Member]" } } }, "localname": "OfficeEquipmentFinanceLeasesMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_OfficeEquipmentLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of office equipment for finance leases.", "label": "OfficeEquipmentLeases", "terseLabel": "Office equipment leases" } } }, "localname": "OfficeEquipmentLeases", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_OfficeEquipmentLeasesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of office equipment leases.", "label": "OfficeEquipmentLeasesDescription", "terseLabel": "Office equipment leases, description" } } }, "localname": "OfficeEquipmentLeasesDescription", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_OperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "OperatingLeaseLiabilities", "terseLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiabilities", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease right to use asset and corresponding liability.", "label": "OperatingLeaseRightOfUseAssets", "terseLabel": "Operating lease right to use asset and corresponding liability" } } }, "localname": "OperatingLeaseRightOfUseAssets", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesExpense": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "OperatingLeasesExpense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeasesExpense", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesFutureMinimumPaymentDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "OperatingLeasesFutureMinimumPaymentDue", "terseLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentDue", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesFutureMinimumPaymentDueCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "OperatingLeasesFutureMinimumPaymentDueCurrent", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentDueCurrent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesFutureMinimumPaymentDueInThreeYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "OperatingLeasesFutureMinimumPaymentDueInThreeYears", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentDueInThreeYears", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OperatingLeasesFutureMinimumPaymentDueInTwoYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "OperatingLeasesFutureMinimumPaymentDueInTwoYears", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentDueInTwoYears", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleoffutureminimumrentpaymentsTable" ], "xbrltype": "monetaryItemType" }, "obci_OtherLongTermObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OtherLongTermObligationsMember", "terseLabel": "Other Long Term Obligations [Member]" } } }, "localname": "OtherLongTermObligationsMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "obci_PercentageOfMaximumAnnaulIncreaseFromBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of maximum annaul increase from base rent.", "label": "PercentageOfMaximumAnnaulIncreaseFromBaseRent", "terseLabel": "Percentage of maximum annual increase from base rent" } } }, "localname": "PercentageOfMaximumAnnaulIncreaseFromBaseRent", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "obci_PrepaymentPenaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment penalty percentage.", "label": "PrepaymentPenaltyPercentage", "terseLabel": "Prepayment penalty, percentage" } } }, "localname": "PrepaymentPenaltyPercentage", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "obci_ProceedsFromCARESActNote": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Proceeds from Cares Act note", "label": "ProceedsFromCARESActNote", "terseLabel": "Proceeds from CARES Act note" } } }, "localname": "ProceedsFromCARESActNote", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_ProceedsOfBondSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds of the Bond sale.", "label": "ProceedsOfBondSale", "terseLabel": "Proceeds of the bond sale" } } }, "localname": "ProceedsOfBondSale", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_ProductFormulasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ProductFormulasMember", "terseLabel": "Product Formulas [Member]" } } }, "localname": "ProductFormulasMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "obci_ProductionOfTelevisionCommercials": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The production of television commercials.", "label": "ProductionOfTelevisionCommercials", "terseLabel": "The production of television commercials" } } }, "localname": "ProductionOfTelevisionCommercials", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_ProjectInvolvingExpansionOfManufacturingWarehouseAndDistributionFacilitiesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of project involving the expansion of manufacturing, warehouse and distribution facilities.", "label": "ProjectInvolvingExpansionOfManufacturingWarehouseAndDistributionFacilitiesDescription", "terseLabel": "Project involving the expansion of manufacturing, warehouse and distribution facilities, description" } } }, "localname": "ProjectInvolvingExpansionOfManufacturingWarehouseAndDistributionFacilitiesDescription", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails" ], "xbrltype": "stringItemType" }, "obci_ProvisionForSlowMovingAndObsoleteInventory": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision for slow moving and obsolete inventory.", "label": "ProvisionForSlowMovingAndObsoleteInventory", "terseLabel": "Provision for slow moving and obsolete inventory" } } }, "localname": "ProvisionForSlowMovingAndObsoleteInventory", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_ReimburseBusinessRelatedExpenditures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount the Company will be reimbursed by the affiliates for business related expenditures in addition to other administrative services.", "label": "ReimburseBusinessRelatedExpenditures", "terseLabel": "Reimburse business related expenditures" } } }, "localname": "ReimburseBusinessRelatedExpenditures", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "obci_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "obci_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "obci_RepaymentOfCARESActNote": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Repayment of CaresAct note", "label": "RepaymentOfCARESActNote", "terseLabel": "Repayment of CARES Act note" } } }, "localname": "RepaymentOfCARESActNote", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_RepurchasePriceOfFacilitiesIfBondHasBeenRedeemedOrFullyPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repurchase price of facilities if bond has been redeemed or fully paid.", "label": "RepurchasePriceOfFacilitiesIfBondHasBeenRedeemedOrFullyPaid", "terseLabel": "Repurchase price of facilities if bond has been redeemed or fully paid" } } }, "localname": "RepurchasePriceOfFacilitiesIfBondHasBeenRedeemedOrFullyPaid", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "obci_RevolvingLineOfCreditMajorityShareholdersOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of shares required by the majority shareholder to own.", "label": "RevolvingLineOfCreditMajorityShareholdersOwnershipPercentage", "terseLabel": "Majority shareholder's ownership, percentage" } } }, "localname": "RevolvingLineOfCreditMajorityShareholdersOwnershipPercentage", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "obci_RevolvingLineofCreditLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revolving Line of Credit [Abstract]" } } }, "localname": "RevolvingLineofCreditLineItems", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCredit" ], "xbrltype": "stringItemType" }, "obci_RevolvingLineofCreditTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revolving Line of Credit [Table]" } } }, "localname": "RevolvingLineofCreditTable", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCredit" ], "xbrltype": "stringItemType" }, "obci_ScheduleOfCompanysLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of company's long term debt [Abstract]" } } }, "localname": "ScheduleOfCompanysLongTermDebtAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfComponentsLeaseCostsLeaseTermAndDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of components lease costs, lease term and discount rate [Abstract]" } } }, "localname": "ScheduleOfComponentsLeaseCostsLeaseTermAndDiscountRateAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfComputationOfBasicAndDilutedEarningsPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of computation of basic and diluted earnings per common share [Abstract]" } } }, "localname": "ScheduleOfComputationOfBasicAndDilutedEarningsPerCommonShareAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfDeclaredCashDividendsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of declared cash dividends [Abstract]" } } }, "localname": "ScheduleOfDeclaredCashDividendsAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfExpensesIncurredWithRespectToTheCompanysLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of expenses incurred with respect to the company's leases [Abstract]" } } }, "localname": "ScheduleOfExpensesIncurredWithRespectToTheCompanysLeasesAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfFutureMinimumRentPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of future minimum rent payments [Abstract]" } } }, "localname": "ScheduleOfFutureMinimumRentPaymentsAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "terseLabel": "Schedule of future minimum rent payments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "obci_ScheduleOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of intangible assets [Abstract]" } } }, "localname": "ScheduleOfIntangibleAssetsAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of inventories [Abstract]" } } }, "localname": "ScheduleOfInventoriesAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfPrincipalPaymentsUnderLongTermObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of principal payments under long term obligations [Abstract]" } } }, "localname": "ScheduleOfPrincipalPaymentsUnderLongTermObligationsAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_ScheduleOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property, plant and equipment [Abstract]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://oceanbiochem.com/20210930", "xbrltype": "stringItemType" }, "obci_SupplementalDisclosureCash": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "obci_SupplementalDisclosureCashAndRestrictedCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "SupplementalDisclosureCash", "terseLabel": "Cash" } } }, "localname": "SupplementalDisclosureCash", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_SupplementalDisclosureCashAndRestrictedCash": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "SupplementalDisclosureCashAndRestrictedCash", "totalLabel": "Total cash and restricted cash" } } }, "localname": "SupplementalDisclosureCashAndRestrictedCash", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_SupplementalDisclosureRestrictedCash": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "obci_SupplementalDisclosureCashAndRestrictedCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "SupplementalDisclosureRestrictedCash", "terseLabel": "Restricted cash" } } }, "localname": "SupplementalDisclosureRestrictedCash", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "obci_TermLoanDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan, description.", "label": "TermLoanDescription", "terseLabel": "Term loan, description" } } }, "localname": "TermLoanDescription", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "obci_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TermLoanMember", "terseLabel": "Term loan [Member]", "verboseLabel": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "domainItemType" }, "obci_TermLoanPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan, percentage.", "label": "TermLoanPercentage", "terseLabel": "Term loan, percentage" } } }, "localname": "TermLoanPercentage", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "obci_Vehicles": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of vehicles.", "label": "Vehicles", "terseLabel": "Vehicles" } } }, "localname": "Vehicles", "nsuri": "http://oceanbiochem.com/20210930", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r160", "r251", "r253", "r401" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r220", "r243", "r256", "r257", "r345", "r346", "r347", "r348", "r349", "r350", "r369", "r400", "r402", "r415", "r416" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r220", "r243", "r256", "r257", "r345", "r346", "r347", "r348", "r349", "r350", "r369", "r400", "r402", "r415", "r416" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r160", "r251", "r253", "r401" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r220", "r243", "r254", "r256", "r257", "r345", "r346", "r347", "r348", "r349", "r350", "r369", "r400", "r402", "r415", "r416" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r220", "r243", "r254", "r256", "r257", "r345", "r346", "r347", "r348", "r349", "r350", "r369", "r400", "r402", "r415", "r416" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r161", "r331" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r9", "r36" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable \u2013 trade" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r19", "r162", "r163" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable less allowances of approximately $492,000 and $326,000, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses payable" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r54", "r55", "r56", "r390", "r407", "r408" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r53", "r56", "r62", "r63", "r64", "r103", "r104", "r105", "r288", "r403", "r404", "r431" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r20" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r103", "r104", "r105", "r262", "r263", "r264", "r294" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r26", "r164", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable allowance for doubtful accounts (in Dollars)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r88", "r188", "r192" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense related to intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Area of square foot (in Square Meters)" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r147", "r150", "r156", "r171", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r284", "r289", "r299", "r336", "r338", "r373", "r389" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r51", "r98", "r171", "r204", "r205", "r206", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r284", "r289", "r299", "r336", "r338" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]", "terseLabel": "Building and improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r8", "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Building and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r32", "r90" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r83", "r90", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and restricted cash at end of period", "periodStartLabel": "Cash and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r83", "r300" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r44", "r202", "r377", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends Per Share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share (in Dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r103", "r104", "r294" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r338" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - $.01 par value, 12,000,000 shares authorized; 9,485,799 and 9,481,799 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r58", "r60", "r61", "r69", "r380", "r396" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r137", "r138", "r160", "r297", "r298", "r409", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r137", "r138", "r160", "r297", "r298", "r409", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "CUSTOMER CONCENTRATION" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentration" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r137", "r138", "r160", "r297", "r298", "r411" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r74", "r371" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerListsMember": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information.", "label": "Customer Lists [Member]", "terseLabel": "Customer Lists [Member]", "verboseLabel": "Customer list [Member]" } } }, "localname": "CustomerListsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r97", "r101", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r237", "r238", "r239", "r240", "r311", "r374", "r375", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r235", "r375", "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r14", "r16", "r246", "r374", "r375", "r385", "r388" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt Instrument, Description", "terseLabel": "Term loan, description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r217", "r237", "r238", "r309", "r311", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Original principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r41", "r236", "r309", "r311" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Percentage of interest rates" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r43", "r97", "r101", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r237", "r238", "r239", "r240", "r311" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r42", "r386" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt payment, terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r43", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Notes payable equal installment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r43", "r97", "r101", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r237", "r238", "r239", "r240", "r246", "r247", "r248", "r249", "r308", "r309", "r311", "r312", "r387" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsCurrentNet": { "auth_ref": [ "r50", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Current, Net", "negatedLabel": "Debt issuance costs, Current Portion" } } }, "localname": "DeferredFinanceCostsCurrentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r35", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedLabel": "Debt issuance costs, Long Term Portion" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r99", "r271", "r275", "r276", "r277" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r268", "r269" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r196" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r88" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceUnderEquityCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendDeclaredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders.", "label": "Dividend Declared [Member]", "terseLabel": "Dividend Declared [Member]" } } }, "localname": "DividendDeclaredMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Payment Date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends, common stock", "terseLabel": "Amount" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable", "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of declared cash dividends" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CashDividendsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format.", "label": "Dividends Payable, Date Declared", "terseLabel": "Declaration Date" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Record Date" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableNature": { "auth_ref": [ "r92", "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Describes the declaration as being a special dividend (over and above the normal dividend); as the annual, semi-annual, quarterly dividend, or other normal periodic dividend; or as some other type of dividend.", "label": "Dividends Payable, Nature", "terseLabel": "Type" } } }, "localname": "DividendsPayableNature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofdeclaredcashdividendsTable" ], "xbrltype": "stringItemType" }, "us-gaap_DueFromAffiliateCurrent": { "auth_ref": [ "r46", "r330", "r331", "r335" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).", "label": "Due from Affiliate, Current", "terseLabel": "Receivables due from affiliated companies" } } }, "localname": "DueFromAffiliateCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r70", "r108", "r109", "r110", "r111", "r112", "r116", "r118", "r123", "r124", "r125", "r129", "r130", "r295", "r296", "r381", "r397" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings per common share \u2013 Basic (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings per common share \u2013 Basic" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Earnings per common share \u2013 basic and diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r70", "r108", "r109", "r110", "r111", "r112", "r118", "r123", "r124", "r125", "r129", "r130", "r295", "r296", "r381", "r397" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings per common share \u2013 Diluted (in Dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Earnings per common share \u2013 Diluted" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r126", "r127", "r128", "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCash": { "auth_ref": [ "r300" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of effect of exchange rate changes on cash balances held in foreign currencies. Excludes cash equivalents.", "label": "Effect of Exchange Rate on Cash", "terseLabel": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r62", "r63", "r64", "r103", "r104", "r105", "r107", "r113", "r115", "r132", "r172", "r245", "r250", "r262", "r263", "r264", "r272", "r273", "r294", "r301", "r302", "r303", "r304", "r305", "r306", "r403", "r404", "r405", "r431" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r315", "r321", "r326" ], "calculation": { "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease interest" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r318", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Interest under lease agreement" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Equipment leases, Current Portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Equipment leases, Long Term Portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r317", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Principal under lease agreement" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r315", "r321", "r326" ], "calculation": { "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance lease amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Finance leases \u2013 right to use" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate \u2013 finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomponentsleasecostsleasetermanddiscountrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term \u2013 finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomponentsleasecostsleasetermanddiscountrateTable" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r166", "r167", "r168", "r169", "r170", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r234", "r244", "r293", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Intangible assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Office equipment and furniture" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r73", "r98", "r147", "r149", "r152", "r155", "r157", "r171", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r299" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r88", "r195", "r200" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment of equipment" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r67", "r147", "r149", "r152", "r155", "r157", "r372", "r378", "r383", "r398" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r100", "r114", "r115", "r146", "r270", "r274", "r278", "r399" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r85", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes during period" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseDueFromAffiliates": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in receivables to be collected from an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.", "label": "Increase (Decrease) Due from Affiliates", "negatedLabel": "Receivables due from affiliated companies" } } }, "localname": "IncreaseDecreaseDueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable \u2013 trade" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses payable" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r119", "r120", "r121", "r125" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of outstanding stock options" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r189", "r193" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r189", "r193" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible assets, Cost" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r187", "r190" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "verboseLabel": "Intangible assets, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r65", "r145", "r307", "r310", "r382" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest (expense), net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r81", "r84", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest during period excluding capitalized interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "terseLabel": "Inventories, gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r49", "r338" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r49", "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofinventoriesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r7", "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r325", "r326" ], "calculation": { "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofexpensesincurredwithrespecttothecompanysleasesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of expenses incurred with respect to the company's leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Expires date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r8", "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Lessee, Finance Lease, Description", "terseLabel": "Lease agreement, description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r98", "r151", "r171", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r285", "r289", "r290", "r299", "r336", "r337" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r98", "r171", "r299", "r338", "r376", "r392" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r98", "r171", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r285", "r289", "r290", "r299", "r336", "r337", "r338" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCovenantTerms": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Description of the conditions for borrowing under the credit facility including the nature of any restrictions.", "label": "Line of Credit Facility, Covenant Terms", "terseLabel": "Financial covenants under credit agreement, description" } } }, "localname": "LineOfCreditFacilityCovenantTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDescription": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.", "label": "Line of Credit Facility, Interest Rate Description", "terseLabel": "Description of interest on the revolving line of credit" } } }, "localname": "LineOfCreditFacilityInterestRateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RevolvingLineofCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Term loan, Current Portion" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r16" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term debt, less current portion and debt issuance costs", "verboseLabel": "Total long- term debt, Long Term Portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "terseLabel": "Current portion of long-term debt, net", "verboseLabel": "Total long- term debt, Current Portion" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtDescription": { "auth_ref": [ "r43", "r246" ], "lang": { "en-us": { "role": { "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.", "label": "Long-term Debt, Description", "terseLabel": "Promissory note, description" } } }, "localname": "LongTermDebtDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r101", "r203", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r101", "r203", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r101", "r203", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r101", "r203", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r101", "r203", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r101", "r203", "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofprincipalpaymentsunderlongtermobligationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "LONG TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Term loan, Long Term portion" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcompanyslongtermdebtTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r75" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and Advertising Expense", "terseLabel": "Advertising and promotion" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing Expense", "terseLabel": "Charter boat services" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r83", "r86", "r89" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r57", "r59", "r64", "r68", "r89", "r98", "r106", "r108", "r109", "r110", "r111", "r114", "r115", "r122", "r147", "r149", "r152", "r155", "r157", "r171", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r296", "r299", "r379", "r395" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income (in Dollars)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow", "http://oceanbiochem.com/role/ConsolidatedComprehensiveIncome", "http://oceanbiochem.com/role/ConsolidatedIncomeStatement", "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash lease activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment and furniture [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r147", "r149", "r152", "r155", "r157" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r314" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r314" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r319", "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Annual minimum base rent" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r313" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease \u2013 right to use" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Discount rate \u2013 operating lease" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomponentsleasecostsleasetermanddiscountrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining lease term \u2013 operating lease" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomponentsleasecostsleasetermanddiscountrateTable" ], "xbrltype": "durationItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInventoryInventoryAtOffSitePremises": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of merchandise or materials to which the entity holds the title, but physically at another entity's facilities (for example, but not limited to, work in process may be temporarily at the site of a subcontractor).", "label": "Other Inventory, Inventory at off Site Premises, Gross", "terseLabel": "Inventories managed at the customer's warehouses" } } }, "localname": "OtherInventoryInventoryAtOffSitePremises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other operating non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r79" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid to common shareholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r76" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r30", "r31" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r78" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from term loan" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r77", "r261" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r57", "r59", "r64", "r82", "r98", "r106", "r114", "r115", "r147", "r149", "r152", "r155", "r157", "r171", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r283", "r286", "r287", "r291", "r292", "r296", "r299", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r201", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT & EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r197" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r199", "r338", "r384", "r393" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/PropertyPlantEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r197" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r71", "r175" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for bad debts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r255", "r329", "r330", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails", "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r327", "r328", "r330", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r80" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r267", "r370", "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r11", "r90", "r95" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r250", "r265", "r338", "r391", "r406", "r408" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r103", "r104", "r105", "r107", "r113", "r115", "r172", "r262", "r263", "r264", "r272", "r273", "r294", "r403", "r405" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r72", "r207", "r209", "r210", "r214", "r215", "r216", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Sales to the affiliated companies" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r66", "r98", "r143", "r144", "r148", "r153", "r154", "r158", "r159", "r160", "r171", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r299", "r383" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RoyaltyAgreementsMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Agreements [Member]", "terseLabel": "Royalty Agreements [Member]", "verboseLabel": "Royalty rights [Member]" } } }, "localname": "RoyaltyAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r137", "r160" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Net Sales [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/CustomerConcentrationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r43", "r101", "r237", "r239", "r246", "r247", "r248", "r249", "r308", "r309", "r312", "r387" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of company's long term debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted earnings per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of principal payments under long term obligations" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow", "http://oceanbiochem.com/role/SecuritiesAuthorizedforIssuanceUnderEquityCompensationPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsDescription": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Describe the nature and terms of the financial instrument, and the rights and obligations embodied in the instrument. Include settlement alternatives, if any, in the contract and identify the entity that controls the settlement alternatives.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Description", "terseLabel": "Bond redemptions, description" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96", "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/SummaryofAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r45", "r62", "r63", "r64", "r103", "r104", "r105", "r107", "r113", "r115", "r132", "r172", "r245", "r250", "r262", "r263", "r264", "r272", "r273", "r294", "r301", "r302", "r303", "r304", "r305", "r306", "r403", "r404", "r405", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r103", "r104", "r105", "r132", "r371" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r17", "r18", "r245", "r250" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock based compensation (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r245", "r250", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Options exercised (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r17", "r18", "r250", "r258", "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r45", "r245", "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r23", "r24", "r98", "r165", "r171", "r299", "r338" ], "calculation": { "http://oceanbiochem.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedBalanceSheet", "http://oceanbiochem.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade names and trademarks [Member]" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r133", "r134", "r135", "r136", "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofpropertyplantandequipmentTable" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r117", "r125" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r116", "r125" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://oceanbiochem.com/role/ScheduleofcomputationofbasicanddilutedearningspercommonshareTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r421": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r422": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r423": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r424": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r425": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r426": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r427": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r428": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r429": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 65 0001213900-21-059044-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-059044-xbrl.zip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

^BD MZ(MR.I3LLD?-98^Y92X8'CBG"YLL#JMV)8B7%T@=%"'58=QGN]GTS ,#ITRS MZ,X-LL2)L8\]:YR]G0AZ:6#.(C[ IJ1"8@MLOU"LVW3>B&&Z5 FR'"53:?1#G:/:CY@M&U-Y-V%]\4;FHWM\V_ 5+.T)8O!746)_@3' M8OCSXXGJU%3RI%H:,]=4 ["K\R$$P)_?!E]&=V2I@R:0+I7F+P( N5BN6,]@ M YA0:34_*"V13%1;LR]W)G#T=)V8*\<&]PX-P#53\D<"JMIL M#99FUV8K2E9+>,]Z_V%\BZF8P+ F;@C4B!0;+I!V4"+YGM+(SMMI)PL7S>"- MA RN%#I%&-3A(ZC)"05*&28QZ(/*MGD-=-%TO3$_J9H.?B R-6[/<]"(MC?> MUS=5;+;%VRO=\4(PUZ-_#&[J4A?<.V"1A38]![(FHDX>!7)[EM.+/Q.9V8PU MCQ"/Z@QI.3$MB[4+M\EZ ]MK@OEFFKL;P39EH8BR8Z38OCQ.2.80 MS=/[VZ;Q@'.*;NC$B>UE^WH_[.;*O2[ O6Z?UKW^-@+/^KY_]YW<]+^B^*WU ' JTMZ[PO4R]P**OSF"O2()?)19^"[1G1\:VW_[_-##K_B <&=NA MAMJ[V#$&OD_N"2YL_W@@JB!O1A5JX5$%6!\_/U#Y'#X=MZ3@6WU.\F%V;1G3 MT@!3:./ZUBZ/.R $7Q&8I(&'#&T$D0<&A@T;"V(&# W:8[!$).Q'A!1J@2$D MZ&SB?OW %@V[^Y32F>T99CYVV*F92O@)9F'+[%E4'%+LS^J& M1P7L/U>JA<-/3.8OJ(:-H,$Z./-Z;D?-U<8@&ZLYW+L"ZCX(P"L6?317-G? M9QJ@6INLV.KFOEF'K/$=UOJ Y2 O OA%ZD1=J#PJL$;582","XRMIF!BLNF,*"06,9&:SYH-OP);H4=O3@ :]KN] MEJ+-9Y>4X/L,^DYW(WB))$5YW8BX9&*89BR&*= 5W-1#.Q$B4"_!R!!ZZ K8 MY+]X:@)9P0 *VN! M9R!S_E5I"G*CR](Z!!Z4\I?M(-N[X2E@?3!<##:<=QU+\BP)KL?G;-,/O*%F M/Z(\3"C##Z(*!(UY;:81-$44"9&'*.9F OT3$8UVC[YA1!BS+>#6 X-Y].P2 MVY2L%GQ/1JKIGNG!@VEL)^"2"+_.,,:'.Y\;>$-+!Q@'P (F,C *[H2MBCR; M*WV&J_JK)'3;;4%LM$\GS^&N2]X*O15+/IL%*_1M&]B-J-B]W-2?H%!,GR+,ZY9H$L%2 MR@5[&T2\=>[FP_["T\R\M8%M.P>QA_L<3>=?X"(-,XR*_-(YNAEL_O4E^=U\ M!N/-%6=W;T>C0$5&8L=6SRI>SLUX[X$UQEUH"MLEW:U32W,[EC2G3.C,>NZS M96OPVN])_\O@_J9'O%2]A0GRBX>-!AJ9>*ZD4X?.:G-SA0R, D/0-0-^MO'E M*WY4#1N<'_W?.M ,>E_L]$"#71XV8?30=, :4,E1?P(2V(Z'^^G*P),&7(ZZ MU+!P@Z75 NI ,G'/9$AQ=0=LGDQ:WGUY[^ZD[G=>)!MT ]S _#T T,.@;B)> M43O-@,^V; POBQ?(@P\!'^J)AF"GYF.'A&'G/3.]'38EW"'2I2PBG)CH0=EX M3_\9@^ M1RQ>S^ 3+]M-%RS5#Q-0@PT?9>IN,K:VG:','\)-+=#FH17"EX MZ^0,Z"W17QNS8.F<^; &BX#Z &N.N')@R[3,/^>@H8$Z6$ZQR,>/\L,2<[> MMB@WOX:UU2WTUQF3P=,_P +QRZEJ/P+;V+;[4O7+? :,V8_:DLQ,BG )UCFTO7NH_=2 M.>5>ZJ>(! _,OKM0C@.R/?* BVE=[$:"?O&X,F ^U!@> HYLJ3;#.!G#C;>3 M,2Q7&C&$H;.D86!;?"^1/AY-T&K'ZWE MJ6=![7"LFXX#4B&@=8.1+R88SB.F? A(7)8E9N%! AAIFQ*#5CY/$ &K"NZF M+V#'X!$1OJX@MA\$ /!K'EDOOUL>>(NJ+&KNX6JVZ!H82 9O ^@%\>RUT>X> M_!D()OI5*\MF[#]Q1Z&F M3IG9AB'#=;X<1A#YD^$BI)MI<0BY3O/5#YJX6,+(KW!/ KQ /H?*/\@$_*G6 M2\B*7IL(2V(L&>X6FILP6!^WW02.V[[@<=M7[[CM%>8M2%*\Q!"QT,R%W:-+ M/WT!%!N(VQ3#%-YA9TT]I,12E'"[T5)^DCZ:(^''H*WV*ZV&T-RW&;-\!;;Q M>BD7UVZ(HS=[4IE[))"!,;TD^[,PN.NX?;3/GORH/E&>U+FRN:Z:K_"TP:ZQ M- O8_M=)(,%4=#"Q0'^BYK&HMI@PO3(U;6?3"F.A@?U'\23V&7SMX!D\BT8\ M4P8[#X&NK.FCZC[+/?=P3SOGN-.9Z/[CGJ9.82.D;O8\.M++G&&E 5 M@^\^9E^;",?,[2HPN>O>8TW,WGVY\:BM_W*,PLFIA8LS?:=^Z[\+C2T^[ M!Y0[BG@J\8Y*S=@HO((OU@E*8*=QK""R]FXWJC7S(ZP:/Q@*"$[-%9R-UPQN MOFPJ#;9I:9BPS?PBC&RN+1#WX7"3=X#L'8S:IHX'D.A/P47@4%!@0!X%8V4I M2P?M(PO[D=1\KP+#GNQ@UB*VJM,0?;'6 I>P;+1@4=\\P$+7.MYWT?B9"'*0 M!^6:<]S#EJ S!]CD!W$( L:!T;ET#^+ M)[$%:]_V1@@\^W*]=X%9QPC@H0JP[%@K5)Z4IW:@A\8.TUR[ M M 1[ &I^-K*^P[;WJ*IVH M]JK;W,XO9(%F>\Q/T._-[R"Y*E;.(1\LV+G;F#J.SAPT7(^]6XV%9-Y-K'$/ MR9@8*)=B^Q=T"6N8:[, KU'5I[S#$G&C2JS.BADB1&F)]1G("3LE5EUEA381 MZ!^#I=(6'*N:4GVU-&7RP MMZ)"9JK9C:V]%[8U^*$TH&Z*#B_ITH!V>TY'I %)@B(W-I-\AN83]PK!&=U,FG0?MEFNS "4A':W*P 8 MN^=B/G=Y*K?FG^;X+V8LAIV?\+W!1) 9"@0_(9[C1L".PO"TDH4@7/OIA\$V MD+$#3[')/?+-"NS>&[I4+78S/^QEU8BX^CN^;]= ')] BPHL1D1L, 1TX-4' M/)PS>'D>CU3LPNNRNV=%\&BKQU_XRP/&<[UC.G<+<7,;6)8IR*7%\I;P@IJC M_O2/#E^=+HV7;2H5F&[ZPZ_^8GM_T*9R3QB92;50_Z"NA53S+20O&\ M/P[: MAIOIJ$!X=A#O)K3QDVR'?^>P-6!."]@T!K-0,&Z%%=D&XQKFV'G&VWPSL:ZV M(:*8)Q?D/E9IRD)C_&P9,*.A*@0/,J#RW#Y"06.&V\'<&&*QV$V+:,/2P3V_ MMK:"X('/CZ9.>0B/H)2QW%N>G8/Z1V,.<]#6W$B[W4@GM%?SN3;57+W#2R+< M4CUO\[HDR;;#S:J"C;T.S&LL1\,_A)K/$NM ])YS%[S2]Y:)ZRT'CUG6QRNL MFA>\>]T];4>D>_J/!2H$/*8W;8V18V5@@*+F!S'<@I(ISF:8H>_C,1X/O>)* M)JCY\$C;3:LWGJBK(^%YL(6@#?I(=3]"N_.L'1W]VE1.O'QEJ<"$Y=N ,+L* M83O)-M!4 ;BCMA9DKV6>ZA>8,KT12(K?;)C N<#Q O>P-G;.S9X!>ZD-KI]J M>;XE_&I0;O?XAX;^D]>OK.WK:.*7R>(+_1N%A (:UBS RR!C]NG%5?"E6#FR M-@JFU&(I7_Y145 .0_+'R&;^6"TT?^R=]GY?#EG\U+&=++#(#+!:Y@PP+]WK M<(97_4"&UWL,-AW,S'JG,2SY2P_D4(4=#;GL\;)FJ_>'4K-J6ZE96YE9VV!= M1F==1>4"'LJZJN6==4529UW5H1U#MCL*X516*9# M%DM=8\_WU*%-PY3(JS/+X]4,2$47#7@:WB,X([]?O.>>O:"'68S7CJOVSRYQ M*&W$$;S4;0EB=S?MOZ:%;ZO^*IBI[1\DL5J'1_/9\!J&X,2=0-B986"BZHPI MF1=AH#444J%% M%%G67DK+NXQ?B>L'K-N[?*,2O ML4+\L BMFQ@9])9\(_2=N_FL+PO=8/!?0&>0 M[X;!E^Y4K/@;)!J5-7<1"/G[77,Q&=ML!I=<1]]U6N_=EVR=./"*V9VH?K1) MDZ%]^1:(K Q(F[J@1HV1$EJMW=%C')!G$4H$IQ+P_ MRX9BKC'FBI3==FR5'ZG?2;A^OWZD8%E>F];2_/_;>]?F1I&D4?@[OX+3I_M$ M=[S8+4#7GEU'N&WWC&>[;8_MWGGF.7'B"21*%ML(U%Q\F5__9E9Q%4@"! AD M;6S,C"5$9>4]L[(R6;^)I<[%P?U5K"A+/,R_5\<*?Z[,%^R[?]CN HD[Z )Q M\;\_<&]%3Q6O5"%@!"SS&52 @V4I;[N"W!WZXBK)1QND]7<%N $4NMCSN^C% M#PF]F[8I\AJ>/?:B+0;\K0>:^>UH('1$*6X6^!2S( FCX7"S5> \J\"$0#X6 M>S'3X)\@9K,,DNQ-8DAH'%_&PGD+^R/,4K928K'*6F**5]J-RR"<)/G*@6?=INY=SSVE0"B>WP:_8[\R M\;"*A/64C/&][[P"+3N68O84@"?,(Q3FONS)LW_@'QPW,D^M-QQ$WPLV;Z*# MWM&F&N-I)4B*T0=6")_"L9_KFG]5@J7S@P-KEJE=N@#,;N#"*_#,T&26E(Z$ MPHVXO@)DVF3I3:"+0!@=/'H$R^O$"T_1!WN+&11YA&4B?H=>5;/9^9;O[T&D M+K]+\='V4QBSE99+%9:6%^ZRBGY_6)+(SHN6),MF.7=:D;(D-]X):>0>R?*% MM(77Q1*;&8-?->@GEX=H5GH5@ AK*8?=AP>-R/Y0.O M*9@7/I14K22+I1*;806/8-D>'BQZDPG-5]PVKW?VBS8?2H5WM8<_[*;7^FT> MI@3:JQX0Q54EQ4H:HW(KZ.$E@MP$BAV/^@0,\VZ-[GRB6]1*//2&HQ:%/ M>*2(9QEQ:FY 5:PQ2W>+T"W:0/W";Q:9L6T+Z-&4*^2@Q#< +S4 >/DX98A6 MI/8PO_).38OH+HZ&I9ODJ&C%?M33\4+Y-6+4 M$_K#E%!^0RO/0M!%AG&& /K>?A9(Y4YRO-U2B6)-8/LLZT%];7SU?:*NM+ M#8_2X_A/^T;3C),%I(TCK=8-.KGS)JE=3^-A3AU#1;V:%MH?:&&33[S_7TNS M3G!Z^>IQ)ZPFY$UBQ+P_*MT;WG@L1L:9^*/1CN(?QVIF5HVZ3ZNNH9-%G@@F M%!$@7?V%7Y[43FMU8N\, (9M8QKPGV_Z 1(WE?ND+IFVAS.OB/8&:ZQ,(\MF M4B%/67 _$(32Q?K85HXBG"7S:GA9*I]4@27P#LKP<&5L?3RA1J'EG%T!NGP+ MZ6%+C&"K<\#6@;G*9:XZ>"NK @77 O;U8)D0 :![85J?>.MA_%[J="&N' I2 MK_=A6R7K>2@]Z5W:B+1[?WK1BN%JXKMTDBT_E?;NMRO>.5IZFIYOOED__D?L M;%&0A%03>9_UJ)H+2MITO.#G :J5\^LLGD2'L^FFDJ M\,@GGOW["#LE'?4[;TZ.O%B@E?NLD'=84!/EH74]>?K#D=#O)*/_=J(U*_N( MV[-/=IU9IMO)X(B4A@?W/VD-8H8)5_Z&U]$D*X7S$5GH_(<2$)WE#Q/6K?1-(3D0V:"J_/CL7 %0$5X!",T'":/,1J/QWKY M\UUAU-D6F4URD).0XNS$H-XV8@^6KGW0 M2CS:%O ;2,"5>M+=]N-V ^'2OD:VNT$AKJE6%?K]N3[XL/!:M\JL" MC]V!T!DV%Y%90WQI98C?=,CE@I WV4E=F5^_7J["C1?;+F,@1Y8^QP[WIQ)HTFU-6[1=>T]REU!%D<;.):2*F2N6I+'GDH= 9 M=81^KYV)KE(9*UO:?=B5A%%_LUGBQUY79)U_#-(HEVC+/^PYB;:X\5B41.)(Z(N;ZY(.)*I&BD*/ M>#V5.@.P;9M3YP"*,,)X\IZ"Z>N6@E MK;80^I)HA;,3^Z/-=2P'6E4N5VL$2A@-9:'7RZ^G7Q^9*A>I=>'I0.X(XC!_ M?CT#F7R+^I%>[JSKXFQL/$]=%VFSS>J2RIC5]>;DUI^]%28ZEP:3KKSV[#5@ MC8PYI5WUB8-,Y\S8>*1RKCF7=J,Y"V*[)=U0_A;TNKJ>QI9$#@[6;=M]Y9/[ M)Z(_DGA;4V_B8>SN^]K47.2NUYI,WFXR51YRAL/4RPI21Y*6]5G#;KJ49*I# M_KTEODZXG@89RTOC"E9DW/"-=LK9_OQ@Y]=$EDDMMRP?7XB.?Q'%NG\RUY"O MVQ$Z&9).34T[+U.U^VJHBGWTUD0_(U'HRMO>+ZE+%GNOA6I?3-=:4QG1&0F= M87NO7BR3M?]JR*H]KI'%OMB!,'?;>O4*9'%%HOE^1BRB3"$&:'UFN@$<=S7D1K&'$I@;3&7L!;5F1:N638CP,6 MTA,"G>-5#B0=8Q+=Y-%4F6OZRZ=-VZ3/VMK?A&$%WC0^&1[_X^/X))ARL=KQ MBD]1*6OYVXNOI_<7Y]S-Z>W]7_S][>G5W>G9_>7UU=TR6!Q5O*4EP]?FO>-J M-4>:NXB ^(U!BPE7+5-R;10P[!6*(V/I].\)_09G&BC3J:9K"#D;C'5#0+WS MOQ[SYZ9E**[ /\U,'-B2EE,_FRF:1>&[L8BMX4$_[1QZ-M/(E+]X)A,7.\7R M[&J/Q>;-A M&H,#I33B2#>>PP7O\P7O?P2W 1M8.':Q 7ZT8BJH(DW%T//,X;8V4',^3' MKJT9Q+:/_#N:L5'68'G8&,64K0KT6S919VE6O46T^=BU;*(>\W?@&?F@1&D4 M(9PW,P0G$^08&;+%S8A;\DA 5+X CB/,KJV;RM$;#HM.#MGB8D !0&5YQ8@3 MGY9YYSLD>[7'J+2A!W2!^^A;;%X4^MW"$UZV:%%5"%2YWU]/J4@C_+R$.N:_ M$$]^5VF'4.RXBL6.5EZ#BK4>B'UOG@8ZX,Q7 5],Z\X#:UU3 ;%&"2P+Y@TD M+ED8-^"A:'.(K?'0%U=KSPT*I(!4E@1SMTKQ//4FKHXU76>=$5;96?PN,*BQ MP7H(B&^_^53[/5=4.JYR3&:*/O6'AZ6N4I\5IN2Y]7?TV=N IS\4M:FH'+F68((WP;X@M+T9=#^R YP.C$_OG=JQS4 M<.X?CG"DL4([7_*6.T--]^+*F?/![H!8.[-"PK)-:+O\XL' MIWUV<;UV<%6J*&V:IE0$WC#0LXEB36:GAAIIXGC!)FNO 55:[4I:WBO9&+1( MD]N8@JYP3]\4ZP=!U;YQ&RO,-^YB NXVYMO&IA)"SE&IB+JLKNU-A&>X2!RVC9EKHE]=U$#)AIF@GV"WELK?":]HHEP7@ MW9*2\IH0;R,EA2H(D%\H<=)@%JGD0N.16RKINWRQK)3W;IC/"F^\GMX3G3QJ M-G9X,^>P\D2#MZUQ =>'ZXO@S30.#MZ-?K3_+RRU51UMM"KM98NZQR]:&4I!EWD78VE<%_ ML@@B77=Q.8B5\5> 5A7)CV&T0>M$:-1KXP$=NX$#FS$7Q/)F$F!0#3_%PSV< M1TCS+?%XFC!^LH_Y5##36:8$T#@/-$6E!0 VC='QF ]B4Y.2)8#L582*W2U" MQ3+N=64XQO;&LGOCVI%83\ (,]/%@U]E@NV_\+ 6B/K%M!R&V:\*\(BE@H@* M_!?=M( K6%9("6)0W()ETGPR!*":4^!<^PY<4NQCS-;L(O=R"DB5/;&T12#C MP9A4O(76"K8JS!'="I,'O*I9H-Q 07A(C1RAWY(' U"_H!(W+^164(Z8I@. M&S, ;MJ69VR9/VC@;YGNPRSE8-XV70MUSMRTZ:^10<*?&X2H=BR1<)Z>G"XT MDWNK!(-4-%M]Z>\.L#;7W#GUO-94:XJKDG.;#;-4M&MX3AB[@_13T/4SU;F< M9K=D^A5- ^?$#9[^%\X"BU+1/'!.*$?#] J%. 5!,KE0.!?>F_$L;P$>P02S M_N88*WC0P_1$'JFVK ^.LZC.ZG5W]OK@P>NI#^X=ZH,KJ@^^4"S0> _V#;'N MP._.7PV\\@6'VM\*:G]'NZW]O3B]O;J\^O6.N[FXY>]^.[V]J+CF-Y4T2VVF M.L> ^6J*@S=+AU\*G$6.*C,?GQ4;!)UX(&"[ ]Y&(&C0#+P^<=E)-<0ZL&D- M)9$SB(/QM#DG_AD<&Q&+52UXA 8J"TPY>CW@Q-"WV;14UU%8%X7(R;Y%%CBD M!?YBC1:.^7--=^G1>!(DBTQU,-T\*@2'.NZ^40!ICK))H[M-0!A MB83YPG4H!V =\ICBDSJ&:1OQX<+]@/]H ^9T'?^M8"&":4SH*7B[ M8@CFO(/+?%3!*3$!T+B-5L2<>85.SBQT4DE=4I97HA*'F5Z&ZI8W2TF_I5K2 MG.Q^^7.R:<, GK7SX"\P2&.#LE,[NVRX:YIYE'AST7&%(6LMV,AZ];8NWJI@ M!GO:9/J&L$XUNTV,EM_KW1YH6XO8K\%.JB-QLY/9LGM_5D]ZM8.VK(-!J>$.V+:X)PAXOZ1:_FO;:WIO2H",,^YL; M@V1NL=98;&YQES$C-KM"O]<7AO+F3J;MQ^86ER,S8G,@# 9]H=O=W-NH_=C< MH@0V(S:'P@ +FW;=3+&>^3N;'ZQQ&- !F#*!J=9W2/47_BR0+-QE<[HMW 9_ MJZ=LIU=TH]=3FF&SK\/M4=\_5=DP5& %8G?8$P:C;8=.[0:%6_@*I:*P+PEB MIYW#Z+=P$,KE0EGHMI0+M_ *2D5A#QQ;N;[I<0=OX0!,>[V%,A)G*_>6B#FV M\@VD7"HE]<1M5< !#_D*I',L;]MUN'8T]7:!IF[=5FIK-'5V@:9AW?.$MT93 M?Q=H&FV+IH/!/@"S9P:[O,,OK\RD@1@\ -,*8 [:]0!,@YENVW"(K9T\:=UE MN+/C$]2&.:5-.@YM&&J:=+;9,-0TZ:#R8& /P#0,F&H,[.$$\G ">3B!/)Q M'DX@#Q[! 9AV 5-OR+WRJ@/-5])63],I7O9<=T%S>8/M&\P8:31P9)/)D?9\ M---4E< C[-]'4] @1_WNFY,C[P9DECUG!WM_4=8[H"POROH'E%7L:UP:$XOV MEU/T,QH/,2_CU'$L;>S2J[_WIG]^BEVTZ"#5T[#%='H^PG= NL*@,]SUZ-2# M3W( IA4^2>JXW2(9#/YH^9AU[1)YU=[ZB;XYM-XV8WW+SY1X*$O$627E2@H, M^]U'NI6?GBE*MXP)F@/=*LH)%9:W;%FA ]TJ2D05I5MO),C=095#T0^^X &8 MEON"55?0-:D.WMO(H1*^3$2]ZEKX/(AZU=7P>1!56CU\I9TTPR53NF9NW44^ M2R._RC9&^YY&9PEP.#'2,..'#VDM+;&5M]>XD75SQT:085MPK\EEAN[@;,S) M$\%&G( ;U3L4H2,QX.T6;4<,(#F)P18;VTX&73UA$\=>_]4E4M;6Q=KO-Q59 M/WL3Z^'K:6+=/S2QKJB)=3B6XGJ*TDX,F[*]-\;BS+0=.Y&/MY/J:$.KZRV7 M.33$9E:NU([48F>W';'O+LZ^WU[>7U[<<:??[W^[OKW\[XMS_LOU+7]Y=_?] M].KL@O]^=7YQRU_\\?WR_B_^[/K;S<75W>G]Y?45?_/U].JNX@[::TU\CL;8 MU**7)V@5V_W"6?"I]DS4H[^)92:: 0?[BNY\=65QX81N>2!PX;#F8$8*42:SN'N4=5C*,>^Q^1WUP-)6Y-+GA6=PM1#4 MT@>Y%\5[KR<,AG5-;R\*I"0)DI1A/(ZN([G9D"0V\CP8JNP?HDTY?P1.HF4[ M&^N7,N(9_%[CB,P7NOE"2##?R<8VZ@O%K), ??J3+%GYS@W ,0PN]=$)_ZD__3@"57A"8F[]83.3N]^ MX\XO_WUY?G%U7K57DS^;47@&R ;N]P> ;!22,ERY^Q0].O;U7ZA#P4+HBD78 MX/IP],4$0.14'T:^J*W]5,I$B02QRAD>L8$,J\X]+HX/U\@>K*]]3=MF=&Q34AE3\_1K4! F&XK["?TP0A4X0Q1C MA'-P;1(J?$/E54H%HI\:C/E&!4M%\RR7;<.8KVO8)K?8S2U^J+X.RGF9!099 M?3LN-*UAQ1J!?F+#6K)L_(98%!0:Z06[74&64FF\0_25SSRG<],UG$HYIN*: M5\^.=#NK9@ZL,[BBU(WG%7!H^A%U4]""'JG*R]$+4:PC8JRTJ2!_:#Q1\GSS M>JZ\T!%$IX;Z%_SZS:2[GC*;D2#=-\6:S-@>1%%@_]$T"FZ'A@@6[LW/ M!.<0IV.A2NY=T^=_Q4^*-/NGV"I: N'=;\'\5LA!WG$^^OWK!CC'ZB$Z8-"]B<,2-[=1[>5725M46-9N M##*AHBFX;)1ZWT45]AJMO[)1P'JI[==B#$[=!X"2E_HY'+W\=Z'3:LV*(J6* MZ&6W.ZK!\@2Y=[:E4=ZXILT(RF*]EO CR=4C:,O^ -N]+IN*WZ)\O'9S6:0E MP.LC8AUVNC?(:*=KZ^*0RSC3BYN9&XX,WIS$;E4K_6%/%KJK+L=M M3Z4&WP8KOZZDEZVNI%M7C4ZG634Z67#3>[.R@#]K<N-FD>SFD[])+FRK==5JS!H0IR;,8+:KRJ109V1JC@<"5*W9#S7 M724R;)8=*K=68=CD*I%2,;^]-6G8YLJU%SNL;!BVR!@TO4IDV%CUOA]5(J,= M5(ED<_1V6#(PVKLJD5+)7*!*I TDWVF52%4(:D&!P:A%YO)0)9*%B(VRTWM0 M)3(06U E,I!:47\AMP+*[JNJ$FE$G6#_4"6R%=VJ5OJ]_D 82)51*5$EDBPS MV%3%T>0N5*:!BHF=OMUJ]H^P&6%:_<+:YB!9WG5H4E5%DRIIQTVJOM_=7W^[ MN.7.KJ_.+J[N;VDCSCUJ5I5'2(+65?DDJR*$H!^Z-L"5Q7AKN2C4-@4;1-[2 M:.>]3:_JY'G5>=@H*]KQDMO8*4N(-C[D:?]Q @$*& ?:0C%LI8DOG0 :3 #6 M9FW# 6! BT/;@&O8=7!";&RU"-A^A__2'#M\VW%JN5[D;^XJNC! 99/$LM&^ MC_#' OY&1U#EE<7",I_!!#KXS?HH2I:B!E7.9%"3-$ 2@&N#'R@/)#"H1U+$ MHBYH^JK;/4[>CGC'O]\ I5POE))TG.RT^4[8A,MNO5""REA86W M9F]0EE+]@DW"6[,G",*;= HRB47=SF O#5!?++AL8K&)R]OAH^3W,JH<:+;6 MQQBN)_V]I:CDEDR(]H@Y+3OF*[?BJ)4U?/E@F MJ!\'%^:5R02O2*!.\4%(^A/8W'S#C_BQHBNPM8#9[(BWP1566#7'!WWY.'F? M=Z/"ZG5JU@/#-/.XR=OHU>RYB?TT7&Z$LF[/K7>6#YN MS_)N>K9^"7:>EX[Y;XH!2&97WCW3C"&3:]NH(U%OGAJ*_F)K-#GQ13/ X&J* M#@K*4#7'?^:6V*[NT$>N%\3+EL8.ZA-SAJL;1EL"?XQ/OIC6DV*I1[II_L", MT)T#O@,=D/F)[:O\56O6F6?$@E77->,&T%+AC68('9^NEJ M./!JHBS@69T.Y7,7]/6:\0B0F-8+>)"/1+=9@HU,IV2"4P:YA87#!&%9T$LV MP8&7O*4\\>C86<"67JX<9VXOB&.9.G'G."!P,B-SK,,!C]&&A4UO/K>*D/G? MV;@W!)DASV9> YV#!B?_I \:X!H MG%8([YS0P8O\E(D/)AAAR_"P/7VA2^*P+Q\O 2D\?QH]D1@KA@0[YKY0QQ<( M!5[%PK2)0 >BKR6IQ0@9( I'FD=^ &#"4T "BB^L#@6$O/!C NX1/$)'*(X3 M0'$1H/@_H[S@IU,?B 'XH;S@^3AH4QY,^%[@G\" VH#GR0Q'2J(FDCJ_C(FN M 1,(]$_Q%_]C@&;YHR=-U_W/..\SG/PX<9:?Q-'N$VT!L"Y_HX$I-M3@4\"K M]P4X6WKX>4"S@ZP!+VRKAMH5C44P-&G6N& MJ9L/.*_30F9V6.(-$(LEBBB=ZVB.D1$$.A&2X5ML=_P?E!%XR0_#?&)JV37H M?W,6N*7 SRZ8?BKSCD88DS*8D;F=T]R4-PBA5 M [&T )^:IES^#7P'P["F=#K4&+4O>69/LP=X M!KOF9P#R6P+ TZ.BZ;Z1T@S.(SQB*OZZI+@HJNJQNL:&V]IDPO0_"K&CPQ>> M"L&PT&?P4)& GPYZ^%+@J2\FG@;4,2!4TSDK87#_%63M\6Z8EZY?$?;M8Y W M/KE^Q''"Y*DB'VSUPM'&/S6M^B>AW$N,!W#0 QZ#E[G(@"!5@B=3*$? G9P* M9MO20#&B( (O*?S8,A443X-J*F6Q +9![22 3%@TP4'_0-:>*]0.4=WEJY6 MW7R=%*H>>(/Y!$QG(X_:<6W%1;45^ &J":]ACZ.'0Y6#!SHU2A ZTU7 Q?8N M*HXMT.?PGX/N+Q&YH]D/_)U-O4T/(=\-U/WL=]1)9Z)Z!G&-JAQSEP;*J<8< MTB=_;_AO[1$>YD'VB4Z3/:[N>6^ JCEZ49XXQK"!YMUT[4B:T=.?U+-EG_)@ MYMF@:OJ=,OFA/% 7B8W"CF8KP\WYJX#W!!_KMIE&:?I\0&98;Z:;2!GXS'P& M (Z8>ZL24X7/_Z:NE8IJ'FT :&RJ[&T%,$:_C"]J$QP>'MVP[]D:OAFR"!@T MW=\UZ.[@&_P;O#GV1P ACO?FERF ZW#A&B8[R*;Y+NJ6@*\--A3M"E*9OR&@ M@?E?C_ESTS(4ET459S-%LZA>@?!1"^GE&9%1P";3Y'E5P>^*LV'Z M(3A7!%_:.>YI1NT(N2/$M^+94R51\:>2&F!VX643E67\=G M^55G;XWAFY-[FJ#3=?.)ANDT=>6YN> (\;8[G^.X6,_N3 -CYR=J0-*Y_-7P MGRK#9D;$M:J-=NPZ<:%^'T'S77&X?3MBS$7?9Q"=L'UN'I@SM\BH!#]A<^*, MG8$W+E?.;_8#TGSCN[T"BP;LH+^]T(35(JA+L,[9M&9^X7+8E"=R@+'9SVN@*63:U@=@F^.!+$OBC( ZD9X*]]\:H] M2%CVF0/Z=TT!O$,OQ[\FR,OJ=,=TQCK/,:,J.3-M6BOP8)I8@V+JZA8!0R$- MOHX*A7HGBEVA(PV%WD#.M)7LT+0/$QVA"]@0Y81^>&V8D+M8<%X0!PFMT[KM M]WO'Q86A_=OO=;???GTMQO/[@[_2^Q$+RYQJCK_/PEWDUS>0'PC=7A=&M&N"(IN+P<4Y?I&>>3G M-*P(Y&,5@16C9]3K"4,Q$7KLB'4'DBQTN_V&0".G1#4[8.#C1%Q;/Q!R%HVR M(S-50@AR1W3=ESQ%G6L&5B?1PO+6.QZ2((TD0>Z\>O];$CIR1Q@,BSOA>X(( M4<(F *_6$Q<[KSH.@^TG[&MU@4C9;I)7( .J6C,FYIQ4;7L%J=,7Y'X&XU>+ M1](31B-9Z'2: L][:=2(4 /8(X/36+F3)"9C_,9X27FD[-*_!O2>7FNRR0 MK3QG1=MHCGA'>4X>B;;.1W@_'(V$P18I^P_M1X$(<5-?Z/6+9VWW GR-L[B MA_8[R]VDTGE%H4(_Z=LU_>0VPTH2 W*,FY_L\YN]-99Y\A".V_WQJ4, MQ\OK-[X\#6TW7>/VJH$ K!HIDQR?9)I0P05WMEDO?W38;T^_>7X)P4/\C7L.:"_<(K#[FFSWCEF!"K6 MQ]J<\D^T;4C\1CN85[#SM$V-.9W:@ ;8A$H2OUUQ@SYXS?L;KU'"!+[\A^TN MD)"#+A#2^^\^]A12N5@[@0]U70^O[U)8+1*TYDYZHD:/1XY>S:+<6UGH8QF< MQZ)8# LJJ8/!UMY,6U+IN:6F=K ECG(E(IW48ZUVWK #A",)Q]-W9T3UG=H MKCWC]]ZTF7"S$P\;L08U C_%9CDS1XATE0A[2& #"OJ[H'=:A$DKI5U5FF_U MBO%B(%!\H> G51D&VC+E$PY56?=X^"[G+)]MF"0*:@@FI[K$?U&4"8*N3I.D M/*BT2?P8FQV/S4=RS)_B/F4_A4E&MY;>8\7:]'%Z_IEY=^))#J/HQ M3W2T8Z&R-V\I[N+&9,IO-^AWDD2O-Q2"B""RA[R17MC,5*-M:&SF(ZL$VP%B M5R3V0- +GP+B=3+RIA;1)^;$6.K4M#S8R(.*S!>Z^4)8+R4 B[:+H(9B3 PR MQ;%%GBBA PV$9TU0QR\QJ/R/P5TV 3G@@N.0H_46*P-BN9BX8J5%,7G%(H5\ MO_0%=H_[0JTXE:6.>!JJ5D_<7>>.49<=17E$'?;"GM7N")&E=9#X>EH'C0ZM M@VII'=08/;'Z8#JI*C8-Y$N)3-Z.P-;[]EX245$'77CI4HQ5V(K'_)<<.:\. M[_4"].!/61RCQ4%T^>'ZY??>*EQA\BQO3$H$U3&9Q6^B[SM&[*M^%D*Z>VB%KI#%0::EF+ MGD8R4C6[W5@_LC^[]5M)O9;]'GBY6@UX:$T5WM?I"')'%J1D%7$K6E-U):$_ ME(3N*'$+H46MJ0;)VX[[W>"IO9 ?6E/5T(:H(XBCGM"7BM\!WI-[T)(L=(8] MH7MHTB5WMJ_T;_'V^RGJZA5MO]=-MCEI^CV//$J\QM94$BC7SD#HRQE:MM1R M05L<"3T\+Y&: I#4A(O:W12!WP$4O:1G6I-KE$=\=M692A;$/H1.G0PXJH=S M(8SK"?*P*;VRY$;T/.CG:'E0&1 IK24;8ZD.W:G6NE["J-,7!H/B_M>>N.!] M0>I*PK!?_+[QGB"BC/Y$;=Z^_+J[4W4/W:FR._<=H2-#M-'+T*JFGFA#%#K# MH3 89O"N:P'H_>@X2QN?JOT3J1'QAM3/ 463 _H=M:<211E8NPG]J4:RT!\U MH#^5)#:A-^VK;D_UYN1713-XTP"38[MTN#QO$\?1Z9SDBC=]U! U+TK@/HN- M,3JIYU\[,#N-L#J=ML7F^]W931+$[D#H)O/!KZFMF23(PUY:5<9K0H*XS:G7 M7O1V>]7S:)H69Q\ZMYT,L/VMT.TF//NF]RXK9?=#82#WA8Y6\[MQ5E^W9O7.ILN_%*.[>]WB9M:R[W9>O1-A#ZDAAVQAC0SA@I M]^DSW"),:7-A$,=K/K&F10S#9TK+MCM'L=B78TMS5C56&UL*A0?[9!@D:,HF M\+%N:USB:SRH3&L*)Z2VD5&"?@2T?<=^=(:KNSE2@09M T$4PYO<6 ,8[]R2 MY79K20S- >%36FK1^]\Y&K4%O)'6D$OP?Y[>M0V9EDMIVD;ALDMFF\;<'D]T M:EO',#TQ5&?2<3_2IJUB5HE"&6DQXS5IPSO:*9RQ90,VK!%[QWL-V$;OTK:Z MNL%*+?W7UM\ KXYG2NC#-AP-0\4SHJQ4@^+A$HV]V#_KZ,NVIA=;H=9J8%^= M&67]"9 &@EYK8_^FE;OBTKNM]8_E5+;?U+RIE_-W5?9::Z*[64;/M7X_;*U* MFV75*$ E=UR+J.^ 6?FGF3:9>0]1.5KN.\Q%6Z[APNO:HP5@"#'9],_+PF]3 M.J=MD"HNR^9#:<:N:'*T*UH.N<+:F#4_Y!K8$RU+*R[IU;3BDCJ'5ER-\&"R M=-++Y.>M;='>\3OI89G$-J'_.>L>G?4'R=:1FK]?[RR3JA,%WT->O&:O_-QU M7$7GIR[JL22?Z?8LL$\2BTP(6!N@&C^9$5!UR,'+31U%VJ*5$9[U2O.AG+#78&>P M"43)%J]#6 3X\'@$7CG'(QUD'8VV#E4<^H9_:<9"@<64B:9KS@L #U\XIOF# M7X#"IQDRF!DZ[K'#\LCJW49U MW*O8C:<+?-5^NIJ*7(Y>WD19: [K!@=(F!#[4U5+UYA"O,9(4K%G_%C1J5Y( MZ[W8$?I#9M44)^ENLK3'\F]$092ZWF]"C2"+OBJ+]3Q^(M1>H:VRM EZ_A0F M8+=EA388^'"DO!/5X_([)A H.)KCX@?*',V;S<_ L:'Q/@NB5>SQY]L^T(=C MPKMHVZDJ=+0Y&PG@_9L92@]R1>=\KJ >!7SJ6C2>QG4-3 "A<&'(CO(&^G# M7SR#WJ5"!^KC/_ (1!I.JO^8$% V+B8-V()$/8;?$N[*= @_ M\/T+6%Q%_T:EVT?G5\']AQT-;0<^0!-%8W_=55FPY&U*BU??WO#5K;G4K-*S;[G1G+E(:"MR-[K[UJ'76%-[C0WZ[U;H M3:P(H%K>ZPI,XWLSN-VEX($.&,0FM!C#T$X6\[6X2N>K^F$7!1G\."E9C)P9 M^K)J$).4=VT_[_SHS> M)[03*6]AN.2^,,&_-J2-[65UTGV>&U7>]_WT]JM;RW+FI7,*G5Z4SK M1$O7J ;"(&\I]]#6BFS0&:+0[6YL%+BJ(KFU^^X/1[#OPI78-93E%LV5I#)W MX?QD9CF65AFDPG: B MKEF:#2",O&9=N9WDOX8FG:EII!G%)]/Z00L3O8PC=7,2,_DHFF!+5J":BE=\ M[#Q?5=%RR+]L$J:7];6]TS2:'E.<)"Y$7GEXL,@#3:,NI[HQE!GX) LK9)+9 MZZ$0G:$D=OIII>&)W\CLY1PK_EX#N.DZM@-,0V4P+>F>5O:VKJ -DYYA;8X: M'D<[,\U2^9^N8D'\CT_2LU[^-H#%ID6:["QQ.M5TC2*.G3FB7EB-S;[4\T\- M4HN7 @GD4O [" M5>\-CZ9U706-EABOY3K"$H_[J]]80#FF"+>4+FWHBR(@_YJUJ#: M,D&?>"&N$,[C9*5;ZX05YYC+X?GG &LYN+SD2]3,:>'>>2TN>9'9T\"08XA= MZ>D10@;PXE/(J][\45J=S@[>'A5-5\;L-'YY.'ED<#7NV0U>"8ZJ"1NADKVC M\YPL16+RZRD2$P]%8KLO$LN4!O2]VDS>X]I:,5D8BJ.P(E[NK9J]FJ6D(ZEL MPITL6WEX+<%S:)7:^-C%%P$>MLC,=/'L&1Y0L;!5&[M4 RL-%ZH)*\+FJF87](._GW2IFR:^#] M]V$3,5A:PC/?U,*4\@^6TJ2&-\Z8QK*PA,LGZ3>2**/G.3F/A6H9*Z93F2]@ MN66PN+==833JA#5R"B#;FO.Z";Z!171J<3T1)$'=1L#YC(59Z<4'6M)2"%!N MH6@H9TA&0Z6A(E:YPTKVC(JB#B8K])DI>9<TK /! >!(XGO$1'0T^W MI9*QDT*:GL@N%7!+] TAH@#F!ZO7'P9@Y8"(>RL/&<-EKS3M+&FA#8S 2GLH M58DUT9@#:#LF. /FPLL]3[GEX%HL5+6Y"PU4@?]VY[&ZS?P#695 M."K0E'1F5- 9KWC\B:]@Y<^T)NV1\ \0Y8(##FSCA?>JBP818%$)!!7F@OYL M#$@(]=_Z5W+Q5ZHT9'PT]4>$34>6PFO0=*,K:L-6!3M>'5TT$>#5]:W0?1&] M\78I6.)=(*NU&I]\%)TT*1 B%&Q&M]L/7RT+ ]_/B<=C= UN-6<$Z]70B%4'D*P+QT#K/#["[R$RTO!].K85DE,-VI^P +^RR/"2'= M 5_U@64YT7NA*HDF8[#LDBB6KA%K2" U(Q!3VTP%;$(,MTKPXWC!Z!U^9_./BJ6! M9TY+]H'9'7:S#50JOB$L[PR^9OA#<,-;\;!#ZK+T$PJ<*UPMZJ<65U2R@EZB M.1Y:%SM?Z!HK-?;J8H%6*:"SU-I*8<7LB>V.L8 6]V$CZK$,]Y$Y&5/8\%2! MT"**()H\]/%,^P8'^M.P< MRLZL/-:#!^9IO3WU'60NCVJFO!BA6XD,S959_KRR*'L3*W-IK'PP+ 66NTP6 MT:/L*9.?KF9K06[4M@D5>.[. /_FA?]&N])00FFV[=(+4GCE'?XPK1?P"IS@ M!AM3[?B6M^S@@'HH(?\%]^?>>_HB?"SR6^\FC;< 7I.#U=^.@&5ZTI":)# H MF'94^6@61@ARLQ:8#V84WO9'0G<@I>2IYPO7(9$;?;16!@]>CH>#=VA7X"G# MG0NH%L<$#6UTT>!GWKU'GM[X"IPV;Q,(^8=UC(^^)0"3XEY2',K]OM#O#SQ7 M*P4M_/L0MV_E'@X D=*1P]S&D3 <];P;&=FV$Z(RN;%]S03] ^MZX]+"A=(2 M^!Z QH5K36;H&@5"PY_1JX-GI@5*C[GU[]6QPI\K\P7[CG98NO_&NBM]H&Q MWTG])?"!4M[P5F0R@B>6Y*=++X\ P^CZW+?-R[D]0>X.&1$57I*/:$2-3*V9 M*E/XF'C =+B*[M;OB@$6ZH47>]Y=-KI;A>IW/8BZ\#C%2SR@G\:9:"4>&5=[ MOQ2/^3\CG/46)Z:)TF8IE831<)A=2!D_R,=B[QT7D=0G3=>S<[8D>XF&#[ZO M!21!PA<15W1_WPZ%_J@?$TGXI+]6(.5N"=(8L.3^BB1PE:+;X.&/T6TG4?_' MF5D8KO Z)NE9;YN&%.+OB$J>AJZ0^QG.?KK MOIZC/^EP]%=+ \K:]< =UGIY,:-GQ6MTEG?,'X^;)JYE 9.\K*F>IL9--='[X8GQ@%3"H,7_X8RH#V$#&Q4T M@QU\R5F:_8-F(- "4+U%?>E,=\SC1BBTKOV!3 ^)3&R\%P'$@6#3UIGK$*V8 M>^^5U: S&SUQ\&)1JB\A=!^_T%=784QJYY?(<==" 8LZA9=Y:2@_'0W6EC8J M E91>/ CQJP RX G_3:(L;Y:X!XX#([((\%;6"!/7VPA/O'DQZ4G4&%E#.8[ M:')%#ZI7V(5X[V>L5Q,RKFY":!QYR'$M@SH#R)MQL#"W0^@5 .H0PKJXI;3? MTE60A^G=9[^RQ4\L^I"9P>%Q;)D_"29O-/)(O,2!KH<;]0LIX57HIZ"I!A&; MS(*]V\Q'\VIGB.?[I!2]^LVH6%\VY&MG*>,823CBO6KX%L@!:YN8FJ2=,_RC M B1^2D:ZM3S]#4_@O'W%:Y,H19[H97L_(H]5(G#TN,YF.G)!@&-UXLX194%W M$M8;EA;*XM$D[=7@?QG)%4449Z A:7]:\+ML5CU F4]=FU,$]N@/XG- M,0U*L[U,.$ X[<"38X&N-B$1OO&XDY5PT9X1P%TZB73M8W$%>RPHL3#Q<]J< MQF>VB;ZYY\3-VE;.G+V$S M $^5>'$MC5\=ZMD[S$@"M+SS1/1'WU;6Y7,OC5#H'/,K),A"EW%78Y*9CZ)QWUZR'&#@YO'S,_^%B5::CL :=P$_P M@>[_?:[9$]VT:2\090P!.&8EL=O6+?A5[%8]C=U30J+62=\5*$<(4W50N: @ MZU0G2^PDMI:=NL?\F8D>F5>P>X-V3T7NV3->@0U?/$)0'Y0AAX*R"@.M:K*T MX9CJQP[W/U&\T#:^^(.!) MKVXL.W8Y_SNL6&('B:PCWEID\BN0B9OV-I!U+]2_#6B)9[&>X\.CHV@RKQ7< M5:_Z-@ N6FT51$0LP/'@])<*Z^AH;00N:O-3\&;5"#EC- 20N/?:AR#V%WC/ MD\?_#)HJJ=Z=67PAEBB# 'A1 .VUQ79M\YBPU*::?T(;XQQ\0;#R6= 9.,"X MA7OGGN_1N=.8SIW^F&%D'[@S0E- M5<3NI"58'H=S>/504V \@,*_]8>:A,."+3\$#>)+E'*LY[1#%?0" =8/PBX> M))X74I?.C(T6BT%*J)3E:*3W>HY&Y,/1R YF<_E\V;"$@90>X6W3XO7F]/:> MO[SDC_CK^]\N;OG+JR_7M]].[R^OKVJ=#Y$QQI5;&^.*I\N0?\SZKN.70>/5CA=FVN!XPN> M?[RX\@8,/G\I\!X=_1SYJ6%@;0_SR3"6^@(^-B#TZ%]!VP\\N_*.!Q/%"+&H M#C_@@M^'<1VF NCJR>7_8'X([# )P1\!!+ZWPH#XIEB365 \'H/@#Y%^%@#Q M1P!$Z#_-B$+1YOTDRLZ"]SA/3SLPEVRQ)AS!Y8^)Z>K@&*D0:$V0+O3&B_^7 M 3&8Y 41XC#XQ#LT)_"0)&F*S[;L4[5'EMY%;8O49^+7GW"TT7JI+%;;Y'[ MY5,7ST%2^97;L%HES?YWWZX --B?>#+U$CF(\<]4@C-,AE7+A&A[#B2S;7/" M>DO0O([M+A8ZGDSA$2.[I!<[MBG?U.P>;:@53>/!I#7RT?W[6/+C^>\&U3UW M6)-MTXA"9ZHHO#G-NAVD-C> <-ARO2M[B-QUW1!H1002DATG\S0WXOAE6MX! MI/-?1O'F#6+'@Q^MCQ8:(QZ1'0"!H8>&@-Z&([0'TN+9R //G8Z'5$2Y5$''/I.5QI(G8]3L?.STY=$\@R^O?@_YH0HQE@S MCV?./-!+1_#J(^!A"\SI)W#VJ/"].3EC)2&GP4T*=IOL=Q>,IQ24.HZ)\X0% M:EYG"+1^M^2!NB588N]=CV"1&^R)6-2-!-/O"3F./SX*Z,K[JC+%Y( M?\L'_5T[FW?WB,V[^?P2O!-IT12=5Q*Q0J&7S^C=VAE]@]->#I^7R>7+#O^[ M,L,<601?T0=_=228;;++AK MPNZ464?(K+*X[$0736R<(:*G6'CCE02NJJ59 MN):--;?4^W!UPNH=NN^5#%5EQWR )J6P^BRX0:!59A]S#4E6D4&JE R)*L(= MD6$[^Y*14%+V(#;8/%W'41[8534\YU;5 M>$GKI4%O&-$'_?6.M_3GMZ#+W=EONZ1+%!OWRK-IF/,78'J'L :K=WB%3PGH M501-=3'XV>G7!B/R3-$GKG>U^JMF_,#KDENAM1RDG5]\:3#2SK&P5BL/9W6Q MXM?3SPW&ZE=E3/0F,>'-[46#T77#.@N5*+KUL&'F=$P5.#VC)>*TZ#;59M,T MA?B+]R_6*1!_L6"],<)?8-*&7G%IADM0Y2BQAET17E?VWG\]9>_=0]G[EB7J M2Q4_O5)+Q]-!N;O\]>KT_OOMQ=U^U>>O[2EP$XEG6<^WL"6"?WMUXUU/? B3 MT#;V G)H&V@5,]=4G:JQZX[LBJ(-@+'B.=2U8S)3]*E_2DG#:.\!K(4FKN&8 M''V?XCHSD]X]K*X1P]Y63'FO[GK. MXRP5FLUK#JRIF>.#I)4O:?SO9#JUR M_A[T'+'.BV$WA@N9"]F^\!]5@R4DD M]PL$;[$0(AE 9'#QMG_#QM F[:U2;QN8U@9^>"QR%(TA4E^;'F_%/* W\9B( MR3?]=S3BH= E8YP$D*60AOXO&5DNN*_KJN??2@ M*(M/MP1[X.'=QC/%GIT:]%\7$$L\*CK&$J?.F6)9+^ 8TQS &W#S-?9ZUU;? M\,^V]LG0=&!FRT4,?8S#92R?'TFH9L2N$CUF814Y"=, M0HT:)Y4OL!GUE(ZU_(WH*NSFNYW_8#8_9+W @-'# M-C0,L#"N?\$F$-NG0?_-/S5G=N8-A /$TTJ2ZD\#>V(,PI7'@45.H_(#D[!F MEUYCS7,V8!,X\G0R@055QIK 7\2^86.S:P%0CF$KP!,= D14^Y9,"+(:$/A< MF2L/1/VF3&::0:P7D),+?VQRZ:"FY/!Z"2OF _G%,N=H)1!P)A[WQ)J?DW$1 MN K@,'X2'H7J[/3VXNYTXER93MEE$VF Q$_";XDWC_UZNA4"G+ M&\H/UC"&HCMLCDO5@:*'\[#B]3"U@#6*@<6JV\A75!"WVL/,L>]-4+-,W_ME M_"B3T0>_AI.-RRYUZ*2X0?U$*(,MGWS=Q>QJZ347J8 D0AA? T0!*OVT-.T8 MNR_%R'@]UK4'ZD7<$CKNZ-X$>PCAE-?H!]T+).GI!/2H3:^]7IG&I"#J,IR\ MIQU7]^5&PYQ2O=!/& )J5)D4>U$K!@?VJ<-&NR+][\TP8+AA:O'4LE".EIT! M.N_:+L-6I!RJ]1,Q3D-A3ZNS2@0^.X<]:ZEE/V&-@C2'IQ^P:AU\,AU@4,^5 MEV_P0JR$_(LHUDJ0DC68F>%9??3BP7-%9R)O7CKWRJM38A%,7$]OZ?RXZC$Q M6)D1BX!S;WXF-XJ6'YRUT*3XF(/5Z;#J^20-GM6%6F7R2=K*B>Q6C7R2!D]" MZ=?&)[$Z[5.S':)__0->/')YMVR8'%^&?Z-VMNA0[4$5YUZHSDSO$S]8#HU\[+ M H"QM3D$&\A]\7"_&\]S6AV#ZA'P4?TO0,#ONT> H9B2WH=]@\N_Q7 MG"S+/S[QE_JXM%9D?39>=&E]V(+E(*.>( :/.OA__R7A=_Y.(GM1(S\:'7AH-N.W"PK$8 CO1:BKE,$=9W24==O)^KR&Z_R43?8">I"E) '=!4C MF_:^4@&0YX6N333G&[LAKFISUGHK>O(+N\??XQ$#>(;F? $.'%ZX>]; VXS> MQ/-J%-B[&&"))2+0?5P";WMCTR_7V Q? =U.53;(#!QS"-:5!1K MIUS#$"#M.>ONR/XW,1[3>M=^PR-)'IWWXG>*#^CD2S0VW,6V*5[TDB" M]_>B-F] MX>N4GH*0ZL_!O%K#5P'U]CV!U%C#5P$M]SU!U!##5P'EZL_R- P!^Y[C:$(> MNR$5']*^IS=V[3 TDNA[GQYIE)_12!;8]QQ+8_+832'XOB=B&A'.EUT)O>\Y MF%U;YVJIM_?)F$:9V6IIN>^IF>:$\V53KOY$3,,0L.]5*TVP_&7?_Y'W/0?3 M*,M?.O7V/JO27,M?.BWW/5G2&,M?.N7V/WMBUO6PBT;M[ MGQYIE)EM) OL>XZE,7GLIA!\WQ,Q.X]FQ5'YW2SVO1AFU]:Y6NKM>P*I66:V M6EKN>UZI&=%L%92K/Z?4, 3L>R*F">%\0[KI=/<]=;-KAZ&11-_['$ZC_(PF MLD!OWS,ZC0GGFT+PUN9O;BP3]NJ\W.C@UT2GLWQ^N7]9D#C9ORJ&NB]7.GNM MS<"TA&3EGX3U6IM_R46RSZX&;S4>+L&LFH]LY,%KSY?V6IN\:17IJ]6XK4W: MM)6&%:C@UI4$V9;SZ19'QS JX9_?-$.;N_--1*F&3>C I&^*X>*$"CJ?%)[\ M4X$ RG1M$OQD,\?LN\9O79XLC=.4YP.G-9[36INE:RT;5.MGM#8!MP_T+-_G MZ+$STQ=S9?+VG?MWKH\9E/=A@-_I?)7ZW*L+25^M4Y$ MZ_*7[:=B!;[$*\@-?M$,' 1,*?GJ#YK[KR!YN#."5ZIP!ZU+$[:3NAER ^Y!E@Q 6R2PM5FV-J53F*1GKNV8P]JB/#[\]6)\/W>??AU8H\&_I/]\OW^Q]<'CY.^._KOST;DCO_\] MD'\\BY.O3N>_OWR1[O[U\?'Y\]E?G4?USOKK]YOK[_]Q#/OST^3LO/]?%_;5 M[WUM_-.Z&ZCZSTMI=ODDWO]+_/VOY][G[E?W:O3W_.'G8OR[,[VZN?SS+X48 MO]Z9/]V7OCH>=2\^3B]#JJ^_/F_LMH^O./_SZ; M7O^J_']?SUYNSW[>?/SW]=VWE_G7F7'U\\^;7T>__7FCC)Z?_NO%[/QX&?SU MWZ.>.' O1K_/Y/G3S_/)PZ]GSQ]?_KP\^_ORC_Y?'SN?K_]^LG\7^V-1'$H_ M?Y>TAW_^\__Q9W>W1T )Z&"5_'%M/"NZMX8I&%KLUR%M=>M^:+H MSLOI@T4R'B^TA9:MS7NUTSTLW\$?MC:9M2?N804D;6VFJ]7N806$;&WRJ\4. M3P5D;&T.K.T.3P6T;%7S+_3X!B5[?/6GD[9 @#@\Z@Q+YH#6)E_8T;NFZ)V+-OYJ*L:N#A[+YM+55,$TC4Q./X$>MRR'46,!\8* ,#-2ZQ$6- M-RP.#)2!@5J;-VD:=2M-4(Y:FPM93R:(S%SX&+X^)X]$-UEE@FFHWL^,AQHC MKJA\B@.D84[Y9#^2^F7*9VMS)RTB?+6BV]JT28LHV$C3VMJ:H_6$IZV&OYK& M ]K8Z[&N/2A8,E9G;JR1Y&YM@5*5Y,X#QRVAK:QO@'XO]Y9BV JM18R6*,[( MY,>9:2U,BP+QVN](C?8TB=6 M].=D[+R&$SVQ,SC0J/$AUW#_:!1Q<+WDU[W9*(U:L=B-#B3=)4DKD%*QO2FM ME22],AURH[PH8YT$)*75ZJ>3GZYF:]E./UHCE6+[*5B&C[-=55]/"$YFRFD>G%,YFXCO9(& VMUYYD%]N7RFD3F9N2 M4!?;EPUJ$YD;4E,GBNW+$+6)S$TY(Y':FS7:7+0('I=KH3_UV3)_' RTU-[T M4FMHW10K+;4W#]4:6C?%5$OMS5"UAM:-L=662S%.^_+6Y? M)BP/E;^8[F9W:^]IW+XT6"X::X\9!'G/:2RW-P=V9D)D9#CLR/Y6LW]\?OE, MC,D,&R+'W>P[12?V+7DDADNNB+.!Z'N>"9/;FPEK&<6;D@^3VYL/JY3B6P*2 M'%EW.IF8KN$ &!.B/6+9WR[;4S1#V[0W/]<.WF,=*KRN\5D2#'O/<>W-$K:0 MX[(D//:>X]J;M6PCQV5(P.P[P[4WB=H.AFN@0]>88**]Z=UV\%YC'+K&<%Q[ M4\TMY+A=.G2-X;CV)K[;R'&[<^B:PG#=0Q:^/A>^$:?DW?9EX5E[-AR3Y@FN M7!TA0V,8[G#H\.H< MNJ84C74/YP^OQ*%K#,<=3AU>B4/7&(Y[#:<.#;)MC?&K#KG_5^=7-87W>J_A M&* PW??/NVH,W[7O,*+U?'=(F@'?O8:#@:;QW2%UUGL-IP,-8[ML%VKWGO,. MIP2O+K@HF-"(=:(MA?=>PX%!P[1>"U.WY?/=X;#@D+JME^->PV%!PS3=;HMX M=\1VKJ$QGK-GBD7LV#ST.5%LUR(G'E#T ?\U_G?AB_%-B;>ZMOHFV,32:S7; M[$KBX-/WN_/$6_DHR*O>?$.L .K8"K1Y,%E"./[RR@4Z*XZYI, RPQ0C_](+ M$XN=$\.<:X;W[8H%U^(V=Q[ ^X6\/8UE,:O4W>_]J7VS_E*4KN. M]0F^W\0\'[7G3X 'B+,FQ&9_SHBB4LV%[)_X_QZ;Z O^:.7/]Y/\'4$L# M!!0 ( .Y-;U/&:HJ<)0< +4B ; 9C$P<3 Y,C%E>#,Q+3%?;V-E M86YB:6\N:'1M[5I;3QLY%'Y'XC]8D;8"*5P"I0^01B*0MI%8H#0/VT=GYDSB MQ3-.[9F$[*_?[]B3"Q @=,,N6\$#,![[^%R^\YUC)_4OG=_/&NMK]2^MXU/\ M%?Q3[[0[9ZU&?2?\Q=N=\G6]>7'Z77SK?#]K?:PD)LL/16UWD(N.2LF)M5OM)H5\4E067Q>5N<&IO) C;87"5CD?=E?OAZ=;_M^#\+QTI7 M&K7ML$];].60A*6AHA'%L$8Y\;60%L;JL;BB@;'Y^IK)Q"=C4VR_]5681%Q$ M)#/15&;KI$]I5;2S:/O%=?YW/+-7>J8I'?P!P].QN,[,2%/>W*F*M M.,T&\#8CA1&D]0P*91#<[;T9;;%BP=7U-4PI-&8 9 9!\OLYKU D75\DVHS\ M2Y9@J:=<;B5VDCP8%(>:U;D8NXDV]]3]1<+\O@QSYY9'WEGWHS!'KHQCR>Y( M!Y!?DB@\>V>UA;3DXP(WJZXF=I\@@*&KE>MS^O"T%&3 A,#/L7*1-J[ .J8) M:W2(S\":B&(,.[&!<,2$ >?MVZBOLQZ)(Z1@%>%QHS:OMRJ'6S0YOH:KZT= MQ.%QTXM27$ZS@ S>0'":S@$FQ(^567JG)$@N-TJP$1MZ&T5!%RX@JRN X??V MP:[*ED-)Y[AYUA(GK;.SR^/3T_;YYX^5W8I__G9Y?#)Y_DFEMG(S\(I-![HF MSTU:CHU4G/=9WNYO:,HZ5Y-MAHR>2.J)[I#R@#%LP.ED62D.UJNLPHWH:6/1 MV[V#N[[1E* KE)MWERS<\I01F>5JU4D"Y B6&^Y-5PVN@2DE5N% M0F0*BTU!,T/EF+UX%F5>#G=1,]Z;YTY+6GKHEI5H!C^P7R!6?JO @5#&&:UB MF7OKND[%2EK%)JA0,3V?9RRJ<%S$?+([7_$\UQE'T"@'N?*B@>0P%EHR1\,N MK\6L&&*%+ZU<>6=- ?[K$L\$C4( Q4<^*GROD#1:R:[2*A]S,[!H M7TY@#VX/VY![MZ;.]8Z^YMV4%@T*.T#>.-^]1)&QL=? =Y$]RM"3:#U&J8@B M&G!B\ASTR"%%D,!J@++SEB2O,$FBY9*D-92Z\)S+^*$D0?MFB)_6(4E"AU .IU.W-(G3Y]]1'=R6O!Y M3L$74.B(I;^A^O6A.EZ2^@->[N..S_AEU^S?+$(W=R9+$SZW/B:*"LOHFFLS M%B1-:ER.<;X_@RP'WXD?X;)&;#RD28)$ 17?F5ZJCD,B^0L*OKO(BJEBFT&M MOG33K@P]D/2)1;%O";U'RM(S%EI=DRYO*^[,]Z=+/JG>,V=I)[VR9'JAD^G! M\TZFHCR8AF-8>9,73V!;G3$3,^4\A9PRQO0<'.S@+%DC(6.IH3U(*E/6FBL 5+1Z59#^^ 00E>DB);ZB[PY M9:U8>!WXRLCL#HP%(+/BM"F"1)V5 TU^BER"NANJILJ'10^(2FLF> M/SOY@V$@P=(\=NYBZW8\./A' M8GD-NL@[LEN1T5H.'!V*R7\5_TGNXRBJE)_VWH?%!P_!3Q?GG7FG;"4R57I\ M^)12?JY#]@<;T#[R@>@PN.<IU'&9;$^[U>J3G-\ M^.BFI5,GR=G4,KH6M>T#A,-?J4U3=?_#2O7:<3MW/UF=U]-#MHSJ?:47QG>" MR$56_N,%P3^K=,"2QB\'Z86V+!Y T80Q!P F", !L !F,3!Q,#DR,65X,S$M,E]O8V5A;F)I M;RYH=&WM6EM/&SD4?D?B/UB1=E6D< F4:@44B9!TFQ4+%*+5]M&9.9-X\8Q3 M>R9I^NOW._8D!!@@; -;5? Q'-\KM^YV).#C]T_3PY75PX^MH]:^"OXYZ#; MZ9ZT#P\VPU\\W2P?'S3/6I_%9??S2?M]+3%9OB<:6\-<=%5*3IS26%R85&;U ML% 7EV154L-&;#U_ZKY]D4K;5]F>8-*M?9'3UWQ=:M7'DE7]05X[/&@>MO_^ MV&EVNF*GL;%]L-F$VN?+$5@[_#7KN>'^]S-F[1N?PN4JF2S/SH>E=.KB#TH22Q-QN2&:TII( M.AAL^;'(!S+?^SD,;6R48$$_KU#<*.L%UJRL#.2)A M::1H3#&\I9SX5$@+L.B)N*"AL;DPF?A@;(I-ZY^$2<191#(33676CP>4UD4G MBV \:[6\+/E?/;U=>KHI'9P"\].)N,K,6%/#JLQ= &(C57+98! BBB;%2DH,NP'ZK$9,5XH**!< 7_NF8P)DLE%Y@@ M4N4TR5AE?3%6^0 FNB%%7D.6/(1N)A:1&6%;+'J3>4<\>TQ>)O([CT6>1*(R M>):C=.W)^NJ*S$"/YW:.0&4)\D;F"HQ4%NDB!E/$:\YO=<1:<:X-X6U&"B-( MZVLHE$%PMV0#;;%BQG6F*#0($'^#&'EQ+BB$2C@0B39C5Z(#Q'WE[@4BFR10X+"+IO X]#LLXM*I(% M*N'JRH)[N%?T"/ J187N8PH+H:@M(^5\R0(599X/SV?7Q6Z^8%K2TN.U;#_7 MF$.U#=64GRI4/BCCC%:QS+UU/:=B):UB$U1HD[Z(9\RJ<-RY?(8[W^9\@3.. MH%&.BLJ;AI+#6&C)A1EV>2VN.R!V^'ZZNC(_">"_'C$E:B<84+SOH\+'G.X% M!Y7QNIP$";\W=N_@X357'LN5WG_)E85K*Y YRYDG;ET\MB'W;I#.#8R^T7TM+1H6 M=HB\<7YDB2)C8Z^!'QW[E&$2T7J"_A!%-.3$9!H,QB%%D,!JB%[SFB0_8))$ MBR5)>R1UX6LNXP=G<,RI:H3(NXIQ1<&:JZB+A8_4(ZG,"&]$ ."5 MW#-%?K\*"S0Z@'1&3CS')X\?>$1O>D3P>4[!%U!HG[F_HOK'0W6\8.D/>+F+ M.S[8EZ.R?U*%;IY,%B[X//J8*"HLHVMNS*A(FM2X'.M\C0=>#KX37\(UC7AS MGR8)$@6E^!9YJ3I.AN1O)?C"(BMFBJT%M0;2S:8RS$#2)Q;%?B3T'BE;ST1H M=46ZO**X15\/]Q$5YBSLI!\LF9[I9+/[M..H*$^CX>S5\:>O:9GC&,TJ$U?* M>>1<%RD._>)3S=T1?*:;Q!2>&UO>-S"17P'/-%5Y3O1 )^@9C"K\/%90D+F( M-\ 7RJ[CNHZ_?!J89@5]*13T]QE09)&_Y5A[/73^X(?.(XT!$DL*B.5+)[YX MB!0!866;GYW]QB2ON&^'@=)7CC ,^YO2Z<76DX!;7GN&ZYJ*BB5C;'0T*UCW M%O7I"(T]0"HFW7H8'QQ"Z(H4T5+?R)M3]HK*.\ 7*6:_W5/+RD6%8P6S7P^1 M?07X]YX4CS 5)!9%KPZTD:_4P*N_3B^170\M564CHT?$?363?7^@\J?%4-TI M'6HS(3P>#TRHZ/)&X@#G#\P=B^?$QK,!\*D5=!Y0MP%W,TB,B/#Z:C&U>LA0 MLNN1T5H.'>V)Z7\U_R[Z86C5RO?5=['RSN-R:6_?6GQTV@ON.46XTAXBUMBN MB^VM[<;L?5JW=:\^;Y>J3G.R]Z#0TJG3C&UJ&5V)QL8NPN$OWV;YN_-NJ7IM MNLV*%[SSJGHHEX&]JW=EB*>@K#+TNS<$%RW3!XO;OQBP*\VI7ER>$7]A9A7G M.&\K;D$O9<"#Q7MYQAT/%"7BPZS>GH41O=K*6=5]KIH[J[:;_,V:\%4;_D;. MOU!+ P04 " #N36]3V]OWJ]4# "?$ &P &8Q,'$P.3(Q97@S,BTQ M7V]C96%N8FEO+FAT;>U846_B.!!^7VG_PRC2[K52" FTJUO((D%(2R0.6 C2 M[J-)'/!M8J>):9MEM#Z;#[[#POX_=+UHDN.R 9:82?);0'";T#N8B M(5PO'NBPH!F+-)R(4V=OG=>%A&1KQCN@AII=D/1>-DC,UO@H8^N-U'KVH.=^ M&WD#SX=VR[#LY@!AST[A\,]M+EFTTWH?^2I/NR?R$E N::;U''?N>U>>T_>] MZ01FR_EBV9_XX$]AOAR[!02K31K6Q=GJ_,18EI.A.P=_Y,+"=99SS_?H$%Z:M8$[<>8?UM?3848Q<+@V8"@R3K8Z M.!M&(W#O:;"5[);"-(I8@$-$]/[=-*"$%] &3#2<#4UT\'A@P)G<4/AXLQ6R MZX@D)7Q7-,YUV-",KG:8XDPY!;DA4H<5R6D(@D.R@Q]\R?47S=3V[5E_.*S:)9([%LJ-@F)^Z,+K8:U$%M*L$8@X)FE. MD6KEG;8O0;8_KQS$S&*9QR7B!HY&SOV@!YA"A/WQA M:NOX7/MJBKI[E/A&1!(6[SJ_BO$G2Y9A-Y6QWE,@U=V)5M='"I;D^RV'KUN2 M(;7C'* \1&8N:"IILL)VV]2A9;:L MQQ0O+)8,AV@;HY< /<<,8[AC0$%QZAY.&Z;,:ELN??!AO UA7X@5;?UN7W1!<+#@L.GS.9!*_M%Q+_Y MVQA;%[ZGLJW5Y+,8?U+,"272.BZ1RO:1)3FI8I5V&$8X]:E;$..&!>HX&0[8WC>Q5 MH[9QH0J1TFSO,Z_X7VKX28(.]&ONJW;O_TWBUYO$)X4B)6'(^+JQ/T4BG O+ M^%PO=X:X]F'GL:(FXK8HGE:K*)XO_&A3E"#7>=%IV7*5T)*D71@$)/@ M!UC&)2Y6+F(6=J&$U?Y4*ZYFWGQ^YCK.\_+Z!/31U7]IR__7$XK\U)F 5P;_ MRCWF6"S''Q[*15$$&FBIHXI V:R88-89K+/!>HD#J](V$"0+]8>8JPWMZ:;V M=GRO>S6=8=5E(9;MX@#Q@.'TN:]MV_Z'EY-:CP9'4E+?GJ,=WMF;Z@-#\<5! M?9CX&U!+ P04 " #N36]3@3U_BJ,# !?#P &P &8Q,'$P.3(Q97@S M,BTR7V]C96%N8FEO+FAT;>V7WX_:.!#'WROU?QA%:F]7@D!@M[I"B@0A6U)Q M0$DXM8\F<<#7Q,XZIEONK[\Q#MWN7;3=WD&?C@?RPYZ9K\=& D$J66FB(IHL?M>M#3N2&\1[HKNT^*/I%-4G&-OA*LLU660-W M-/ _3()1$$&W8W?*$E.NJ+0&GK^,@IO M&T;!? :+U3)<#6<11'-8KJ:^D>!T2=.YNEA?GEG+:C;VEQ!-? A];[4,HL / MP?_@38:SMSX,O0B&LS$XOQI5*SNT/?NH\+I],G%GSOS7^0T:\(ZFJ:1["&T8 M$2EB@AZ\+:,IW#!.>,Q(!O,T93&5SY^)%.8Q)=RH&S'1]+8T;T# 8QLNU);" MR]N=4'U/Y 7A>_-PV8 ME72]QRQ+'1?4EJ@&K$E)$Q <\CU\XN(NH\F&]GXR MTM%P-/7!\Z?3<#'T@MG;-U;;.CPOAN/Q\;E2=H)AD1]5*%%95J=QH_#<9;?N:<:.C6;(_J1%S M/\)H_(AII][6O9GCTOLF\[XC$99WM84D+(96&[4;(O%JQ[>9[HR85$C2\MZ8_4)X@F2$M%,W7^-QM M-Z#3[CC?(FX\5H1#NLLP2HR1,X9CN&-J>_ HZ>V.29IC>2D!5T](8\4$/Y:, M"W()&-NYOD@NC13LH^VPWTXRI7WY7^(MX1L*PUCI9N=U]ZH/A">&X7-F\WZM M'"81_Y;_CM@?8O2,4';JH3SZKDG"6=>(II5QI"\GF@KDARO".++'^ &#"MN4 M, UQ(6FI06KH9I)E.(=(JR[0V% @6=BBK=*OA1L=)NS@&GG1O7:9X5 45!YB MED?BJE7S($'W$]XZU,G!_V7Y^V7YE591D"1A?-,\;-U0SI5COSXM.V.<^Z1G MTF;^9^*S*5=.QY2K1UFOU%Z].*6HT;[W:- JY6NAE,A[,,I(_ D<^QHGJQ09 M2_I0R>J^.JFN5MFJV>C4HUY='^BN!>"Q&O:?#4R*3IF#IX__:=C7#J?^Y>D& M\3ON0V&!A8PE6 E_V@!.])G%LT[]SOJ$GW)K4/.]/EWYMN[/G"U]0#8G9GVP M_@M02P,$% @ [DUO4ZCR(_ 'B(!P[JB!?)\HM+)H'&T]UHH-%H@&__]33UP!QBXB+_9*?U MLKD#H&\CQ_7')SOW_=W3?KO3V?G7.P!^>ON7W5UP!7V(K0 Z8+@ ;32=]6T7 M#+#EDQ'"4_ BF/X#[())$,R.&XW'Q\>7-BU#;!=#@D)L0\(>@-U=2C AV<:0 M$3P&'RC56S0'K29HO3E^=7A\\ ;<#]I@K[G7BJK\]/:)'!-[ J<6@!Z<0C^X MI,V>PY$5>L')SD-H>>[(A-/ M0^SQAO::S?T&>SVT"$R*/Y7*/^[STJVCHZ,&?YL414/;K8XC)#*&DSA<_H@^98(\39=S! M$>"B/F9@3G:(.YUY3$7\V03#T'MDFHW7)E%;C:FIH< M.'IVOFB;KN\*N-H23[;E/3M/M$T[](2JRG'%"@\H'X#]N+_KR(S?T3&+3D!]VK_X]$!_4T(. M] F=7+(D04P3<*+D;:-(")2;"2F1KO^._RYVXYA 7$19-=]3BA75S18T4JB< M**61TTK)L+:DKC][%J8BF,# I;!()>T5Z^B4N;>.,L&+?"O_$&BW5FU1M1WJ M]TUA*FRI.HOE1):2T^%^-1VF10A (]"=,3^3$J#:O/>MT'%IF5J1513)W'(, M)U3$[AQ&VI(J4U2V+)F<.E^MH\Y<.R!JJ%9L!<7V)W0HFR#/H6NTBX?0#1:L M\A["^SF=*HIIU'FPCCJSS?WMKV_V6H?_!%&S&J766BV;JT4FEQYZE-MH4D#( M2DZ9K]>R34H?L ;JH;:218;3J847:'1JVRCT ]IDYTU244X[9QY2 MY9V[Q/80"3%D6HVH,7TMZ8&$H-!]K=7%U-7QYY13A(OJR3[7#)%OBLK(U*T7 M#G+1]Z+5YZ)'G?. 30^SDF,I*:*UCZ.B2A)"/P-."OS-FLZB.8E3K-4D5],U MI.OZO''$C]1VT6H6E1!5JV6M&HT"RQ^[0P^>$D*7JH4AJ?!2(_]6>5Q*"("( M@E@5M2ZX+N[@''ES.HW2%B$:M3&DGD].(>(2&JWL%;624@&,#/>X.*':/9:. M2,@?#R#;V!GF%9)[H9LD6ONE\8E6!ZP^8 1J^JD9M Z*.DD( M $HA6N[7"T+9@A#:(7;9)LMI&$SHJN K=$8(=P@)65#ZGB[!<10<85$PNASG M\)B;6E@P;D!'9W.O2^O)M#&P; W0YD#2'N -)F&=;)/*0FK5W/7U+QAR1 4XC;B/9C/X@V$O)J$);0#)*E M.$!"!>3(U$ZW0C7E8-C9@O]:Y/2C**914BDR( B7_8NTJ,BUU2F2Q8P)T_(=F(LN2"Q14TF;X[B_>E1"8JZSM![' B@8 M )4)0W4'6(8P1.::?Z.E$8S:!E>QP5$84/%-*?II.&6'7F;6@F?VJFQ0 M4TEO@^7,BH+R"J86-0CB%@%K$B1M_N#;6/R,\[\_W/Q^\)]_?[1GX=,G_^#( M^7HX'W]:^/?GX>/5(3XZ_'7O\_U@0;S#N?VUZ;T/&D$?OO]ZN/_EJ65?!\T_ M+B_W^K\VYD]G[4_-N=/'G][WNO>? Y^'GV=CA]FP_?!Z+;7^?#)@OY5'SV$B]?.\.C516-D M+R[>6(U?CAK-]_/?NOCAXJ#IA ^]P>71Z.&W/]JC[I7U?]?MQ5W[H=?XO=N_ M64RO)_[MPX?>U=$O'WK6T=/CQP5J?ED+COC1Z;CRW0XRA\^@&$]IK9M . A1,(#N3;OE4VLN0J\10UJ&D]BSWR\$HM>DD$$"" M 3 0($8! @0H#A #^3L!GCP'\P>RJJWT$R8TY+,QB O-1B3^%4 \I=Z 0]7$ M%LSLP@-5+UF=CLYS+47%-)UDB2#2/^ 8?H[_83"X=Y, 0Q)';2IN$$@7O.+ MRZA]GE(\3; _H'9_:A65UO^)!*WE5HTT"" JJQFO2P$UALJ#:^DIA-UEBMMH(:X45]^B$2T'!>]VL5PJZ%??I:K6LYMQPUY3* MD#D 3K);JG!BQ.6UR\%7Y8- $L4)W);8:V45N)_BB#/S:_468V]T/>#.+"]9 M1H&"='S""FQ:94NFFN MA6)87X>:?M OQ0!%F1N*@3]&Q?[EN.(5*D<&$FB 8@,1.$ DIU#J/K3Y011A M-L+FY#2C2"D6MOFIE'JT66VT<:#M4;-R;(M,G%QZD&1 4530:+L4U"IF$TD& MBZ1%P)H$CNKX2ZU@U0D8D9$K"RK7TZ_*V6'"XS!U2*N2QLZ1'3+G]]1W+OR M#FX=GUVIFSFZI"RA2[1L\C5:3"'[DU(#$3F0H?<_L,)^V\C=$,L>1H]R=\GR MQ_2I.YTA' "_=#.PXHI:$%U5?(UL3DY1A?VWF]3;98]V6WN[^ZV73\1)KMM< M$05C.KKOH&X_IZO!42S.?O"VDU;C1N,[P7FK)SN)#]$=99+W3H>$SDLV%7MT\2Z_ M;_J8/J.KC4X IVR(V %67.ID)\ ANS*7EZ)K$1NXG,2S%*%4\=6"8TO@%Y:=FN%T5>C.%-@R_GC*FZ-#>& MS.:@.1Q6Q%EM9.LEFQK)R,CC5@G![G(_PT3^5P=?<3R+8[[=T1F+^/)!@,=[ M,Z<'VSS8R\/')HIF RY4'2=W.L\1RR,Y2MJD"EO?K* M(@S=L=]FWHUO1WN%4 M?6Z#>L+,C(SN%*LS(Q>,U*R(R1)0H)8:0UJ:=B@;0H?<01NZI;K<.4M UB,F,%J58"6 M.JG"*G>0^:%V_+6-[X[C OS5>&=5Z-CVG8M S(72LW5]AH=;QIT[G@1D@*A3 M$ 5L+I[LB>6/^420+7CM6L,X]F'R(+ Q;W)_1Q+J'L"GX,Q#]I=$+$Z CX/D MX9I2V7(X?HE1N=D@C'29Q9\&HEQ[PO,3<;[/,R_+G>!XLF"YA^$0=HK3M12E M;&P35F&_&6GRWX\Y:/ I9N;\S4TF=4,),I5Q=?R 0IA2?PSA]'ZC^&I7HWBK M!K1:,+BT799&5ND(G'?1HE0ZHR2Q%3ZD:XGE-A$;KG4;12;(8T7$NIDTND/- MN"&X#*X:(P8-N6)8L@GDQO+#$444XB@X]H%_XC D<)MQC"C'*]BV2UP!NXSM MW^'$M;VM>+/?B+D4H6*.+ P^N8$J'J+.0Q@%@;^E'C?UVU?C8V.!=/S!(_H$ M+?PMU?\\,LFPHIJ4*Q.;8 A_&,DLF=FXRWSWXM GFK$-@ [;YF4?NZ9>("1! M,J.;.TIJD4L]L+S8MAO@>!Y5EP(7E3IXO/-C<*1+ ECNB$FN)=%>EV&.V[DF M!XH]JQ7I&>2_;H!=.04N\W?B4[L#U/&=D+%H>>=P#CW$?<8SY#M1?)"R_AWX M3AOQ)?./UZ-ZB_P?56 9UJ16Q_;6Z(S+0*64>1\^M>F"A/#C/C&1'@NO,"LQ M5DQK,*.8A*I02S+M?@S9%+G16UI*JCV!]I9#U^S4(&N3^;H1>81\]C#Y#.^CX\88<7599/N$)W;DX:AI$C2+Z M5 )#CGFYX7H.B8W=67F.EHOK&^Y+?!N^5$9W#F<8LJ1)6C!>G'9\VPL==AZ* M[8IT1U<(.:2//,?@9?9*;$A]7B65/O2\*#1_ZK!;L F_'&$.D^S3[U4Z6KZD M>9)T!&0;B&/(>N<3"]&=^KX5LHQ;S*(=+!OQC&6O9*8LMNLWBRH^MVVM!+=R M#(JGYG1':6:.N7.S!K<\)!5+*TU_6"8^) DL/#W=81'+LY#0YX1<(\L_'6.X MK2,5W\I;W9RWBFY/#&'DC8QP):3!!1-WG^L M %YUII"?M^F.6%R];Q6G=*.\?P%8]?XYLQ'2"[$]H7XB&[0E^PDF9\^OP(7" M@;N#LYA #[LV2Y],%]@=+LU?+'(&H7\''3:6.%U\&7K>@IW=,;CG;\*58NT\ M#)8[.5N9/9XS') M91@FCUQ"O*K>J;D'W+@59R6\\C,BRLH&+40K(U6=&Z&NV1B2 3JE7=[C1]NC MBVWH4,UN H!X3BW!Y)&V*@>*@\KN=!AB I/H2RQ7'IZDAA9BH_FO!%_6V<]# M'I1,14>,W_^3(I:Q>#IEF8V$^18#=,$OL65K$.=LD=S@U+[H&JS?:OCE2RCJ MG#LA'QBZHP%]%=WRP>X>HF,G=59-[MMZ[.IC9.F]#7#JAE.R):_Y&>Z9R."5 M[MLJ+N4V;D;6@U7NVRMJ&S0?5X.IN#TG6X_2+62L -;Z*?+%J)@4I5>!6 M8(F'=:)[87ADQV#-Z>"JKG?RD=]''F^/G-*N[MI6Q[=O( N^9W7IH*GE^L^= M"J)$)S]<6L@=,X0;,2KI;$!9I@WPN;+C\X <(89PHH"FF]PN48@-X:*,2&$H M<>&N#\U"OP2DDSP_#F86^"RD*N["X!$9QD *2+H>BY/4DBLG+]VY(4I0(%.$ M%TJUC+%G!;(5^#'&P.7 Y/'T0A6#+%X%K:KI&&/]>W.0V<=2H@5&ZK!Q/A)PD,84Z-3I4;Q*+BEPA/0\\R MA!DQ*,6$DV0'F@&_@$9YH$7QB45S/E]0"24;*OGW#*,OJ_%XQO\#4$L#!!0 M ( .]-;U.;*?UO$@P R& 5 ;V)C:2TR,#(Q,#DS,%]C86PN>&UL M[5UM<]JX%OZ^O\*7_7+OW*&&O)22:7:' $E)2: A:9KN['2,+4"-L8@D \ZO MOY+!Q(!E&V-AZ-U/)=36<_0\TCE'KWS\>ZADZ]TJHU&[L\_%.6WC__*YY4K8 &L46 H74>IHN&HHT/E'FL6Z2$\5/Y- MA_]1\LJ TM&9JDXFDWX;H$ .";*P#PK]0\GE6H%=D%0->X)GRR$J]16.E M6%"*'\Y.2F>G'Y2'^ZIR5#@JSE[Y[:,)K>>N1H#"[+;(>XEI]19P3.Z.LQS!@OEXP(OXG?^S0_\HXHL@DQH M<.XO-)-7I3, @.847O3#76-1":0#S>I"Q*O(Y5/Y ZKP?=6U,7TC&ZQ=#D&' MLL]#8"6R<[4(9FKJ9O).@<$ 6 2.P0PPB:E!Q:ARU*]J9'!IHDDB,[UWN6VI M6,:[EV&; /7 =,2J#PBT=!MC8$P@9>^2$= I170 N&O1+(>8@'44JV5&LPI< R@.'5FP,G[5,>((,TD;X$8W*?@["'8FI= M8)[G;)+O:]KH1X400$F55XUW&;\"W!+"3'&]3T\C7=<%S5]4N30J,"GQOG'% MRA>*S#"K$=M;"9O1A7+;4WU%QN.-9,51BJTJF'LL%CT53-M(,7\>,BJ M3P"?YA6\7$D-ZYZ1[..2X.M^?OZ$2NSAT"TM#YE;\M[O832,D)&BC0E$V "8 MQ?F<,@&P/Z#\8T+)*KJ.;(9Q!W3 \%B_N 54:D,+ UQ48B_5">=J+LK1BBB) M5*G9X)+95NGUH F9&Y$IB AKO[40,C27X3@-&>X H1CJ\P"9C6?;U(:]]W$; MDSI7]"0%;]>PQ@P"8><6R.E,2P![+\4R'7.>3U/@N8W!2(-&?9:5,8U;+ ?# M\K.8.+AO YM]E246>W.UWJ_ZN6T23(F9I<\'9\=Y8% /I'4UM4K*:QNC$<#4 M:;-1 &5*P\C2917)52D->(S7RRZ-/E0\(Z7V.H] ML&[&S9,B23BB6Y5]5"6"*$&>E2PJ4\WJ0Y9/SZQALM>GNFGSZL8P/OJN.*Q)DB>DO6=)M2Z+-VF$$B-X@$P"5M6$UG]>X"'-="E;J8Y@E0S MW0;=ZIJP[[(OMRX;69!Y;B)6V-_T-J15'%.W=^">P8Y,$2,@#T2U*.+$@7:; MB:6VYO"9DGNL&5*G,<+PLAZ(Q=,GE+$4PRW#P38P=N3,Q6@'TFU"Z!(&UVVC MJ^RPFG%2$U#3I? BICJM<5D-] !?)YHMR=UK4Q^FK*%9%.9>:Q))F#!ZI!CC M;]%L>6^W8=Z'FND .D*A&)R)YL:3.JQ8:6"&:?5>ZQ67/7&0221:AR+]>8!, M5BCA$RW4D2)0 $S2164T'"+++4_B^O$J2+;.6"S2TFKQ&C,I1\F*84!NJ6:V M-&(<^ M6;.D+*[O*-Y&@F;=S^*R(A@(1L\B'DJE@IX21 &^-U%=V9SXA^P=BZN[:Q/N MG;G"S!^V,>I)TGYNQ NVTP^@O\PFM:=0CZ5=9/YOA(YK7X=);G%-QI^!KPL M1DW%& -,(7DK68KY$9"93UD+1?0WJBC>A%T]T7P",$V^XNR>*#)=Q"&T(*'< MSC&0*59,Z$S];RS!XG(H3A.2>X.WP8M5R*@ M^8G#2K*].QX\WX[-\D@&9C.\.3#+*R] #V&P6#< I#YE[9I9 2T-.PU60\+G MJ-F;K/*F6R,*,""R-NC*LS?;3&,'2@2V+'\#3.%@BGM^[(J-V%M6PR(V=D]/ M 4K-^7%!?YL0G#X3OYWU>'%'&D5QF.Y.#\\"F:%^%2/S1&S'O6V-X_7YQ6V\ M^"V@DO. 981,0V=@99?)EJAMRN/LA0WSEG'!P? 7X\W7T__ M_NN;/K*G3]9IV7@MC?M/CO50LR=7)5PN?3[Z^7#O$+,TUE\+YC55:0=WI3OV#IGXJJX7K\9<6?JF?%@S[I7U_6>Z]?/E>[;6NM/\VJ\Y=]:6M?FUU M;IQA3KYYJ#"LU-Z^EX^+9;L>OEZ<#RIKX\OUR6G#[M/G_E$#W+Z^#DK/WY^-ROGYWTJU<\=O0-C[MA_0GD+3QMW/ M4@8=K$^\OKQ:DM0%LC"\Y$'X_\J#QY#,WZ97N$DK2;UD(0#VK=D6-=UQKT^9 M$V'\M F-G:_&*N@0"-^ EGU:\5C5L[-X#_Q\7$#90;"BK7XW@EUP#KB#JVDRXVP:G>]["ZNW8'V7P49K:S6=N*&,&G>"=LHC60@8;!A49F:2D# M2U%JR.[2GFUZAVZDB!4*>,#A+9S( M%.Z1@&B4334,.1 M!C%/[5L]OK&]R<8)QNQ<\B=@&LR:!UDSP[&0#]L_QF1W+F@IO:E%S$\CU,#L MWX:UN=2"O!_-5%%-,_E+L-ZHOI'4S#3]8P)>-F.&SIB-S156,EOG:ZG;BA=#H*58, MV%*Y>7[*;>26L?#K[:YA,1GQN0-@/$(ZJ [ $#("F16L'C$G@S4]IO(,Z#WNY6W7%VZ0,^Q ZU&;.>G"?; M=",1Y.K5K+M)0M91#[ ?;D"I)^&IK![IS13L+HOT(Q[D%$Q,,CWIWJ=TLF,= M;GZ#J#<-'GB3Z(Y$C67*+Z9V//J]9E!*J1D(:L&;'LEN#3H(?O,ZN@G*(C5A M&#H QCRDN0ED31MJ?6#<:/H 6@ [_FM$8R5TB0O?QS 3HODBW4O.9HK+V6W- M<3/,>U31&0 &PKM@Y2S0Q(??TQGD"*63\"S:Z9>B3[J$%FMYF?FD(/CD?M?K M/SQ#:Q!B\SXUFZ?WKO>1M;@8!;N?835$_)5%QDA:19NIDZPU+L"JE;MZA]EV MBVB\7SL2OKR7 \D(^B/H2.?HB MRQY(D9[:HM3'EHG?W=>XR#NE"/H2;5;;U M5NY5%*V1>Z2A/@58AP3(.9\?C;J/:50"3R6@-,7?,%DT$[*#(",$.^C0(J9P M?>_*-I,J[05*#7([+8/(OCLM O) _6-<0M>WM&PUHN:6KOPZT=JO%RU_X7NR M#3!$QOKDP/R*_OI4'VA6']QI%-1[/:#+Z< [KD+F[2L;R5;V?L>>3(JXB>,? M J-&NA'7)_Y#8)2/336WG)G4ZOG-;%G<%BF^+00NVY%7]DT@3 G1KNJ-!W = M>S2:K1!K9@T2W43$QB"P?K$&=9N4EW33AAAC2Q.S&< DU6$QZ SC(YW?;0F! M2:V-K#>.7T:*U9=")V!VE$CR5OK&L<^5;OGN?1*X M;T_0H 6O9IS$K-&]:*6BJJ;[(T^S7 4$_?2<_U">E,80%WL?)=J8OW2O O+# M[N):H#"\K!?L8NL3XVZ?18(6Y. _JKSX+BN)/_,_4$L#!!0 ( .]-;U,, MA=*@FC, ,?L @ 5 ;V)C:2TR,#(Q,#DS,%]D968N>&UL[5U;<]RVDG[? M7Z'5>=FM+466G<1Q*MZMT4CR48ZDF2/)\4FVME(4B=$PYI!CD!QI_.L7X&6& M%Q $0#1!*GG8/8HL=C>^QJ71Z,M/__.\\@XV"(=NX+\_//GFU>$!\NW ^#@W_[Z=^/C@X^(!]A*T+.PV>W"/+3]< M!'AU\!_1ZC\/C@Z64;3^\?CXZ>GI&YO\36B[&(5!C&T4TE\<'!T1@CG)*4:4 MX(\'GPC5FV!SO'[U^B3]Y-]^\ES_\X,5H@,B MMQ^^/RQP>G[ WCK5F^/\#P_3O_SQF?ZB]/=/;Y*_/GGW[MUQ\J^[ M/PU=UA\2LB?'_[J^NK.7:&4=N7X86;Y-&83NCV'RRZO MJ($R5:Y#AK_@O[7 M4?YG1_171R>OC]Z;/>(0OWJW9M7E-??Z&]^Q[]/ S\,/->A M2CJU/#KFNR5"T>$!)?WQ]G(G1F CRW]P XH%U?,Q_8/CQN^/DTD *^3O Y9)L[_Q*[T?:>$'D=X#>BPG(H:)2S!(D5+B^\X$D) MSOS;8UU;P%V\6EEX&RPFMAW$?D1.ASGA9KM(>$7Q2.B:FI?^ALST $N(5?Q$ MHRKG.%@C'&WG9.N(Z(Q9RRSCAJ]UP72%R,$BC%#VUQK!N?3)P?GH/GAH$H8H MDM!5Y3N-,MVB3>!MR*2\A(4J?:-K MZMPBC^XPY!0D6R"U^BR;VCO"*FS\7N=!>FYAGR@CG".<;-RBPM6^TWD&(3O& M;D2VF4D<+0 MX^?,W;@.\AUQ@ZOT42*.'F'B,"+F!";GHTWV4)R,65@HYL<:9T7]+#S=)C]M M147D4-"Z8^].R7N+[+\JQVOVH:Z=B'U&RDG'I:%O#J8GJ)QHI6_TV4?E U16 ME\ROM5DEA?-*$JOZE_J45ST4Y$1K^%K;7:RX:\I)QOI4YRE O21.[!%SR*WL M <+G63,%G0?SCLLZVPW6=#>PR&E9VA#DI6ZAI^]RMN.XB*,8HY7KNZMX1?T4 M:VM+&:KBWD(/8 3HF1HF*'1]8LL0,_K)C([&9DQCANF)SNU.&J.%9Y%E";0'YX6/O#0V4G M8)$!4TXR"\CI0L%R\M-%30EL4@!+:(W)O';7EI-6*N^,%*.GVK@'SEH8<5>='B0L2G*O*-!#.MC M\LEQ]C?']<_[D3586:ZO+&KZ]7Z60@B[W%*#+WY 1SO&Y)!5ZCHB!BYQ<+OJQ M:M!*QHXP] *[Q,6CP3\!SIEXU@/RWA_&X=&C9:U_WP5BS!87KD_HN98W#\)$ MX,E#2#8O.ZKC%N;#7UCA0X)!1N^8;E3'R(O"_#?)UG7TZB2+%/J;%./LOB(] MJM0: I6_PN)XKX"]QB>X+#29(+DLV5R1G>C9UPL7\8X1@51ZBBC"GU:9'S!EXG54[[2=2[9MCSL*Z#&CA JJ#> M=7+BT_^A)M7&\JBG9!)-+8RWQ$#_Q?)BQC:I035BG'='I#EE-%,;GXW*,IDAEE3/(:[08QGS^/BEZGLI'G9J>CL+$871/C) M8N%Z+A$;4EU-O,QI2F3&%C74B); GJBDGEM$IHMK9Q&*9K9'61G,;I22&I4& MN'T9*BDZ]X)N;Q#,XBLQ&)6*RM!D^+_6C/\9![-HB7#IV 51 MBPC?_4UW#.H20C+3XAN]]@>XMFIZ&8E.V.A_J_NT*CV44.]=_E8"M:EQ&8Y' M/7S<,FU]IUM;LS5-2Z-/'_0!Z=9]7!*#]6.8/M> J(O/T:2;0E9C+=AE*ON> MIS)%,Z'\J$:D/'^VO9@F'WX( N?)I0Y!$/-!@+%);X:T42$"9*;'MWKO7'D* M!]@!-29%Y&!D4/^@%^HKUWH@5[7D!<]W[J+ _ES*20-U^0DS'Y>!)XYIIM-W M6JV\ OL^_+8<=@97F>R\;M"?BF]736F%((;DDKUV(\M+#L_9/OP-TG27D\#L MBFR?XB5]RF$+I>*R290/80NITQ:68U)B&WH";J=./ONYM:4[_SVV'% ?,(^? M4:^4G+JXL+6ZJ!051;YVZF)"J:F!VY@6%0>S5@>4ZD'7CW[8BAF%4CC:X#BD ME-ZVT +19)6T/,:]]5Q@#>61:N,Y#)N1]\35!EJ[_:#1>K@)TH2C?@V( M3;4+K@\1O5[:9*NECA: /1JDP,+AK5(*8Z4"*[ ME]J5R'$2<8A@EDL,EFS_+$@ @.W0UZ,(1M5]9,<5:V.^U>N5,E8\+S@B6)U$>"S('Z(%K%7OR^ .L*E)##K M'%?..Y!#&>H!L;#HR:*8X60X3K+^]V4I86]=C7S'J5@A1*'<@P7F":=""CVT M&FO\C!YF&K17!Q#DC;'&D18ZZ$M=&:_QI6TUH@9C+M;8S>*(ME6@D8O]:*K( M\ 6HJX2?T$ND":.QVIM ;857J(!:ADV\E+T+&^3'0-[Q'7%S\[E%-65W00X% MG"T6DG5% Z&3RQ7"&]=&X1VY7P%M,8WL#+K JS.NO(LT P3S0OX!!V$XQ\$" MR(U6I&\0=(EE4$($)CUZ][R>I;/!UNUHYF;V_L&8>LP8A#I(4/O3M84_(\J2 M++Z)LT$XR:I!V:E_"F=9+#I C9 M!D'J3I"UN<-?2G^B0((\\M0D[6E'"*,P@CR4JCP,6Q!2 M$[>22EO&2FMQJ:3VZ0"*.ZUMX>TG6>T@CDLF7 M!!PO&6HZ9P =3S#RCN-F#*HQF&2-G2C9_#\EUBV4JZ.)E^FC$72)U><' VP8 MU]4-BH#MTS('TWH46J,54*"JO%3;:9W2CASDSGB6=N0 T48;3X.;*',J%M72 MBA?,$BF\2NU:C.4BG&6M1Z!?]YH9#UEA8L@)N8=-O.LQ0G4/U:^?A4?1E%:2 M(E'CT%=$F) ,ZGO;G^=<4=1K^WFCR\F;7$TNB(7B/OIII)B=M@'Q$O-EXOP1 MAY'PC4V(T"BU(8$3T&V.(2AHL@6/WU#BLE37%!?+=A]CCT=.["AE3> @A2WTAH.8X-:^T%_#M*XII9S>4$:B M?AR0FR299^>I;^G]88@>L^U;H]6[DV+?1"GMO#EY=H'G$I,CF+:8'7"XVBO- M4*;FV)C!7$\JO,ZRGD,0=T 37"YVCR M!5U8.2V@ =U2!#*:(=4FS-V@9TQ<@^)8@L5%5#.< 977P&H<6V$33B -$_Z, MN=^BUZ/&=&+MMD$_63S,U)T!.%_X:FA,T-%=!B&-;@;S(Q?(#R25E(M[$0V0 MG6?W4E,P_6CG)1#P&YF9M+_$%-&,DT@/%_5#(4UA/(LQ67-SA-T@S1I._FVV M3@(2SI\1MMT0Z%E27HKA*U,!69&H )U:3C=,=H7 MD+Y!Y\WK^U_-;#%&K&8NNJTM9?2O9N-ZYLHQA!J''18S7\V:V]GPBKNQ'I4M M.T'3=YA/S*#/OD"B#GZV0*FHM9>.L0 F8HY>>,'3H?H%>/\0GQ.#S;/E,E3< M@FG16D*+W)RHQ>Z<;C^&M&C#+OMH0O2\2:N500Y-08R!G+0-M4OV0"Z_7'F.4%>N'I;KM#:NYXDXM*@(D:Y4ZC'GV:& MYLRZOO3+QULD@U\^$Z'(\X[8(M?D/Y-Z-[,'0X1ZR-4Q08ASG^*35M0 M"5!9K7GM!)N,I%0V 1FUG?2E[(Y:+>^6LGOW51@*B:90[MR2V$84*L? M.9_<:#E=HA6MED]$H8_C8BEE\E1?L&6MBG/KXY6"NAOKF81">N5\_G)-JU;@ MVI^?%#=>,@!,^Q.>H?1_"R)G@<'0-85%V0\CO$W0'28#*U $7%V$>@^(GG3* M8&RV[H[DE.=KE@4KB+NJROHL1K2ZS&2Q<#VZRM*LD"@O M2>5BV,/5EFPZ$>;6UL IFW-]*=LR T^!8&EMFB04]R\5J'^=-O!_4=IMPEC MW:15S] -U(48ORS3N 8K2%RT>$B+X2@ML]?8;OJ5 ;G=LZ11S=3D"\T'Y?'$ M>!%!>5R:5)0ZQG2N,R&$CY&0W[,3#>6:MK$?D7%OVTO41WA)CC^9UKH5+ MDBD3'USB0_%\,[]$C0N S98I8@&(;(>CZ;/;)X8+^+,YN(,$L]QB];9 M3I.&$MPCO#I##S!J;61FTK^E/N7+I4.:<(2I"9>;!-0'3M/CJ)G0@P8%V(Y? MER+8ZNUXF,=V[=A.)[?G=T3:FR"J>*^:@^38'YNM'MY!&RV8Z'XL2-CM5C'9 MQF4UT/2MV8-)@PX:01'PT7>Y9\P6K (+!I9C5J$HJD!>^N("[J^R13O7 MP3D&.IQ1JN5+8"\(AB\&@[P22BI9!NSV6%#%%7R^6"";[/WGS_;2\A_1+;GI MS'RP>E$<=J,U942@%(CN5"M^2ZC3_Z/^HHWEH23VB8CHVEGY@(GOE']1^,NT MV$;](<+V8B?IL;H?1SHVD"G1\Q#&Y4GH6[\@ITJG00QOS@VB4$H?\T=W"L)N M$/%ZG8936UX^BDM_$>!5FG ,6I]$D/>8$OZ%\10YA12C.-*&B+2,-52N?I6' MX8U<;@ZSFOKNP(+Q(9:">%R8FUB5QXAU4@$+P .8F)B$^$>?D-Y%:ES1,UG( M!<7[WNAV)0][.QZM#D!I^(MBGKDAI1=C5+_I-*#/^=Q@Q6U%Z'E8P&2-LSF6 M38\.>J@0>BD:J>*CO3)QRVRH68<=ETJ=WNA.#'G$VB-GE5QU>:U-A%>O[ MU0C!5NEK9J?L5G ??7?AVC2"KD;]GH!\ZD&], JR-I@UWZK=DD-!$$FABVM? M2Z*8;-C%DY%5V-D?Z\!9]\W\NN3!U:C"+@ N0Y/Y4:W:+'L!>+")M?7N:[J7 M(H;WX<**P=]-X<>@<[^=JVHL>Q/AOI:#E F?3?"BJ]$)TC .S33*3'NNAP1 M*0'0E5%AH5;])R4R6UPA8N>VSOR&"T,K$9.SEZV)G=G?#H!()DU_]DM$KB'N M@Y?=2SK,T ]!X#RYGD?69I5J3V:-G 3=7IX:J$,;/.U\S?JVE"9!Y9VJ'=IA M&46W:!-XM&8F(8:"Q10CQXT4%E(6&KI+&U@I>X=* X?]I1DZ=*$78Q-',S>T]J M4V(IQ+\9L4&]A=PA.\9IPD(<+0/L?D7.(L!YNFL2<46]=M&VV!>$^O/4#X_] MTB>68(%JME5,@S!*6WH^T'XD><(:K.74323U@T>8\6F1,>SZZRJ3N0-*S\PJ M]W[OJ)]A'6DTNF67]WFH&INZH\!>DYRHU/J7*@&:)4IRM^B&3TWXIMOA+ 7 ML@8\M!>3:1Q&P8JVWB5GAQ_AM(F4NMETZX:?PXGO?"3D<$2 !*\XP^>H;$"5 M *$\^KI8"#$V>,T6TG I3TD(R6'MNO70F--M\M.VP]H8;QA65M0N0MA=W:(U M;2"944Q]#8N:9FO1F2$6_BD [- M*&7'O^U6R5]A)3RL-KGL@@WSVW^X(N(@C?QAB#5C\> MBX)ZNG6>B+',\*NY4%U?F5Q,C5QA?3!+%)1!DKT]4%=,1<$E9 (2V^" MP)HILS)2Z[^C=5/"+Y<59"'&( M\ :L:74CN_'M7PS(M-<>K3&%JTY=8##&#:M8B9K;A+!_TV>=/;ZOZ>.[1)?N(CKLJ% ;I=BYLC%NK/Z-KOP2W, 2^^M?=X>66S+[YM M>.HH02"C\1!'O]_2NI639U=HGI(/"JHD_U558YDBU'FR)%]B.WY 1^2WR ]I M*@%38;)3F:JM HIN%^V._'5I_]6#>D83RI&:@WV4'B%ES)F3J01H/F+-(

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end